<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">31940011</PMID>
			<DateCompleted>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>03</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>03</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Electronic">2168-6238</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>77</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>2020</Year>
							<Month>May</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>JAMA psychiatry</Title>
					<ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effects of Family-Focused Therapy vs Enhanced Usual Care for Symptomatic Youths at High Risk for Bipolar Disorder: A Randomized Clinical Trial.</ArticleTitle>
				<Pagination>
					<StartPage>455</StartPage>
					<EndPage>463</EndPage>
					<MedlinePgn>455-463</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2019.4520</ELocationID>
				<Abstract>
					<AbstractText Label="IMPORTANCE">Behavioral high-risk phenotypes predict the onset of bipolar disorder among youths who have parents with bipolar disorder. Few studies have examined whether early intervention delays new mood episodes in high-risk youths.</AbstractText>
					<AbstractText Label="OBJECTIVE">To determine whether family-focused therapy (FFT) for high-risk youths is more effective than standard psychoeducation in hastening recovery and delaying emergence of mood episodes during the 1 to 4 years after an active period of mood symptoms.</AbstractText>
					<AbstractText Label="DESIGN, SETTINGS, AND PARTICIPANTS">This multisite randomized clinical trial included referred youths (aged 9-17 years) with major depressive disorder or unspecified (subthreshold) bipolar disorder, active mood symptoms, and at least 1 first- or second-degree relative with bipolar disorder I or II. Recruitment started from October 6, 2011, and ended on September 15, 2016. Independent evaluators interviewed participants every 4 to 6 months to measure symptoms for up to 4 years. Data analysis was performed from March 13 to November 3, 2019.</AbstractText>
					<AbstractText Label="INTERVENTIONS">High-risk youths and parents were randomly allocated to FFT (12 sessions in 4 months of psychoeducation, communication training, and problem-solving skills training; n&#8201;=&#8201;61) or enhanced care (6 sessions in 4 months of family and individual psychoeducation; n&#8201;=&#8201;66). Youths could receive medication management in either condition.</AbstractText>
					<AbstractText Label="MAIN OUTCOMES AND MEASURES">The coprimary outcomes, derived using weekly psychiatric status ratings, were time to recovery from prerandomization symptoms and time to a prospectively observed mood (depressive, manic, or hypomanic) episode after recovery. Secondary outcomes were time to conversion to bipolar disorder I or II and longitudinal symptom trajectories.</AbstractText>
					<AbstractText Label="RESULTS">All 127 participants (82 [64.6%] female; mean [SD] age, 13.2 [2.6] years) were followed up for a median of 98 weeks (range, 0-255 weeks). No differences were detected between treatments in time to recovery from pretreatment symptoms. High-risk youths in the FFT group had longer intervals from recovery to the emergence of the next mood episode (&#967;2&#8201;=&#8201;5.44; P&#8201;=&#8201;.02; hazard ratio, 0.55; 95% CI, 0.48-0.92;), and from randomization to the next mood episode (&#967;2&#8201;=&#8201;4.44; P&#8201;=&#8201;.03; hazard ratio, 0.59; 95% CI, 0.35-0.97) than youths in enhanced care. Specifically, FFT was associated with longer intervals to depressive episodes (log-rank &#967;2&#8201;=&#8201;6.24; P&#8201;=&#8201;.01; hazard ratio, 0.53; 95% CI, 0.31-0.88) but did not differ from enhanced care in time to manic or hypomanic episodes, conversions to bipolar disorder, or symptom trajectories.</AbstractText>
					<AbstractText Label="CONCLUSIONS AND RELEVANCE">Family skills-training for youths at high risk for bipolar disorder is associated with longer times between mood episodes. Clarifying the relationship between changes in family functioning and changes in the course of high-risk syndromes merits future investigation.</AbstractText>
					<AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov identifier: NCT01483391.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Miklowitz</LastName>
						<ForeName>David J</ForeName>
						<Initials>DJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schneck</LastName>
						<ForeName>Christopher D</ForeName>
						<Initials>CD</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Colorado Anschutz Medical Campus, Denver.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Walshaw</LastName>
						<ForeName>Patricia D</ForeName>
						<Initials>PD</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Singh</LastName>
						<ForeName>Manpreet K</ForeName>
						<Initials>MK</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sullivan</LastName>
						<ForeName>Aimee E</ForeName>
						<Initials>AE</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Colorado Anschutz Medical Campus, Denver.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Suddath</LastName>
						<ForeName>Robert L</ForeName>
						<Initials>RL</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Forgey Borlik</LastName>
						<ForeName>Marcy</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sugar</LastName>
						<ForeName>Catherine A</ForeName>
						<Initials>CA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Chang</LastName>
						<ForeName>Kiki D</ForeName>
						<Initials>KD</Initials>
						<AffiliationInfo>
							<Affiliation>Private practice, Menlo Park, California.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<DataBankList CompleteYN="Y">
					<DataBank>
						<DataBankName>ClinicalTrials.gov</DataBankName>
						<AccessionNumberList>
							<AccessionNumber>NCT01483391</AccessionNumber>
						</AccessionNumberList>
					</DataBank>
				</DataBankList>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>R01 MH073871</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>R01 MH093676</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>R21 MH097007</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>R34 MH117200</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016448">Multicenter Study</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>JAMA Psychiatry</MedlineTA>
				<NlmUniqueID>101589550</NlmUniqueID>
				<ISSNLinking>2168-622X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005196">Family Therapy</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D019964">Mood Disorders</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011619">Psychotropic Drugs</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<CoiStatement>
				<b>Conflict of Interest Disclosures:</b> Dr Miklowitz reported receiving research support from the National Institute of Mental Health (NIMH) during the conduct of the study; receiving grants from the Danny Alberts Foundation, the Attias Family Foundation, the Carl and Roberta Deutsch Foundation, the Kayne Family Foundation, AIM for Mental Health, the American Foundation for Suicide Prevention, and the Max Gray Fund; and book royalties from Guilford Press and John Wiley and Sons. Dr Schneck reported receiving research support from the NIMH during the conduct of the study and receiving grants from the Ryan White Foundation outside the submitted work. Dr Walshaw reported receiving grants from NIMH during the conduct of the study. Dr Singh reported receiving grants from the NIMH during the conduct of the study; receiving grants from Allergan, the Brain and Behavior Foundation, Johnson &amp; Johnson, the National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Stanford Maternal Child Health Research Institute, and the Stanford Department of Psychiatry and Behavioral Sciences; serving on the advisory board for Sunovion; being a consultant for Google X and Limbix; and receiving royalties from the American Psychiatric Association Publishing outside the submitted work. Dr Sullivan reported receiving grants from the NIMH during the conduct of the study; reported receiving a grant from the Caring for Colorado Foundation to provide clinician trainings in the family-focused therapy model, covering approximately 50% of time, outside the submitted work. Dr Forgey Borlik reported receiving grants from the NIMH during the conduct of the study. Dr Sugar reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Chang reported receiving personal fees from Sunovion and Allergan outside the submitted work. No other disclosures were reported.
			</CoiStatement>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2020</Year>
					<Month>1</Month>
					<Day>16</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2021</Year>
					<Month>2</Month>
					<Day>4</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2020</Year>
					<Month>1</Month>
					<Day>16</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2021</Year>
					<Month>1</Month>
					<Day>15</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">31940011</ArticleId>
				<ArticleId IdType="mid">NIHMS1069040</ArticleId>
				<ArticleId IdType="pmc">PMC6990706</ArticleId>
				<ArticleId IdType="doi">10.1001/jamapsychiatry.2019.4520</ArticleId>
				<ArticleId IdType="pii">2758325</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Axelson DA, Birmaher B, Strober MA, et al. . Course of subthreshold bipolar disorder in youth: diagnostic progression from bipolar disorder not otherwise specified. J Am Acad Child Adolesc Psychiatry. 2011;50(10):1001-16.e3. doi:10.1016/j.jaac.2011.07.005</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2011.07.005</ArticleId>
						<ArticleId IdType="pmc">PMC3185249</ArticleId>
						<ArticleId IdType="pubmed">21961775</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hafeman DM, Merranko J, Axelson D, et al. . Toward the definition of a bipolar prodrome: dimensional predictors of bipolar spectrum disorders in at-risk youths. Am J Psychiatry. 2016;173(7):695-704. doi:10.1176/appi.ajp.2015.15040414</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.2015.15040414</ArticleId>
						<ArticleId IdType="pmc">PMC4930393</ArticleId>
						<ArticleId IdType="pubmed">26892940</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Perlis RH, Dennehy EB, Miklowitz DJ, et al. . Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord. 2009;11(4):391-400. doi:10.1111/j.1399-5618.2009.00686.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2009.00686.x</ArticleId>
						<ArticleId IdType="pmc">PMC3992980</ArticleId>
						<ArticleId IdType="pubmed">19500092</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Post RM, Leverich GS, Kupka RW, et al. . Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry. 2010;71(7):864-872. doi:10.4088/JCP.08m04994yel</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.4088/JCP.08m04994yel</ArticleId>
						<ArticleId IdType="pubmed">20667291</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Axelson D, Birmaher B, Strober M, et al. . Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63(10):1139-1148. doi:10.1001/archpsyc.63.10.1139</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.63.10.1139</ArticleId>
						<ArticleId IdType="pubmed">17015816</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P. The developmental trajectory of bipolar disorder. Br J Psychiatry. 2014;204(2):122-128. doi:10.1192/bjp.bp.113.126706</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.bp.113.126706</ArticleId>
						<ArticleId IdType="pubmed">24262817</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Axelson D, Goldstein B, Goldstein T, et al. . Diagnostic precursors to bipolar disorder in offspring of parents with bipolar disorder: a longitudinal study. Am J Psychiatry. 2015;172(7):638-646. doi:10.1176/appi.ajp.2014.14010035</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.2014.14010035</ArticleId>
						<ArticleId IdType="pmc">PMC4489996</ArticleId>
						<ArticleId IdType="pubmed">25734353</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Malhi GS, Morris G, Hamilton A, Outhred T, Mannie Z. Is &#8220;early intervention&#8221; in bipolar disorder what it claims to be? Bipolar Disord. 2017;19(8):627-636. doi:10.1111/bdi.12576</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/bdi.12576</ArticleId>
						<ArticleId IdType="pubmed">29268003</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Vallarino M, Henry C, Etain B, et al. . An evidence map of psychosocial interventions for the earliest stages of bipolar disorder. Lancet Psychiatry. 2015;2(6):548-563. doi:10.1016/S2215-0366(15)00156-X</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/S2215-0366(15)00156-X</ArticleId>
						<ArticleId IdType="pmc">PMC4629930</ArticleId>
						<ArticleId IdType="pubmed">26360451</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Chang KD, Taylor DO, et al. . Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial. Bipolar Disord. 2011;13(1):67-75. doi:10.1111/j.1399-5618.2011.00890.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2011.00890.x</ArticleId>
						<ArticleId IdType="pmc">PMC3077951</ArticleId>
						<ArticleId IdType="pubmed">21320254</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Schneck CD, Singh MK, et al. . Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy. J Am Acad Child Adolesc Psychiatry. 2013;52(2):121-131. doi:10.1016/j.jaac.2012.10.007</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2012.10.007</ArticleId>
						<ArticleId IdType="pmc">PMC3558946</ArticleId>
						<ArticleId IdType="pubmed">23357439</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60(9):904-912. doi:10.1001/archpsyc.60.9.904</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.60.9.904</ArticleId>
						<ArticleId IdType="pubmed">12963672</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rea MM, Tompson MC, Miklowitz DJ, Goldstein MJ, Hwang S, Mintz J. Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol. 2003;71(3):482-492. doi:10.1037/0022-006X.71.3.482</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0022-006X.71.3.482</ArticleId>
						<ArticleId IdType="pubmed">12795572</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Otto MW, Frank E, et al. . Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007;64(4):419-426. doi:10.1001/archpsyc.64.4.419</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.64.4.419</ArticleId>
						<ArticleId IdType="pmc">PMC3579612</ArticleId>
						<ArticleId IdType="pubmed">17404119</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Chung B. Family-focused therapy for bipolar disorder: reflections on 30 years of research. Fam Process. 2016;55(3):483-499. doi:10.1111/famp.12237</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/famp.12237</ArticleId>
						<ArticleId IdType="pmc">PMC5922774</ArticleId>
						<ArticleId IdType="pubmed">27471058</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Schneck CD, Chang KD, Singh MK, DelBello MP, Miklowitz DJ. A pharmacologic algorithm for youth who are at high risk for bipolar disorder. J Child Adolesc Psychopharmacol. 2017;27(9):796-805. doi:10.1089/cap.2017.0035</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1089/cap.2017.0035</ArticleId>
						<ArticleId IdType="pmc">PMC5689113</ArticleId>
						<ArticleId IdType="pubmed">28731778</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed, text revision. Washington DC: American Psychiatric Press; 2000.</Citation>
				</Reference>
				<Reference>
					<Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 5th ed Arlington, VA: American Psychiatric Press; 2013.</Citation>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. doi:10.1192/bjp.133.5.429</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.133.5.429</ArticleId>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Poznanski EO, Mokros HB. Children&#8217;s Depression Rating Scale, Revised. Los Angeles, CA: Western Psychological Services; 1999.</Citation>
				</Reference>
				<Reference>
					<Citation>Birmaher B, Axelson D, Goldstein B, et al. . Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. Am J Psychiatry. 2009;166(7):795-804. doi:10.1176/appi.ajp.2009.08101569</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.2009.08101569</ArticleId>
						<ArticleId IdType="pmc">PMC2828047</ArticleId>
						<ArticleId IdType="pubmed">19448190</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Schneck CD, Walshaw PD, et al. . Early intervention for youth at high risk for bipolar disorder: a multisite randomized trial of family-focused treatment. Early Interv Psychiatry. 2019;13(2):208-216. doi:10.1111/eip.12463</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/eip.12463</ArticleId>
						<ArticleId IdType="pmc">PMC5797511</ArticleId>
						<ArticleId IdType="pubmed">28776930</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Chambers WJ, Puig-Antich J, Hirsch M, et al. . The assessment of affective disorders in children and adolescents by semistructured interview: test-retest reliability of the schedule for affective disorders and schizophrenia for school-age children, present episode version. Arch Gen Psychiatry. 1985;42(7):696-702. doi:10.1001/archpsyc.1985.01790300064008</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.1985.01790300064008</ArticleId>
						<ArticleId IdType="pubmed">4015311</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kaufman J, Birmaher B, Brent D, et al. . Schedule for Affective Disorders and Schizophrenia for School-Age Children&#8211;Present and Lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988. doi:10.1097/00004583-199707000-00021</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1097/00004583-199707000-00021</ArticleId>
						<ArticleId IdType="pubmed">9204677</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Axelson D, Birmaher BJ, Brent D, et al. . A preliminary study of the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children mania rating scale for children and adolescents. J Child Adolesc Psychopharmacol. 2003;13(4):463-470. doi:10.1089/104454603322724850</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1089/104454603322724850</ArticleId>
						<ArticleId IdType="pubmed">14977459</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sheehan DV, Lecrubier Y, Sheehan KH, et al. . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9881538</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Weissman MM, Wickramaratne P, Adams P, Wolk S, Verdeli H, Olfson M. Brief screening for family psychiatric history: the family history screen. Arch Gen Psychiatry. 2000;57(7):675-682. doi:10.1001/archpsyc.57.7.675</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.57.7.675</ArticleId>
						<ArticleId IdType="pubmed">10891038</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Begg CB, Iglewicz B. A treatment allocation procedure for sequential clinical trials. Biometrics. 1980;36(1):81-90. doi:10.2307/2530497</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.2307/2530497</ArticleId>
						<ArticleId IdType="pubmed">7370375</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Marvin SE, Miklowitz DJ, O&#8217;Brien MP, Cannon TD. Family-focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomized trial. Early Interv Psychiatry. 2016;10(2):137-143. doi:10.1111/eip.12144</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/eip.12144</ArticleId>
						<ArticleId IdType="pmc">PMC4194178</ArticleId>
						<ArticleId IdType="pubmed">24725329</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Keller MB, Lavori PW, Friedman B, et al. . The Longitudinal Interval Follow-up Evaluation. a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44(6):540-548. doi:10.1001/archpsyc.1987.01800180050009</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.1987.01800180050009</ArticleId>
						<ArticleId IdType="pubmed">3579500</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ger D, Everitt BS. Handbook of Statistical Analyses Using SAS. 3nd ed Boca Raton, FL: Chapman and Hall/CRC Press; 2009.</Citation>
				</Reference>
				<Reference>
					<Citation>Nadkarni RB, Fristad MA. Clinical course of children with a depressive spectrum disorder and transient manic symptoms. Bipolar Disord. 2010;12(5):494-503. doi:10.1111/j.1399-5618.2010.00847.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2010.00847.x</ArticleId>
						<ArticleId IdType="pmc">PMC2924759</ArticleId>
						<ArticleId IdType="pubmed">20712750</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>West AE, Weinstein SM, Peters AT, et al. . Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2014;53(11):1168-1178.e1. doi:10.1016/j.jaac.2014.08.013</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2014.08.013</ArticleId>
						<ArticleId IdType="pmc">PMC4254579</ArticleId>
						<ArticleId IdType="pubmed">25440307</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Tompson MC, Sugar CA, Langer DA, Asarnow JR. A randomized clinical trial comparing family-focused treatment and individual supportive therapy for depression in childhood and early adolescence. J Am Acad Child Adolesc Psychiatry. 2017;56(6):515-523. doi:10.1016/j.jaac.2017.03.018</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2017.03.018</ArticleId>
						<ArticleId IdType="pmc">PMC5482237</ArticleId>
						<ArticleId IdType="pubmed">28545757</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cuijpers P, Hollon SD, van Straten A, Bockting C, Berking M, Andersson G. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? a meta-analysis. BMJ Open. 2013;3(4):e002542. doi:10.1136/bmjopen-2012-002542</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1136/bmjopen-2012-002542</ArticleId>
						<ArticleId IdType="pmc">PMC3641456</ArticleId>
						<ArticleId IdType="pubmed">23624992</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Brent DA, Brunwasser SM, Hollon SD, et al. . Effect of a cognitive-behavioral prevention program on depression 6 years after implementation among at-risk adolescents: a randomized clinical trial. JAMA Psychiatry. 2015;72(11):1110-1118. doi:10.1001/jamapsychiatry.2015.1559</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/jamapsychiatry.2015.1559</ArticleId>
						<ArticleId IdType="pmc">PMC4635056</ArticleId>
						<ArticleId IdType="pubmed">26421861</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Richards JA, George EL, et al. . Integrated family and individual therapy for bipolar disorder: results of a treatment development study. J Clin Psychiatry. 2003;64(2):182-191. doi:10.4088/JCP.v64n0211</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.4088/JCP.v64n0211</ArticleId>
						<ArticleId IdType="pubmed">12633127</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Axelson DA, Birmaher B, et al. . Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. Arch Gen Psychiatry. 2008;65(9):1053-1061. doi:10.1001/archpsyc.65.9.1053</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.65.9.1053</ArticleId>
						<ArticleId IdType="pmc">PMC2610285</ArticleId>
						<ArticleId IdType="pubmed">18762591</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Schneck CD, George EL, et al. . Pharmacotherapy and family-focused treatment for adolescents with bipolar I and II disorders: a 2-year randomized trial. Am J Psychiatry. 2014;171(6):658-667. doi:10.1176/appi.ajp.2014.13081130</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.2014.13081130</ArticleId>
						<ArticleId IdType="pmc">PMC4083000</ArticleId>
						<ArticleId IdType="pubmed">24626789</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Birmaher B, Axelson D, Strober M, et al. . Clinical course of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry. 2006;63(2):175-183. doi:10.1001/archpsyc.63.2.175</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.63.2.175</ArticleId>
						<ArticleId IdType="pmc">PMC3079382</ArticleId>
						<ArticleId IdType="pubmed">16461861</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Birmaher B, Merranko JA, Goldstein TR, et al. . A risk calculator to predict the individual risk of conversion from subthreshold bipolar symptoms to bipolar disorder I or II in youth. J Am Acad Child Adolesc Psychiatry. 2018;57(10):755-763.e4. doi:10.1016/j.jaac.2018.05.023</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2018.05.023</ArticleId>
						<ArticleId IdType="pmc">PMC6293466</ArticleId>
						<ArticleId IdType="pubmed">30274650</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Van Meter AR, Burke C, Youngstrom EA, Faedda GL, Correll CU. The bipolar prodrome: meta-analysis of symptom prevalence prior to initial or recurrent mood episodes. J Am Acad Child Adolesc Psychiatry. 2016;55(7):543-555. doi:10.1016/j.jaac.2016.04.017</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2016.04.017</ArticleId>
						<ArticleId IdType="pubmed">27343882</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Youngstrom EA, Van Meter A, Frazier TW, Youngstrom JK, Findling RL. Developing and validating short forms of the Parent General Behavior Inventory mania and depression scales for rating youth mood symptoms. J Clin Child Adolesc Psychol. 2018:1-16. doi:10.1080/15374416.2018.1491006</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1080/15374416.2018.1491006</ArticleId>
						<ArticleId IdType="pubmed">30040496</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Arevian A, Walshaw P. Technology-enhanced family intervention for adolescents at high risk for mood disorders. Bipolar Disord. 2019;(21)(suppl 1):52.</Citation>
				</Reference>
				<Reference>
					<Citation>Simoneau TL, Miklowitz DJ, Richards JA, Saleem R, George EL. Bipolar disorder and family communication: effects of a psychoeducational treatment program. J Abnorm Psychol. 1999;108(4):588-597. doi:10.1037/0021-843X.108.4.588</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0021-843X.108.4.588</ArticleId>
						<ArticleId IdType="pubmed">10609423</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sullivan AE, Judd CM, Axelson DA, Miklowitz DJ. Family functioning and the course of adolescent bipolar disorder. Behav Ther. 2012;43(4):837-847. doi:10.1016/j.beth.2012.04.005</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.beth.2012.04.005</ArticleId>
						<ArticleId IdType="pmc">PMC3500638</ArticleId>
						<ArticleId IdType="pubmed">23046785</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>O&#8217;Brien MP, Miklowitz DJ, Candan KA, et al. . A randomized trial of family focused therapy with populations at clinical high risk for psychosis: effects on interactional behavior. J Consult Clin Psychol. 2014;82(1):90-101. doi:10.1037/a0034667</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/a0034667</ArticleId>
						<ArticleId IdType="pmc">PMC3909734</ArticleId>
						<ArticleId IdType="pubmed">24188511</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>O&#8217;Brien MP, Miklowitz DJ, Cannon TD. Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomized trial of family-focused therapy for individuals at clinical high risk for psychosis. J Fam Psychol. 2015;29(6):945-951. doi:10.1037/fam0000123</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/fam0000123</ArticleId>
						<ArticleId IdType="pmc">PMC4673032</ArticleId>
						<ArticleId IdType="pubmed">26168262</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Perlick DA, Jackson C, Grier S, et al. . Randomized trial comparing caregiver-only family-focused treatment to standard health education on the 6-month outcome of bipolar disorder. Bipolar Disord. 2018;20(7):622-633. doi:10.1111/bdi.12621</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/bdi.12621</ArticleId>
						<ArticleId IdType="pubmed">29528180</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">29044718</PMID>
			<DateCompleted>
				<Year>2019</Year>
				<Month>02</Month>
				<Day>04</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>12</Month>
				<Day>07</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1943-278X</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>48</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>2018</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Suicide &amp; life-threatening behavior</Title>
					<ISOAbbreviation>Suicide Life Threat Behav</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Child- and Family-Focused Cognitive Behavioral Therapy for Pediatric Bipolar Disorder: Applications for Suicide Prevention.</ArticleTitle>
				<Pagination>
					<StartPage>797</StartPage>
					<EndPage>811</EndPage>
					<MedlinePgn>797-811</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1111/sltb.12416</ELocationID>
				<Abstract>
					<AbstractText>Despite high rates of suicide ideation (SI) and behavior in youth with pediatric bipolar disorder (PBD), little work has examined how psychosocial interventions impact suicidality among this high-risk group. The current study examined SI outcomes in a randomized clinical trial comparing Child- and Family-Focused Cognitive Behavioral Therapy (CFF-CBT) for PBD versus psychotherapy treatment-as-usual (TAU). Although not designed for suicide prevention, CFF-CBT addresses child and family factors related to suicide risk and thus was hypothesized to generalize to the treatment of suicidality. Participants included 71 youth aged 7-13&#160;years (M&#160;=&#160;9.17, SD&#160;=&#160;1.60) with DSM-IV-TR bipolar I, II, or not otherwise specified randomly assigned, with parent(s), to receive CFF-CBT or TAU. Both treatments consisted of 12 weekly and 6 monthly booster sessions. Suicide ideation was assessed via clinician interview at baseline, posttreatment, and 6-month follow-up. Results indicated that SI was prevalent pretreatment: 39% of youth reported current suicidal thoughts. All youth significantly improved in the likelihood and intensity of ideation across treatment, but group differences were not significant. Thus, findings suggest that early intervention for these high-risk youth may reduce SI, and at this stage of suicidality, youth may be responsive to even nonspecialized treatment.</AbstractText>
					<CopyrightInformation>&#169; 2017 The American Association of Suicidology.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Weinstein</LastName>
						<ForeName>Sally M</ForeName>
						<Initials>SM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cruz</LastName>
						<ForeName>Rick A</ForeName>
						<Initials>RA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, Utah State University, Logan, UT, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Isaia</LastName>
						<ForeName>Ashley R</ForeName>
						<Initials>AR</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Peters</LastName>
						<ForeName>Amy T</ForeName>
						<Initials>AT</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>West</LastName>
						<ForeName>Amy E</ForeName>
						<Initials>AE</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>K23 MH079935</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2017</Year>
					<Month>10</Month>
					<Day>16</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Suicide Life Threat Behav</MedlineTA>
				<NlmUniqueID>7608054</NlmUniqueID>
				<ISSNLinking>0363-0234</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D015928">Cognitive Behavioral Therapy</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D039721">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005196">Family Therapy</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011613">Psychotherapy</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D059020">Suicidal Ideation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D013405">Suicide</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D000092864">Suicide Prevention</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2016</Year>
					<Month>8</Month>
					<Day>23</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2017</Year>
					<Month>8</Month>
					<Day>16</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2017</Year>
					<Month>10</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2019</Year>
					<Month>2</Month>
					<Day>5</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2017</Year>
					<Month>10</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2019</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">29044718</ArticleId>
				<ArticleId IdType="mid">NIHMS904943</ArticleId>
				<ArticleId IdType="pmc">PMC5902658</ArticleId>
				<ArticleId IdType="doi">10.1111/sltb.12416</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Algorta GP, Youngstrom EA, Frazier TW, Freeman AJ, Youngstrom JK, Findling RL. Suicidality in pediatric bipolar disorder: predictor or outcome of family processes and mixed mood presentation? Bipolar disorders. 2011;13(1):76&#8211;86.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3076793</ArticleId>
						<ArticleId IdType="pubmed">21320255</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Altman E, Hedeker D, Peterson JL, Davis JM. A comparative evaluation of three self-rating scales for acute mania. Biological Psychiatry. 2001;50(6):468&#8211;471.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11566165</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>American Psychiatric Association. Diagnostic and statistical manual of mental health disorders. 4. Washington DC: Author; 1994.</Citation>
				</Reference>
				<Reference>
					<Citation>Asarnow JR, Baraff LJ, Berk M, Grob CS, Devich-Navarro M, Suddath R, Tang L. An emergency department intervention for linking pediatric suicidal patients to follow-up mental health treatment. Psychiatric services. 2011;62(11):1303&#8211;1309.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3251923</ArticleId>
						<ArticleId IdType="pubmed">22211209</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.</Citation>
				</Reference>
				<Reference>
					<Citation>Bhangoo RK, Dell ML, Towbin K, Myers FS, Lowe CH, Pine DS, Leibenluft E. Clinical correlates of episodicity in juvenile mania. Journal of Child and Adolescent Psychopharmacology. 2003;13(4):507&#8211;514.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">14977463</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT, Posner K. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2009;48(10):987&#8211;996.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2891930</ArticleId>
						<ArticleId IdType="pubmed">19730274</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Brent DA, McMakin DL, Kennard BD, Goldstein TR, Mayes TL, Douaihy AB. Protecting adolescents from self-harm: a critical review of intervention studies. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2013;52(12):1260&#8211;1271.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3873716</ArticleId>
						<ArticleId IdType="pubmed">24290459</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Brent DA, Perper JA, Moritz G, Allman C, Friend A, Roth C, Baugher M. Psychiatric risk factors for adolescent suicide: a case-control study. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 1993;32(3):521&#8211;529.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">8496115</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. Journal of Child Psychology and Psychiatry. 2006;47(3 &#8211; 4):372&#8211;394.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16492264</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Conners C, March J. The Conners/March Developmental Questionnaire. Toronto, ON: MultiHealth Systems Inc; 1996.</Citation>
				</Reference>
				<Reference>
					<Citation>Corcoran J, Dattalo P, Crowley M, Brown E, Grindle L. A systematic review of psychosocial interventions for suicidal adolescents. Children and Youth Services Review. 2011;33(11):2112&#8211;2118.</Citation>
				</Reference>
				<Reference>
					<Citation>Diamond GS, Wintersteen MB, Brown GK, Diamond GM, Gallop R, Shelef K, Levy S. Attachment-based family therapy for adolescents with suicidal ideation: A randomized controlled trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2010;49(2):122&#8211;131.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">20215934</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Donaldson D, Spirito A, Esposito-Smythers C. Treatment for adolescents following a suicide attempt: Results of a pilot trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2005;44(2):113&#8211;120.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15689724</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Esposito C, Spirito A, Boergers J, Donaldson D. Affective, behavioral, and cognitive functioning in adolescents with multiple suicide attempts. Suicide and Life-Threatening Behavior. 2003;33(4):389&#8211;399.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">14695054</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Esposito-Smythers C, Spirito A, Kahler CW, Hunt J, Monti P. Treatment of co-occurring substance abuse and suicidality among adolescents: a randomized trial. Journal of consulting and clinical psychology. 2011;79(6):728.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3226923</ArticleId>
						<ArticleId IdType="pubmed">22004303</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Geller B, Williams M, Zimerman B, Frazier J. Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) St Louis, MO: Washington University; 1996.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11314571</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Glenn CR, Franklin JC, Nock MK. Evidence-based psychosocial treatments for self-injurious thoughts and behaviors in youth. Journal of Clinical Child &amp; Adolescent Psychology. 2015;44(1):1&#8211;29.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4557625</ArticleId>
						<ArticleId IdType="pubmed">25256034</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Goldstein TR. Suicidality in pediatric bipolar disorder. Child and Adolescent Psychiatric Clinics of North America. 2009;18(2):339&#8211;352.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2827306</ArticleId>
						<ArticleId IdType="pubmed">19264267</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Goldstein TR, Birmaher B, Axelson D, Goldstein BI, Gill MK, Esposito-Smythers C, Keller M. Family environment and suicidal ideation among bipolar youth. Archives of suicide research. 2009;13(4):378&#8211;388.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2822384</ArticleId>
						<ArticleId IdType="pubmed">19813115</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Goldstein TR, Fersch-Podrat RK, Rivera M, Axelson DA, Merranko J, Yu H, Birmaher B. Dialectical behavior therapy for adolescents with bipolar disorder: results from a pilot randomized trial. Journal of Child and Adolescent Psychopharmacology. 2015;25(2):140&#8211;149.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4367513</ArticleId>
						<ArticleId IdType="pubmed">25010702</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Goldstein TR, Ha W, Axelson DA, Goldstein BI, Liao F, Gill MK, Hower H. Predictors of prospectively examined suicide attempts among youth with bipolar disorder. Archives of general psychiatry. 2012;69(11):1113&#8211;1122.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3600896</ArticleId>
						<ArticleId IdType="pubmed">22752079</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Green J, Wood A, Kerfoot M, Trainor G, Roberts C, Rothwell J, Byford S. Group therapy for adolescents with repeated self harm: randomised controlled trial with economic evaluation. BMJ. 2011;342:d682.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3069684</ArticleId>
						<ArticleId IdType="pubmed">21459975</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Harrington R, Kerfoot M, Dyer E, McNIVEN F, Gill J, Harrington V, Byford S. Randomized trial of a home-based family intervention for children who have deliberately poisoned themselves. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 1998;37(5):512&#8211;518.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9585653</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Huey SJ, Henggeler SW, Rowland MD, Halliday-Boykins CA, Cunningham PB, Pickrel SG, Edwards J. Multisystemic therapy effects on attempted suicide by youths presenting psychiatric emergencies. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2004;43(2):183&#8211;190.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">14726725</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Jolin EM, Weller EB, Weller RA. Suicide risk factors in children and adolescents with bipolar disorder. Current psychiatry reports. 2007;9(2):122&#8211;128.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17389121</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kaufman AS, Kaufman NL. Kaufman Brief Intelligence Test&#8211;Second Edition (KBIT-2) Circle Pines. MN: American Guidance Service; 2004.</Citation>
				</Reference>
				<Reference>
					<Citation>Keenan-Miller D, Peris T, Axelson D, Kowatch RA, Miklowitz DJ. Family functioning, social impairment, and symptoms among adolescents with bipolar disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2012;51(10):1085&#8211;1094.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3462361</ArticleId>
						<ArticleId IdType="pubmed">23021483</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kowatch RA, Fristad M, Birmaher B, Wagner KD, Findling RL, Hellander M. Treatment guidelines for children and adolescents with bipolar disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2005;44(3):213&#8211;235.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15725966</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lewinsohn PM, Rohde P, Seeley JR. Adolescent suicidal ideation and attempts: Prevalence, risk factors, and clinical implications. Clinical Psychology: Science and Practice. 1996;3(1):25&#8211;46.</Citation>
				</Reference>
				<Reference>
					<Citation>Lewinsohn PM, Seeley JR, Klein DN. Bipolar disorders during adolescence. Acta Psychiatrica Scandinavica. 2003;108(s418):47&#8211;50.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12956814</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nock MK, Borges G, Bromet EJ, Alonso J, Angermeyer M, Beautrais A, Williams D. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry. 2008;192(2):98&#8211;105. doi: 10.1192/bjp.bp.107.040113.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.bp.107.040113</ArticleId>
						<ArticleId IdType="pmc">PMC2259024</ArticleId>
						<ArticleId IdType="pubmed">18245022</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ougrin D, Boege I, Stahl D, Banarsee R, Taylor E. Randomised controlled trial of therapeutic assessment versus usual assessment in adolescents with self-harm: 2-year follow-up. Archives of disease in childhood. 2013 archdischild-2012-303200.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23709314</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Pavuluri MN, Graczyk PA, Henry DB, Carbray JA, Heidenreich J, Miklowitz DJ. Child-and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: development and preliminary results. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2004;43(5):528&#8211;537.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15100559</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Pavuluri MN, Henry DB, Devineni B, Carbray JA, Naylor MW, Janicak PG. A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2004;43(7):859&#8211;867.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15213587</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Pineda J, Dadds MR. Family intervention for adolescents with suicidal behavior: a randomized controlled trial and mediation analysis. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2013;52(8):851&#8211;862.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23880495</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266&#8211;1277. doi: 10.1176/appi.ajp.2011.10111704.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.2011.10111704</ArticleId>
						<ArticleId IdType="pmc">PMC3893686</ArticleId>
						<ArticleId IdType="pubmed">22193671</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R. Preliminary studies of the reliability and validity of the children's depression rating scale. J Am Acad Child Psychiatry. 1984;23(2):191&#8211;197.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6715741</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.  Retrieved from  http://www.r-project.org/</Citation>
				</Reference>
				<Reference>
					<Citation>Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24&#8211;31. doi: 10.1016/j.it.2005.11.006.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.it.2005.11.006</ArticleId>
						<ArticleId IdType="pmc">PMC3392963</ArticleId>
						<ArticleId IdType="pubmed">16316783</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rossouw TI, Fonagy P. Mentalization-based treatment for self-harm in adolescents: a randomized controlledtrial. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2012;51(12):1304&#8211;1313. e1303.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23200287</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rudd MD, Rajab MH, Orman DT, Stulman DA, Joiner T, Dixon W. Effectiveness of an outpatient intervention targeting suicidal young adults: preliminary results. Journal of consulting and clinical psychology. 1996;64(1):179.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">8907098</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Schenkel LS, West AE, Harral EM, Patel NB, Pavuluri MN. Parent&#8211;child interactions in pediatric bipolar disorder. Journal of clinical psychology. 2008;64(4):422&#8211;437.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">18357574</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Spirito A, Stanton C, Donaldson D, Boergers J. Treatment-as-usual for adolescent suicide attempters: Implications for the choice of comparison groups in psychotherapy research. Journal of Clinical Child and Adolescent Psychology. 2002;31(1):41&#8211;47.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11845649</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Urbaniak GC, Plous S. Research randomizer, version 3.0. 1997 Retrieved from Available at:  http://www.randomizer.org/about.htm.</Citation>
				</Reference>
				<Reference>
					<Citation>Weinstein SM, Henry DB, Katz AC, Peters AT, West AE. Treatment moderators of child-and family-focused cognitive-behavioral therapy for pediatric bipolar disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2015;54(2):116&#8211;125.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4306810</ArticleId>
						<ArticleId IdType="pubmed">25617252</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Weinstein SM, Van Meter A, Katz AC, Peters AT, West AE. Cognitive and family correlates of current suicidal ideation in children with bipolar disorder. Journal of affective disorders. 2015;173:15&#8211;21.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4258538</ArticleId>
						<ArticleId IdType="pubmed">25462390</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>West AE, Pavuluri MN. Psychosocial treatments for childhood and adolescent bipolar disorder. Child and Adolescent Psychiatric Clinics of North America. 2009;18(2):471&#8211;482.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19264274</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>West AE, Weinstein SM, Peters AT, Katz AC, Henry DB, Cruz RA, Pavuluri MN. Child-and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: a randomized clinical trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2014;53(11):1168&#8211;1178. e1161.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4254579</ArticleId>
						<ArticleId IdType="pubmed">25440307</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429&#8211;435.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">30047784</PMID>
			<DateCompleted>
				<Year>2019</Year>
				<Month>10</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>10</Month>
				<Day>23</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1440-1614</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>52</Volume>
						<Issue>9</Issue>
						<PubDate>
							<Year>2018</Year>
							<Month>Sep</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Australian and New Zealand journal of psychiatry</Title>
					<ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>The impact of substance use disorders on recovery from bipolar depression: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder psychosocial treatment trial.</ArticleTitle>
				<Pagination>
					<StartPage>847</StartPage>
					<EndPage>855</EndPage>
					<MedlinePgn>847-855</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867418788172</ELocationID>
				<Abstract>
					<AbstractText Label="OBJECTIVE">Up to 60% of patients with bipolar disorder develop a substance use disorder during their lifetime. The purpose of this paper was to assess the impact of substance use disorders on depression recovery among bipolar patients randomly assigned to different psychotropic medications and psychosocial interventions. We hypothesized that patients with a comorbid substance use disorder would benefit less from psychotherapy regardless of treatment intensity/length compared to patients without a comorbid substance use disorder.</AbstractText>
					<AbstractText Label="METHOD">We conducted post hoc analyses among bipolar disorder patients ( n&#8201;=&#8201;270) with and without comorbid substance use disorders enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder randomized psychosocial intervention trial. All patients entered during or shortly after the onset of a bipolar depressive episode. Logistic regression and Cox proportional hazard models were used to assess whether current or past substance use disorders moderated the response of patients to intensive psychosocial intervention or brief psychoeducation with collaborative care, operationalized as full recovery from an episode of bipolar depression.</AbstractText>
					<AbstractText Label="RESULTS">Current comorbid substance use disorders significantly predicted likelihood of recovery (odds ratio&#8201;=&#8201;2.25, p&#8201;=&#8201;0.025) and time to recovery (odds ratio&#8201;=&#8201;1.71, p&#8201;=&#8201;0.006) from bipolar depression. We found that 74.5% of patients with a current substance use disorder, compared to 56.5% without a current substance use disorder, recovered from bipolar depression. Past substance use disorders did not predict likelihood of recovery or time to recovery. Current substance use disorders did not significantly moderate response to intensive psychotherapy versus collaborative care.</AbstractText>
					<AbstractText Label="CONCLUSION">Contrary to our hypotheses, bipolar disorder participants with a current comorbid substance use disorder were more likely to recover from psychosocial treatment for bipolar depression than patients without a current comorbid substance use disorder. If this finding is replicated, it has implications for the ordering of treatment for patients with comorbid bipolar disorder and substance use disorders.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Gold</LastName>
						<ForeName>Alexandra K</ForeName>
						<Initials>AK</Initials>
						<AffiliationInfo>
							<Affiliation>1 Department of Psychological &amp; Brain Sciences, Boston University, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Peters</LastName>
						<ForeName>Amy T</ForeName>
						<Initials>AT</Initials>
						<AffiliationInfo>
							<Affiliation>2 Department of Psychology, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Otto</LastName>
						<ForeName>Michael W</ForeName>
						<Initials>MW</Initials>
						<AffiliationInfo>
							<Affiliation>1 Department of Psychological &amp; Brain Sciences, Boston University, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sylvia</LastName>
						<ForeName>Louisa G</ForeName>
						<Initials>LG</Initials>
						<AffiliationInfo>
							<Affiliation>3 Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>4 Harvard Medical School, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Magalhaes</LastName>
						<ForeName>Pedro Vieira da Silva</ForeName>
						<Initials>PVDS</Initials>
						<AffiliationInfo>
							<Affiliation>5 Departamento de Psiquiatria e Medicina Legal, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Berk</LastName>
						<ForeName>Michael</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>6 Impact Strategic Research Centre, Deakin University, Melbourne, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>7 Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dougherty</LastName>
						<ForeName>Darin D</ForeName>
						<Initials>DD</Initials>
						<AffiliationInfo>
							<Affiliation>3 Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>4 Harvard Medical School, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Miklowitz</LastName>
						<ForeName>David J</ForeName>
						<Initials>DJ</Initials>
						<AffiliationInfo>
							<Affiliation>8 Department of Psychiatry, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Frank</LastName>
						<ForeName>Ellen</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>9 Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nierenberg</LastName>
						<ForeName>Andrew A</ForeName>
						<Initials>AA</Initials>
						<AffiliationInfo>
							<Affiliation>3 Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>4 Harvard Medical School, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Deckersbach</LastName>
						<ForeName>Thilo</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>3 Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>4 Harvard Medical School, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>N01 MH080001</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>N01MH80001</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016448">Multicenter Study</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2018</Year>
					<Month>07</Month>
					<Day>26</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Aust N Z J Psychiatry</MedlineTA>
				<NlmUniqueID>0111052</NlmUniqueID>
				<ISSNLinking>0004-8674</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011613">Psychotherapy</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011619">Psychotropic Drugs</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D019966">Substance-Related Disorders</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">alcohol use disorders</Keyword>
				<Keyword MajorTopicYN="N">drug use disorders</Keyword>
				<Keyword MajorTopicYN="N">psychotherapy</Keyword>
				<Keyword MajorTopicYN="N">substance use disorders</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2018</Year>
					<Month>7</Month>
					<Day>27</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2019</Year>
					<Month>10</Month>
					<Day>15</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2018</Year>
					<Month>7</Month>
					<Day>27</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2019</Year>
					<Month>10</Month>
					<Day>5</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">30047784</ArticleId>
				<ArticleId IdType="mid">NIHMS1052911</ArticleId>
				<ArticleId IdType="pmc">PMC6778400</ArticleId>
				<ArticleId IdType="doi">10.1177/0004867418788172</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Cerullo MA and Strakowski SM (2007) The prevalence and significance of substance use disorders in bipolar type I and II disorder. Substance Abuse Treatment, Prevention, and Policy 2: 29.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2094705</ArticleId>
						<ArticleId IdType="pubmed">17908301</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Deckersbach T, Peters AT, Sylvia L, et al. (2014) Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD. American Journal of Psychiatry 171: 178&#8211;186.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3946300</ArticleId>
						<ArticleId IdType="pubmed">24077657</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Frye MA and Salloum IM (2006) Bipolar disorder and comorbid alcoholism: Prevalence rate and treatment considerations. Bipolar Disorders 8: 677&#8211;685.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17156154</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gold AK, Otto MW, Deckersbach T, et al. (2018) Substance use comorbidity in bipolar disorder: A qualitative review of treatment strategies and outcomes. American Journal on Addictions 27: 188&#8211;201.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">29596721</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Inder ML, Crowe MT, Luty SE, et al. (2015) Randomized, controlled trial of interpersonal and social rhythm therapy for young people with bipolar disorder. Bipolar Disord 17: 128&#8211;138.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">25346391</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Jaffee WB, Griffin ML, Gallop R, et al. (2009) Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders. Journal of Clinical Psychiatry 70: 171&#8211;176.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2713748</ArticleId>
						<ArticleId IdType="pubmed">19192456</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kessler R (1999) Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey In: Tohen M (ed.) Comorbidity in Affective Disorders. New York: Marcel Dekker, pp. 1&#8211;27.</Citation>
				</Reference>
				<Reference>
					<Citation>Kilbourne AM, Biswas K, Pirraglia PA, et al. (2009) Is the collaborative chronic care model effective for patients with bipolar disorder and co-occurring conditions? Journal of Affective Disorders 112: 256&#8211;261.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">18504059</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Levin FR and Hennessy G (2004) Bipolar disorder and substance abuse. Biological Psychiatry 56: 738&#8211;748.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15556118</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>McElroy SL, Altshuler LL, Suppes T, et al. (2001) Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. American Journal of Psychiatry 158: 420&#8211;426.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11229983</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Manwani SG, Pardo TB, Albanese MJ, et al. (2006) Substance use disorder and other predictors of antidepressant-induced mania: A retrospective chart review. Journal of Clinical Psychiatry 67: 1341&#8211;1345.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17017819</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ and Otto MW (2007) Psychosocial interventions for bipolar disorder: A review of literature and introduction of the systematic treatment enhancement program. Psychopharmacology Bulletin 40: 116&#8211;131.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">18227782</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Otto MW, Frank E, et al. (2007) Psychosocial treatments for bipolar depression: A 1-year randomized trial from the systematic treatment enhancement program. Archives of General Psychiatry 64: 419&#8211;426.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3579612</ArticleId>
						<ArticleId IdType="pubmed">17404119</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mitchell JD, Brown ES and Rush AJ (2007) Comorbid disorders in patients with bipolar disorder and concomitant substance dependence. Journal of Affective Disorders 102: 281&#8211;287.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2735053</ArticleId>
						<ArticleId IdType="pubmed">17291591</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nery FG and Soares JC (2011) Comorbid bipolar disorder and substance abuse: Evidence-based options: Medication selection May very based on which substance patients abuse. Current Psychiatry 10: 57.</Citation>
				</Reference>
				<Reference>
					<Citation>Ostacher MJ, Perlis RH, Nierenberg AA, et al. (2010) Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: Prospective data from the systematic treatment enhancement program for bipolar disorder (STEP-BD). American Journal of Psychiatry 167: 289&#8211;297.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2918249</ArticleId>
						<ArticleId IdType="pubmed">20008948</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Peters AT, Shesler LW, Sylvia L, et al. (2016) Medical burden, body mass index and the outcome of psychosocial interventions for bipolar depression. Australian and New Zealand Journal of Psychiatry 50: 667&#8211;677.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">26590023</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Peters AT, Sylvia LG, Magalhaes PV, et al. (2014) Age at onset, course of illness and response to psychotherapy in bipolar disorder: Results from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Psychological Medicine 44: 3455&#8211;3467.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4620042</ArticleId>
						<ArticleId IdType="pubmed">25066366</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sachs GS, Guille C and McMurrich SL (2002) A clinical monitoring form for mood disorders. Bipolar Disorders 4: 323&#8211;327.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12479665</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sachs GS, Thase ME, Otto MW, et al. (2003) Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry 53: 1028&#8211;1042.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12788248</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sagman D and Tohen M (2009) Comorbidity in bipolar disorder. Psychiatric Times, 24 May, pp. 1&#8211;5.</Citation>
				</Reference>
				<Reference>
					<Citation>Salloum IM and Thase ME (2000) Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2: 269&#8211;280.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11249805</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sheehan DV, Lecrubier Y, Sheehan KH, et al. (1998) The mini-international neuropsychiatric interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59: 22&#8211;23.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9881538</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Tolliver BK (2010) Bipolar disorder and substance abuse: Overcome the challenges of &#8216;dual diagnosis&#8217; patients. Current Psychiatry 9: 33&#8211;38.</Citation>
				</Reference>
				<Reference>
					<Citation>Weiss RD, Griffin ML, Jaffee WB, et al. (2009) A &#8216;community-friendly&#8217; version of integrated group therapy for patients with bipolar disorder and substance dependence: A randomized controlled trial. Drug and Alcohol Dependence 104: 212&#8211;219.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2735139</ArticleId>
						<ArticleId IdType="pubmed">19573999</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Weiss RD, Griffin ML, Kolodziej ME, et al. (2007) A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. American Journal of Psychiatry 164: 100&#8211;107.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17202550</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Weiss RD, Najavits LM and Greenfield SF (1999) A relapse prevention group for patients with bipolar and substance use disorders. Journal of Substance Abuse Treatment 16: 47&#8211;54.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9888121</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Weiss RD, Ostacher MJ, Otto MW, et al. (2005) Does recovery from substance use disorder matter in patients with bipolar disorder? Journal of Clinical Psychiatry 66: 730&#8211;735.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15960566</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">35985201</PMID>
			<DateCompleted>
				<Year>2022</Year>
				<Month>09</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2023</Year>
				<Month>12</Month>
				<Day>01</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1873-7714</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>78</Volume>
						<PubDate>
							<Year>2022</Year>
							<Season>Sep-Oct</Season>
						</PubDate>
					</JournalIssue>
					<Title>General hospital psychiatry</Title>
					<ISOAbbreviation>Gen Hosp Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Bipolar disorder in primary care: Medication treatment by co-located psychiatrists versus primary care clinicians supported by psychiatrists.</ArticleTitle>
				<Pagination>
					<StartPage>108</StartPage>
					<EndPage>110</EndPage>
					<MedlinePgn>108-110</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.genhosppsych.2022.08.001</ELocationID>
				<ELocationID EIdType="pii" ValidYN="Y">S0163-8343(22)00097-4</ELocationID>
				<Abstract>
					<AbstractText Label="OBJECTIVE">To compare medication treatment of individuals with bipolar disorder in two primary care-based integrated care models.</AbstractText>
					<AbstractText Label="METHODS">Participants were randomized to 12-months of treatment with direct care by co-located psychiatrists in primary care, or collaborative care (primary care clinicians supported by psychiatrists). Medication data at initial and last treatment visits were extracted from the clinical registry for 191 patients diagnosed with bipolar disorder.</AbstractText>
					<AbstractText Label="RESULTS">Participants receiving no medication treatment decreased from 28% to 11% (direct co-located) (&#967;
						<sup>2</sup>&#160;=&#160;10.9, p&#160;&lt;&#160;.001) and 39% to 17% (collaborative care; &#967;
						<sup>2</sup>&#160;=&#160;16.9, p&#160;&lt;&#160;.001). Last visit medication prescriptions for antipsychotic medication (approximately one-half of participants) increased significantly compared to initial visit and did not differ between arms. Anticonvulsant mood-stabilizing medication (approximately one-third of participants in both arms) was higher than lithium prescription (approximately 6% of participants) at last visit.
					</AbstractText>
					<AbstractText Label="CONCLUSION">Similar patterns of medication treatment were observed in participants with bipolar disorder receiving either direct care from psychiatrists, or medication treatment by primary care clinicians supported by psychiatrists.</AbstractText>
					<CopyrightInformation>Copyright &#169; 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Cerimele</LastName>
						<ForeName>Joseph M</ForeName>
						<Initials>JM</Initials>
						<AffiliationInfo>
							<Affiliation>University of Washington School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, United States of America. Electronic address: cerimele@uw.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Johnson</LastName>
						<ForeName>Morgan</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>University of Washington School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, United States of America.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Blanchard</LastName>
						<ForeName>Brittany E</ForeName>
						<Initials>BE</Initials>
						<AffiliationInfo>
							<Affiliation>University of Washington School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, United States of America.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Russo</LastName>
						<ForeName>Joan</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>University of Washington School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, United States of America.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Un&#252;tzer</LastName>
						<ForeName>J&#252;rgen</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>University of Washington School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, United States of America.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fortney</LastName>
						<ForeName>John C</ForeName>
						<Initials>JC</Initials>
						<AffiliationInfo>
							<Affiliation>University of Washington School of Medicine, Department of Psychiatry &amp; Behavioral Sciences, United States of America; Department of Veterans Affairs, HSR&amp;D Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound Health Care System, United States of America.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>KL2 TR002317</GrantID>
						<Acronym>TR</Acronym>
						<Agency>NCATS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2022</Year>
					<Month>08</Month>
					<Day>04</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Gen Hosp Psychiatry</MedlineTA>
				<NlmUniqueID>7905527</NlmUniqueID>
				<ISSNLinking>0163-8343</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D014150">Antipsychotic Agents</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011307">Drug Prescriptions</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011320">Primary Health Care</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D011570">Psychiatry</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">Collaborative care</Keyword>
				<Keyword MajorTopicYN="N">Medication</Keyword>
				<Keyword MajorTopicYN="N">Primary care</Keyword>
				<Keyword MajorTopicYN="N">Telepsychiatry</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2022</Year>
					<Month>6</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="revised">
					<Year>2022</Year>
					<Month>8</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2022</Year>
					<Month>8</Month>
					<Day>3</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2022</Year>
					<Month>8</Month>
					<Day>20</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2022</Year>
					<Month>9</Month>
					<Day>15</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2022</Year>
					<Month>8</Month>
					<Day>19</Day>
					<Hour>18</Hour>
					<Minute>25</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>29</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">35985201</ArticleId>
				<ArticleId IdType="mid">NIHMS1946814</ArticleId>
				<ArticleId IdType="pmc">PMC10686540</ArticleId>
				<ArticleId IdType="doi">10.1016/j.genhosppsych.2022.08.001</ArticleId>
				<ArticleId IdType="pii">S0163-8343(22)00097-4</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. 20-year trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry 2020;177(8):706&#8211;15.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7577523</ArticleId>
						<ArticleId IdType="pubmed">32312111</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rhee TG, Olfson M, Wilkinson ST. Changes in pharmacotherapy approaches in the treatment of bipolar disorder by primary care physicians. Gen Hosp Psychiatry 2020;67:141&#8211;3.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">32184005</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Duncan MH, Erickson J, Chang D, et al. Psychiatry&#8217;s expanded integration into primary care. Psychiatr Clin North Am 2022;45:71&#8211;80.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">35219443</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Fortney JC, Bauer AM, Cerimele JM, et al. Comparison of teleintegrated care and telereferral care for treating complex psychiatric disorders in primary care: a pragmatic randomized comparative effectiveness trial. JAMA Psychiat 2021;78 (11):1189&#8211;99.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8387948</ArticleId>
						<ArticleId IdType="pubmed">34431972</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Fortney JC, Heagerty PJ, Bauer AM, et al. Study to promote innovation in rural integrated Telepsychiatry (SPIRIT): rationale and Design of a Randomized Comparative Effectiveness Trial of managing complex psychiatric disorders in rural primary care clinics. Contemp Clin Trials 2020;90:105873. 10.1016/jcct.2019.105873.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/jcct.2019.105873</ArticleId>
						<ArticleId IdType="pubmed">31678410</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cerimele JM, LePoire E, Fortney JC, et al. Bipolar disorder and PTSD screening and telepsychiatry diagnoses in primary care. Gen Hosp Psychiatry 2020;65:28&#8211;32.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">32447194</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ghaemi SH, Hsu DJ, Thase ME, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 2006;57:660&#8211;5.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16675760</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Un&#252;tzer J, Simon G, Pabiniak C, Bond K, Katon W. The use of administrative data to assess quality of care for bipolar disorder in a large staff model HMO. Gen Hosp Psychiatry 2000;22:1&#8211;10.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">10715498</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cerimele JM, Fortney JC, Pyne JM, Curran GM. Bipolar disorder in primary care: a qualitative study of clinician and patient experiences with diagnosis and treatment. Fam Practice 2019;36(1):32&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6346633</ArticleId>
						<ArticleId IdType="pubmed">29659789</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Phelps JR, Pipitone OR, Squires K, Bale JD. Lamotrigine and lithium in primary care psychiatric consultation: adoption and adverse effects. Fam Pract 2021;38: 381&#8211;6.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">33367908</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">37923395</PMID>
			<DateCompleted>
				<Year>2023</Year>
				<Month>12</Month>
				<Day>22</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2024</Year>
				<Month>02</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1399-5618</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>25</Volume>
						<Issue>8</Issue>
						<PubDate>
							<Year>2023</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Bipolar disorders</Title>
					<ISOAbbreviation>Bipolar Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Bipolar disorder assessment and monitoring measures in clinical care: Updates from a large randomized controlled trial in primary care.</ArticleTitle>
				<Pagination>
					<StartPage>708</StartPage>
					<EndPage>710</EndPage>
					<MedlinePgn>708-710</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.13382</ELocationID>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Cerimele</LastName>
						<ForeName>Joseph M</ForeName>
						<Initials>JM</Initials>
						<Identifier Source="ORCID">0000-0002-8640-7412</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fortney</LastName>
						<ForeName>John C</ForeName>
						<Initials>JC</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Veterans Affairs, HSR&amp;D Center of Innovation for Veteran-Centered and Value-Driven Care, VA Puget Sound Health Care System, Seattle, Washington, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>R34 MH125935</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>PCS-1406-19295</GrantID>
						<Acronym>PCORI</Acronym>
						<Agency>Patient-Centered Outcomes Research Institute</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>R34MH125935</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>03</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>Denmark</Country>
				<MedlineTA>Bipolar Disord</MedlineTA>
				<NlmUniqueID>100883596</NlmUniqueID>
				<ISSNLinking>1398-5647</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011320">Primary Health Care</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<CoiStatement>
				<b>Conflicts of Interest:</b> Dr. Cerimele and Dr. Fortney report no conflicts of interest. 
				<b>Ethical approval:</b> The authors have no financial conflict of interest related to this article.
			</CoiStatement>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2024</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2023</Year>
					<Month>12</Month>
					<Day>22</Day>
					<Hour>6</Hour>
					<Minute>43</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>6</Day>
					<Hour>1</Hour>
					<Minute>19</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>3</Day>
					<Hour>21</Hour>
					<Minute>40</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">37923395</ArticleId>
				<ArticleId IdType="mid">NIHMS1941013</ArticleId>
				<ArticleId IdType="pmc">PMC10872806</ArticleId>
				<ArticleId IdType="doi">10.1111/bdi.13382</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Fortney JC, Bauer AM, Cerimele JM, Pyne JM, Pfeiffer P, Heagerty PJ, Hawrilenko M, Zielinski MJ, Kaysen D, Bowen DJ, Moore DL, Ferro L, Metzger K, Shushan S, Hafer E, Nolan JP, Dalack GW, Un&#252;tzer J. A pragmatic randomized comparative effectiveness trial of tele-integrated care and tele-referral care for treating complex psychiatric disorders in primary care. JAMA Psychiatry. 2021;78:1189&#8211;1199.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8387948</ArticleId>
						<ArticleId IdType="pubmed">34431972</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cerimele JM, LePoire E, Fortney JC, Hawrilenko M, Un&#252;tzer J, Bauer AM. Bipolar disorder and PTSD screening and telepsychiatry diagnoses in primary care. Gen Hosp Psychiatry. 2020;65:28&#8211;32.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">32447194</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nierenberg AA, Ostacher MJ, Borrelli DJ, et al. The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry. J Clin Psychiatry. 2006;67:3&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17029489</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cerimele JM, Russo J, Bauer AM, Hawrilenko M, Pyne JM, Dalack GW, Kroenke K, Un&#252;tzer J, Fortney JC. The Patient Mania Questionnaire (PMQ-9): a brief scale for assessing and monitoring manic symptoms. J Gen Intern Med. 2022;37:1680&#8211;1687.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC9130397</ArticleId>
						<ArticleId IdType="pubmed">34145517</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cerimele JM, Blanchard BE, Bechtel JM, Fortney JC. Clinician preferences for using bipolar disorder symptom severity and quality of life scales for measurement-based care. Gen Hosp Psychiatry. 2021;73:123&#8211;125.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8928783</ArticleId>
						<ArticleId IdType="pubmed">34392976</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">9513752</PMID>
			<DateCompleted>
				<Year>1998</Year>
				<Month>05</Month>
				<Day>05</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>15</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-3223</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>43</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1998</Year>
							<Month>Mar</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Biological psychiatry</Title>
					<ISOAbbreviation>Biol Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Bipolar disorder in adult patients with Tourette's syndrome: a clinical study.</ArticleTitle>
				<Pagination>
					<StartPage>364</StartPage>
					<EndPage>370</EndPage>
					<MedlinePgn>364-70</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although recent clinical and epidemiological studies indicate that Tourette's syndrome (TS) is associated with a higher than expected rate of bipolar disorder (BPD), the clinical characteristics of BPD in patients with TS have not been widely investigated.</AbstractText>
					<AbstractText Label="METHODS" NlmCategory="METHODS">Thirty adult TS patients with comorbid BPD were selected from a consecutive series of 90 referred TS patients and examined using structured psychiatric rating scales.</AbstractText>
					<AbstractText Label="RESULTS" NlmCategory="RESULTS">The full clinical spectrum of BPD was found, including bipolar I disorder, schizoaffective bipolar disorder, bipolar II disorder, and cyclothymic disorder. Atypical vegetative depressive symptoms, rapid cycling patterns, and seasonal patterns of recurrence were also documented. In the present clinical sample, BPD mainly occurred in patients with mild tic symptoms and was invariably associated with a high lifetime prevalence of general psychopathology, including generalized anxiety disorder, obsessive-compulsive disorder, panic, phobias, eating disorders, self-injurious behavior, attention-deficit hyperactivity disorder, impulse control disorders, and personality disorders.</AbstractText>
					<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of this clinical study indicate that BPD and nonaffective psychopathology may be prominent comorbid disorders in a subpopulation of patients with TS.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Berthier</LastName>
						<ForeName>M L</ForeName>
						<Initials>ML</Initials>
						<AffiliationInfo>
							<Affiliation>Neurology Service, Virgen de la Victoria University Hospital, M&#225;laga, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kulisevsky</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Campos</LastName>
						<ForeName>V M</ForeName>
						<Initials>VM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Biol Psychiatry</MedlineTA>
				<NlmUniqueID>0213264</NlmUniqueID>
				<ISSNLinking>0006-3223</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1998</Year>
					<Month>3</Month>
					<Day>26</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1998</Year>
					<Month>3</Month>
					<Day>26</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1998</Year>
					<Month>3</Month>
					<Day>26</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">9513752</ArticleId>
				<ArticleId IdType="doi">10.1016/s0006-3223(97)00025-5</ArticleId>
				<ArticleId IdType="pii">S0006-3223(97)00025-5</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">15212611</PMID>
			<DateCompleted>
				<Year>2004</Year>
				<Month>11</Month>
				<Day>02</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>17</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1465-6566</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>5</Volume>
						<Issue>7</Issue>
						<PubDate>
							<Year>2004</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>Expert opinion on pharmacotherapy</Title>
					<ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Olanzapine in bipolar disorder.</ArticleTitle>
				<Pagination>
					<StartPage>1613</StartPage>
					<EndPage>1619</EndPage>
					<MedlinePgn>1613-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Olanzapine is currently marketed not only for the treatment of schizophrenia, but also for the treatment of acute mania and the prevention of relapse in patients successfully treated with this drug for a manic episode. A large body of good clinical trials supports these indications. In the mania trials, olanzapine was more efficacious than placebo, equal or more efficacious than valproate and more efficacious than lithium or valproate monotherapy when used in combination with either drug. A trial that compared olanzapine with haloperidol failed to show superiority of the atypical versus the conventional. Olanzapine showed a modest but statistically significant effect in the treatment of bipolar depression; this modest effect was substantially enhanced in combination with fluoxetine. The long-term trials showed that olanzapine was better than placebo in the prevention of manic and depressive relapse and not inferior to lithium or valproate. The combination of olanzapine with lithium or valproate was also more efficacious than lithium or valproate alone in the prevention of manic relapse in patients partially non-responding to monotherapy with lithium or valproate. All these trials suggest that olanzapine may be a valuable drug in the short- and long-term treatment of bipolar I disorder. However, there are some concerns about the safety and tolerability of olanzapine in this population, as far as weight gain and metabolic syndrome are concerned, which may be addressed in future pharmacovigilance studies.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Vieta</LastName>
						<ForeName>Eduard</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>University of Barcelona, Bipolar Disorders Program, Hospital Clinic, Villarroel 170, Rossell&#243; 140, 08036 Barcelona, Spain. evieta@clinic.ub.es</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Expert Opin Pharmacother</MedlineTA>
				<NlmUniqueID>100897346</NlmUniqueID>
				<ISSNLinking>1465-6566</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>12794-10-4</RegistryNumber>
					<NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>N7U69T4SZR</RegistryNumber>
					<NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001569">Benzodiazepines</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D015337">Multicenter Studies as Topic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000077152">Olanzapine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D013030">Spain</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2004</Year>
					<Month>6</Month>
					<Day>24</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2004</Year>
					<Month>11</Month>
					<Day>4</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2004</Year>
					<Month>6</Month>
					<Day>24</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">15212611</ArticleId>
				<ArticleId IdType="doi">10.1517/14656566.5.7.1613</ArticleId>
				<ArticleId IdType="pii">EOP050716</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">29389150</PMID>
			<DateCompleted>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>13</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1939-1293</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>32</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>2018</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of family psychology : JFP : journal of the Division of Family Psychology of the American Psychological Association (Division 43)</Title>
					<ISOAbbreviation>J Fam Psychol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Family communication with teens at clinical high-risk for psychosis or bipolar disorder.</ArticleTitle>
				<Pagination>
					<StartPage>507</StartPage>
					<EndPage>516</EndPage>
					<MedlinePgn>507-516</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1037/fam0000393</ELocationID>
				<Abstract>
					<AbstractText>Previous research has found that family problem-solving interactions are more constructive and less contentious when there is a family member with bipolar disorder compared with schizophrenia. The present study extended this research by examining whether family problem-solving interactions differ between clinical high-risk (CHR) stages of each illness. Trained coders applied a behavioral coding system (O'Brien et al., 2014) to problem-solving interactions of parents and their adolescent child, conducted just prior to beginning a randomized trial of family-focused therapy. The CHR for psychosis sample included 58 families with an adolescent with attenuated positive symptoms, brief intermittent psychosis, or genetic risk and functional deterioration; the CHR for bipolar disorder sample included 44 families with an adolescent with "unspecified" bipolar disorder or major depressive disorder and at least one first or second degree relative with bipolar I or II disorder. When controlling for adolescent gender, age, functioning, and parent education, mothers of youth at CHR for psychosis displayed significantly more conflictual and less constructive communication than did mothers of youth at CHR for bipolar disorder. Youth risk classification did not have a significant relationship with youths' or fathers' communication behavior. The family environment among help-seeking adolescents may be more challenging for families with an adolescent at CHR for psychosis compared with bipolar illness. Accordingly, families of adolescents at clinical high-risk for psychosis may benefit from more intensive or focused communication training than is required by families of adolescents at clinical high-risk for bipolar disorder or other mood disorders. (PsycINFO Database Record</AbstractText>
					<CopyrightInformation>(c) 2018 APA, all rights reserved).</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Salinger</LastName>
						<ForeName>Julia M</ForeName>
						<Initials>JM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, Yale University.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>O'Brien</LastName>
						<ForeName>Mary P</ForeName>
						<Initials>MP</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, Yale University.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Miklowitz</LastName>
						<ForeName>David J</ForeName>
						<Initials>DJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, Los Angeles School of Medicine.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Marvin</LastName>
						<ForeName>Sarah E</ForeName>
						<Initials>SE</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, Los Angeles School of Medicine.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cannon</LastName>
						<ForeName>Tyrone D</ForeName>
						<Initials>TD</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, Yale University.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>R01 MH093676</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>R21 MH097007</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>R33 MH097007</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>RC1 MH088546</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016448">Multicenter Study</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2018</Year>
					<Month>02</Month>
					<Day>01</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Fam Psychol</MedlineTA>
				<NlmUniqueID>8802265</NlmUniqueID>
				<ISSNLinking>0893-3200</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D003142">Communication</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005190">Family</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005196">Family Therapy</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011618">Psychotic Disorders</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2018</Year>
					<Month>2</Month>
					<Day>2</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2019</Year>
					<Month>9</Month>
					<Day>14</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2018</Year>
					<Month>2</Month>
					<Day>2</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2018</Year>
					<Month>6</Month>
					<Day>8</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">29389150</ArticleId>
				<ArticleId IdType="mid">NIHMS959940</ArticleId>
				<ArticleId IdType="pmc">PMC5992095</ArticleId>
				<ArticleId IdType="doi">10.1037/fam0000393</ArticleId>
				<ArticleId IdType="pii">2018-04363-001</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Heinssen R. At clinical high-risk for psychosis: Outcome for nonconverters. American Journal of Psychiatry. 2011;168:800&#8211;805.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3150607</ArticleId>
						<ArticleId IdType="pubmed">21498462</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Axelson DA, Birmaher B, Strober MA, Goldstein BI, Ha W, Gill MK, Keller MB. Course of subthreshold bipolar disorder in youth: Diagnostic progression from bipolar disorder not otherwise specified. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2011;50:1001&#8211;1016.  http://dx.doi.org/10.1016/j.jaac.2011.07.005.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2011.07.005</ArticleId>
						<ArticleId IdType="pmc">PMC3185249</ArticleId>
						<ArticleId IdType="pubmed">21961775</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Betensky JD, Robinson DG, Gunduz-Bruce H, Sevy S, Lencz T, Kane JM, Szeszko PR. Patterns of stress in schizophrenia. Psychiatry Research. 2008;160:38&#8211;46.  http://dx.doi.org/10.1016/j.psychres.2007.06.001.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.psychres.2007.06.001</ArticleId>
						<ArticleId IdType="pmc">PMC2487675</ArticleId>
						<ArticleId IdType="pubmed">18514323</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blair RJR. The roles of orbital frontal cortex in the modulation of antisocial behavior. Brain and Cognition. 2004;55:198&#8211;208.  http://dx.doi.org/10.1016/S0278-2626(03)00276-8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/S0278-2626(03)00276-8</ArticleId>
						<ArticleId IdType="pubmed">15134853</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blanchard JJ, Sayers SL, Collins LM, Bellack AS. Affectivity in the problem-solving interactions of schizophrenia patients and their family members. Schizophrenia Research. 2004;69:105&#8211;117.  http://dx.doi.org/10.1016/j.schres.2003.07.008.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.schres.2003.07.008</ArticleId>
						<ArticleId IdType="pubmed">15145476</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cadenhead KS, Addington J, Cannon T, Cornblatt B, McGlashan T, Perkins D, Heinssen R. Treatment history in the psychosis prodrome: Characteristics of the North American Prodrome Longitudinal Study Cohort. Early Intervention in Psychiatry. 2010;4:220&#8211;226.  http://dx.doi.org/10.1111/j.1751-7893.2010.00183.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1751-7893.2010.00183.x</ArticleId>
						<ArticleId IdType="pmc">PMC3065350</ArticleId>
						<ArticleId IdType="pubmed">20712727</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Conger RD, Ge X, Elder GH, Jr, Lorenz FO, Simons RL. Economic stress, coercive family process, and developmental problems of adolescents. Child Development. 1994;65:541&#8211;561.  http://dx.doi.org/10.2307/1131401.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.2307/1131401</ArticleId>
						<ArticleId IdType="pubmed">8013239</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Conger RD, Wallace LE, Sun Y, Simons RL, McLoyd VC, Brody GH. Economic pressure in African American families: A replication and extension of the family stress model. Developmental Psychology. 2002;38:179&#8211;193.  http://dx.doi.org/10.1037/0012-1649.38.2.179.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0012-1649.38.2.179</ArticleId>
						<ArticleId IdType="pubmed">11881755</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cook WL, Kenny DA, Goldstein MJ. Parental affective style risk and the family system: A social relations model analysis. Journal of Abnormal Psychology. 1991;100:492&#8211;501.  http://dx.doi.org/10.1037/0021-843X.100.4.492.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0021-843X.100.4.492</ArticleId>
						<ArticleId IdType="pubmed">1757663</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>De Peri L, Crescini A, Deste G, Fusar-Poli P, Sacchetti E, Vita A. Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: A meta-analysis of controlled magnetic resonance imaging studies. Current Pharmaceutical Design. 2012;18:486&#8211;494.  http://dx.doi.org/10.2174/138161212799316253.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.2174/138161212799316253</ArticleId>
						<ArticleId IdType="pubmed">22239579</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Frith CD, Frith U. The neural basis of mentalizing. Neuron. 2006;50:531&#8211;534.  http://dx.doi.org/10.1016/j.neuron.2006.05.001.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.neuron.2006.05.001</ArticleId>
						<ArticleId IdType="pubmed">16701204</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gee DG, Humphreys KL, Flannery J, Goff B, Telzer EH, Shapiro M, Tottenham N. A developmental shift from positive to negative connectivity in human amygdala-prefrontal circuitry. The Journal of Neuroscience. 2013;33:4584&#8211;4593.  http://dx.doi.org/10.1523/JNEUROSCI.3446-12.2013.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1523/JNEUROSCI.3446-12.2013</ArticleId>
						<ArticleId IdType="pmc">PMC3670947</ArticleId>
						<ArticleId IdType="pubmed">23467374</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hall RC. Global assessment of functioning. A modified scale. Psychosomatics: Journal of Consultation and Liaison Psychiatry. 1995;36:267&#8211;275.  http://dx.doi.org/10.1016/S0033-3182(95)71666-8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/S0033-3182(95)71666-8</ArticleId>
						<ArticleId IdType="pubmed">7638314</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hooley JM. Expressed emotion and relapse of psychopathology. Annual Review of Clinical Psychology. 2007;3:329&#8211;352.  http://dx.doi.org/10.1146/annurev.clinpsy.2.022305.095236.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1146/annurev.clinpsy.2.022305.095236</ArticleId>
						<ArticleId IdType="pubmed">17716059</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hooley JM, Gotlib IH. A diathesis-stress conceptualization of expressed emotion and clinical outcome. Applied &amp; Preventive Psychology. 2000;9:135&#8211;151.  http://dx.doi.org/10.1016/S0962-1849(05)80001-0.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/S0962-1849(05)80001-0</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Johnson SL, Roberts JE. Life events and bipolar disorder: Implications from biological theories. Psychological Bulletin. 1995;117:434&#8211;449.  http://dx.doi.org/10.1037/0033-2909.117.3.434.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0033-2909.117.3.434</ArticleId>
						<ArticleId IdType="pubmed">7777648</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Ryan N. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 1997;36:980&#8211;988.  http://dx.doi.org/10.1097/00004583-199707000-00021.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1097/00004583-199707000-00021</ArticleId>
						<ArticleId IdType="pubmed">9204677</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kim EY, Miklowitz DJ, Biuckians A, Mullen K. Life stress and the course of early-onset bipolar disorder. Journal of Affective Disorders. 2007;99:37&#8211;44.  http://dx.doi.org/10.1016/j.jad.2006.08.022.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2006.08.022</ArticleId>
						<ArticleId IdType="pmc">PMC1852465</ArticleId>
						<ArticleId IdType="pubmed">17084905</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kurtz MM, Mueser KT, Thime WR, Corbera S, Wexler BE. Social skills training and computer-assisted cognitive remediation in schizophrenia. Schizophrenia Research. 2015;162:35&#8211;41.  http://dx.doi.org/10.1016/j.schres.2015.01.020.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.schres.2015.01.020</ArticleId>
						<ArticleId IdType="pmc">PMC5146951</ArticleId>
						<ArticleId IdType="pubmed">25640526</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lewandowski KE, Cohen BM, &#214;ngur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychological Medicine. 2011;41:225&#8211;241.  http://dx.doi.org/10.1017/S0033291710001042.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1017/S0033291710001042</ArticleId>
						<ArticleId IdType="pubmed">20836900</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lisy ME, Jarvis KB, Del Bello MP, Mills NP, Weber WA, Fleck D, Adler CM. Progressive neurostructural changes in adolescent and adult patients with bipolar disorder. Bipolar Disorders. 2011;13:396&#8211;405.  http://dx.doi.org/10.1111/j.1399-5618.2011.00927.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2011.00927.x</ArticleId>
						<ArticleId IdType="pubmed">21843279</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Meneghelli A, Alpi A, Pafumi N, Patelli G, Preti A, Cocchi A. Expressed emotion in first-episode schizophrenia and in ultra high-risk patients: Results from the Programma2000 (Milan, Italy) Psychiatry Research. 2011;189:331&#8211;338.  http://dx.doi.org/10.1016/j.psychres.2011.03.021.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.psychres.2011.03.021</ArticleId>
						<ArticleId IdType="pubmed">21529969</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Chung B. Family-focused therapy for bipolar disorder: Reflections on 30 years of research. Family Process. 2016;55:483&#8211;499.  http://dx.doi.org/10.1111/famp.12237.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/famp.12237</ArticleId>
						<ArticleId IdType="pmc">PMC5922774</ArticleId>
						<ArticleId IdType="pubmed">27471058</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Goldstein MJ, Falloon IR, Doane JA. Interactional correlates of expressed emotion in the families of schizophrenics. The British Journal of Psychiatry. 1984;144:482&#8211;487.  http://dx.doi.org/10.1192/bjp.144.5.482.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.144.5.482</ArticleId>
						<ArticleId IdType="pubmed">6733371</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Goldstein MJ, Nuechterlein KH. Verbal interactions in the families of schizophrenic and bipolar affective patients. Journal of Abnormal Psychology. 1995;104:268&#8211;276.  http://dx.doi.org/10.1037/0021-843X.104.2.268.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0021-843X.104.2.268</ArticleId>
						<ArticleId IdType="pubmed">7790629</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, O&#8217;Brien MP, Schlosser DA, Addington J, Candan KA, Marshall C, Cannon TD. Family-focused treatment for adolescents and young adults at high risk for psychosis: Results of a randomized trial. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2014;53:848&#8211;858.  http://dx.doi.org/10.1016/j.jaac.2014.04.020.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2014.04.020</ArticleId>
						<ArticleId IdType="pmc">PMC4112074</ArticleId>
						<ArticleId IdType="pubmed">25062592</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Schneck CD, Singh MK, Taylor DO, George EL, Cosgrove VE, Chang KD. Early intervention for symptomatic youth at risk for bipolar disorder: A randomized trial of family-focused therapy. Journal of the American Academy of Child &amp; Adolescent Psychiatry. 2013;52:121&#8211;131.  http://dx.doi.org/10.1016/j.jaac.2012.10.007.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jaac.2012.10.007</ArticleId>
						<ArticleId IdType="pmc">PMC3558946</ArticleId>
						<ArticleId IdType="pubmed">23357439</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Schneck CD, Walshaw P, Garrett A, Singh M, Sugar C, Chang K. Early intervention for youth at high risk for bipolar disorder: A multisite randomized trial of family-focused treatment. 2017 Manuscript submitted for publication.  http://dx.doi.org/10.1111/eip.12463.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/eip.12463</ArticleId>
						<ArticleId IdType="pmc">PMC5797511</ArticleId>
						<ArticleId IdType="pubmed">28776930</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich P, Stein K, Woods SW. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: Preliminary evidence of inter-rater reliability and predictive validity. American Journal of Psychiatry. 2002;159:863&#8211;865.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11986145</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the &#8220;prodromal&#8221; sample. Schizophrenia Research. 2003;61:19&#8211;30.  http://dx.doi.org/10.1016/S0920-9964(02)00440-1.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/S0920-9964(02)00440-1</ArticleId>
						<ArticleId IdType="pubmed">12648732</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Myin-Germeys I, Peeters F, Havermans R, Nicolson NA, DeVries MW, Delespaul P, Van Os J. Emotional reactivity to daily life stress in psychosis and affective disorder: An experience sampling study. Acta Psychiatrica Scandinavica. 2003;107:124&#8211;131.  http://dx.doi.org/10.1034/j.1600-0447.2003.02025.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1034/j.1600-0447.2003.02025.x</ArticleId>
						<ArticleId IdType="pubmed">12534438</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Myin-Germeys I, van Os J. Stress-reactivity in psychosis: Evidence for an affective pathway to psychosis. Clinical Psychology Review. 2007;27:409&#8211;424.  http://dx.doi.org/10.1016/j.cpr.2006.09.005.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.cpr.2006.09.005</ArticleId>
						<ArticleId IdType="pubmed">17222489</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>O&#8217;Brien MP, Miklowitz DJ, Candan KA, Marshall C, Domingues I, Walsh BC, Cannon TD. A randomized trial of family focused therapy with populations at clinical high risk for psychosis: Effects on interactional behavior. Journal of Consulting and Clinical Psychology. 2014;82:90&#8211;101.  http://dx.doi.org/10.1037/a0034667.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/a0034667</ArticleId>
						<ArticleId IdType="pmc">PMC3909734</ArticleId>
						<ArticleId IdType="pubmed">24188511</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>O&#8217;Brien MP, Miklowitz DJ, Cannon TD. Decreases in perceived maternal criticism predict improvement in subthreshold psychotic symptoms in a randomized trial of family-focused therapy for individuals at clinical high risk for psychosis. Journal of Family Psychology. 2015;29:945&#8211;951.  http://dx.doi.org/10.1037/fam0000123.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/fam0000123</ArticleId>
						<ArticleId IdType="pmc">PMC4673032</ArticleId>
						<ArticleId IdType="pubmed">26168262</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>O&#8217;Brien MP, Zinberg JL, Ho L, Rudd A, Kopelowicz A, Daley M, Cannon TD. Family problem solving interactions and 6-month symptomatic and functional outcomes in youth at ultra-high risk for psychosis and with recent onset psychotic symptoms: A longitudinal study. Schizophrenia Research. 2009;107:198&#8211;205.  http://dx.doi.org/10.1016/j.schres.2008.10.008.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.schres.2008.10.008</ArticleId>
						<ArticleId IdType="pmc">PMC2737734</ArticleId>
						<ArticleId IdType="pubmed">18996681</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Palmier-Claus JE, Dunn G, Lewis SW. Emotional and symptomatic reactivity to stress in individuals at ultra-high risk of developing psychosis. Psychological Medicine. 2012;42:1003&#8211;1012.  http://dx.doi.org/10.1017/S0033291711001929.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1017/S0033291711001929</ArticleId>
						<ArticleId IdType="pubmed">22067414</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Poznanski EO, Mokros HB. Children&#8217;s Depression Rating Scale, Revised (CDRS-R) manual. Los Angeles, CA: Western Psychological Services; 1995.</Citation>
				</Reference>
				<Reference>
					<Citation>Reichenbert A, Weiser M, Rabinowitz J, Caspi A, Schmeidler J, Mark M, Davidson M. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. The American Journal of Psychiatry. 2002;159:2027&#8211;2035.  http://dx.doi.org/10.1176/appi.ajp.159.12.2027.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.159.12.2027</ArticleId>
						<ArticleId IdType="pubmed">12450952</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rosenfarb IS, Goldstein MJ, Mintz J, Nuechterlein KH. Expressed emotion and subclinical psychopathology observable within the transactions between schizophrenic patients and their family members. Journal of Abnormal Psychology. 1995;104:259&#8211;267.  http://dx.doi.org/10.1037/0021-843X.104.2.259.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0021-843X.104.2.259</ArticleId>
						<ArticleId IdType="pubmed">7790628</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rosenfarb IS, Miklowitz DJ, Goldstein MJ, Harmon L, Nuech-terlein KH, Rea MM. Family transactions and relapse in bipolar disorder. Family Process. 2001;40:5&#8211;14.  http://dx.doi.org/10.1111/j.1545-5300.2001.4010100005.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1545-5300.2001.4010100005.x</ArticleId>
						<ArticleId IdType="pubmed">11288369</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Schlosser DA, Zinberg JL, Loewy RL, Casey-Cannon S, O&#8217;Brien MP, Bearden CE, Cannon TD. Predicting the longitudinal effects of the family environment on prodromal symptoms and functioning in patients at-risk for psychosis. Schizophrenia Research. 2010;118:69&#8211;75.  http://dx.doi.org/10.1016/j.schres.2010.01.017.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.schres.2010.01.017</ArticleId>
						<ArticleId IdType="pmc">PMC2856759</ArticleId>
						<ArticleId IdType="pubmed">20171848</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A children&#8217;s global assessment scale (CGAS) Archives of General Psychiatry. 1983;40:1228&#8211;1231.  http://dx.doi.org/10.1001/archpsyc.1983.01790100074010.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.1983.01790100074010</ArticleId>
						<ArticleId IdType="pubmed">6639293</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Dunbar GC. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry. 1998;59:22&#8211;33.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9881538</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin. 1979;86:420&#8211;428.  http://dx.doi.org/10.1037/0033-2909.86.2.420.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0033-2909.86.2.420</ArticleId>
						<ArticleId IdType="pubmed">18839484</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Simoneau TL, Miklowitz DJ, Goldstein MJ, Nuechterlein KH, Richards JA. Nonverbal interactional behavior in the families of persons with schizophrenic and bipolar disorders. Family Process. 1996;35:83&#8211;102.  http://dx.doi.org/10.1111/j.1545-5300.1996.00083.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1545-5300.1996.00083.x</ArticleId>
						<ArticleId IdType="pubmed">8804968</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Skjelstad DV, Malt UF, Holte A. Symptoms and signs of the initial prodrome of bipolar disorder: A systematic review. Journal of Affective Disorders. 2010;126:1&#8211;13.  http://dx.doi.org/10.1016/j.jad.2009.10.003.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2009.10.003</ArticleId>
						<ArticleId IdType="pubmed">19883943</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ, Pantelis C. Progressive brain structural changes mapped as psychosis develops in &#8220;at risk&#8221; individuals. Schizophrenia Research. 2009;108:85&#8211;92.  http://dx.doi.org/10.1016/j.schres.2008.11.026.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.schres.2008.11.026</ArticleId>
						<ArticleId IdType="pmc">PMC2670732</ArticleId>
						<ArticleId IdType="pubmed">19138834</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>van Lissa CJ, Hawk ST, de Wied M, Koot HM, van Lier P, Meeus W. The longitudinal interplay of affective and cognitive empathy within and between adolescents and mothers. Developmental Psychology. 2014;50:1219&#8211;1225.  http://dx.doi.org/10.1037/a0035050.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/a0035050</ArticleId>
						<ArticleId IdType="pubmed">24219315</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Walker EF, Diforio D. Schizophrenia: A neural diathesis-stress model. Psychological Review. 1997;104:667&#8211;685.  http://dx.doi.org/10.1037/0033-295X.104.4.667.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1037/0033-295X.104.4.667</ArticleId>
						<ArticleId IdType="pubmed">9337628</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Walker E, Kestler L, Bollini A, Hochman KM. Schizophrenia: Etiology and course. Annual Review of Psychology. 2004;55:401&#8211;430.  http://dx.doi.org/10.1146/annurev.psych.55.090902.141950.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1146/annurev.psych.55.090902.141950</ArticleId>
						<ArticleId IdType="pubmed">14744221</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Weintraub MJ, Weisman de Mamani A, Timpano KR. Physiological and mood reactivity to praise comments in individuals at high-risk for psychosis. Poster presented at the Annual Convention of the Association for Behavioral and Cognitive Therapies; New York City, NY: 2016. Oct,</Citation>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. The British Journal of Psychiatry. 1978;133:429&#8211;435.  http://dx.doi.org/10.1192/bjp.133.5.429.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.133.5.429</ArticleId>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">12656935</PMID>
			<DateCompleted>
				<Year>2003</Year>
				<Month>07</Month>
				<Day>08</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>03</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1398-5647</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>5</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>2003</Year>
							<Month>Feb</Month>
						</PubDate>
					</JournalIssue>
					<Title>Bipolar disorders</Title>
					<ISOAbbreviation>Bipolar Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Valproate, bipolar disorder and polycystic ovarian syndrome.</ArticleTitle>
				<Pagination>
					<StartPage>28</StartPage>
					<EndPage>35</EndPage>
					<MedlinePgn>28-35</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persons with bipolar disorder are often overweight and cluster risk factors for cardiovascular disease. Some antibipolar agents adversely impact upon weight and the lipid milieu. Recent data suggest that valproic acid, a commonly prescribed mood stabilizer, may be associated with polycystic ovarian syndrome (PCOS). This adverse event has not been systematically studied in bipolar disorder.</AbstractText>
					<AbstractText Label="METHOD" NlmCategory="METHODS">Thirty-eight female subjects, aged 18-50 years, meeting DSM-IV criteria for bipolar I or II disorder, in any phase of illness were evaluated. Eighteen females received valproate (sodium valproate and valproic acid) and 20 females received lithium. Patients completed questions regarding their menstrual, reproductive and medical histories. During the follicular phase they were assessed for weight, body mass index (BMI kg/m2), and changes in the reproductive endocrine milieu that included morning estradiol, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex-hormone binding globulin (SHBG), androstenedione, dehydroepiandrosterone-sulfate (DHEAS), testosterone, free testosterone, prolactin and thyroid-stimulating hormone (TSH). The blood was also analyzed for fasting metabolic parameters which included total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), insulin, glycosylated hemoglobin (HbA1C), insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding-protein 1 (IGFBP-1), fasting blood glucose and morning leptin.</AbstractText>
					<AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine (50%) of the valproate-treated females had menstrual abnormalities versus three (15%) of the lithium-treated females (p &lt; 0.05). Valproate-treated females had significantly higher levels of follicular phase androgen concentrations than lithium-treated females (p &lt; 0.05). Nine (50%) of females who were overweight (BMI &gt; or = 25 kg/m2) and with a history of menstrual irregularities also exhibited laboratory evidence of hyperandrogenism (p &lt; 0.05). Persons receiving valproate exhibited significant increases in fasting biochemical parameters suggestive of an adverse metabolic syndrome (p &lt; 0.05). Leptin levels were significantly elevated in the valproate-treated females (p &lt; 0.05).</AbstractText>
					<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this pilot, open-label cross-sectional study, valproate-treated females exhibited higher rates of menstrual abnormalities and biochemical evidence of both hyperandrogenism and adverse metabolic parameters when compared with lithium-treated females. These preliminary data suggest that valproate may, in some predisposed females, adversely impact upon the reproductive endocrine milieu and result in aspects of the metabolic syndrome.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>McIntyre</LastName>
						<ForeName>Roger S</ForeName>
						<Initials>RS</Initials>
						<AffiliationInfo>
							<Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. mcintyr@uhnres.utoronto.ca</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mancini</LastName>
						<ForeName>Deborah A</ForeName>
						<Initials>DA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>McCann</LastName>
						<ForeName>Sonia</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Srinivasan</LastName>
						<ForeName>Janaki</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kennedy</LastName>
						<ForeName>Sidney H</ForeName>
						<Initials>SH</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Denmark</Country>
				<MedlineTA>Bipolar Disord</MedlineTA>
				<NlmUniqueID>100883596</NlmUniqueID>
				<ISSNLinking>1398-5647</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>614OI1Z5WI</RegistryNumber>
					<NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011085">Polycystic Ovary Syndrome</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D014635">Valproic Acid</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2003</Year>
					<Month>3</Month>
					<Day>27</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2003</Year>
					<Month>7</Month>
					<Day>9</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2003</Year>
					<Month>3</Month>
					<Day>27</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">12656935</ArticleId>
				<ArticleId IdType="doi">10.1034/j.1399-5618.2003.00009.x</ArticleId>
				<ArticleId IdType="pii">009</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">37474761</PMID>
			<DateCompleted>
				<Year>2023</Year>
				<Month>10</Month>
				<Day>23</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2023</Year>
				<Month>11</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1740-634X</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>48</Volume>
						<Issue>13</Issue>
						<PubDate>
							<Year>2023</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title>
					<ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Ventral prefrontal network response to alcohol in young adults with bipolar disorder: a within-subject randomized placebo-controlled alcohol administration study.</ArticleTitle>
				<Pagination>
					<StartPage>1910</StartPage>
					<EndPage>1919</EndPage>
					<MedlinePgn>1910-1919</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41386-023-01657-6</ELocationID>
				<Abstract>
					<AbstractText>Bipolar disorder co-occurs with alcohol use disorder at a rate 3-5 times higher than the general population. We recently reported that individuals with bipolar disorder differ in the positive stimulating and anxiolytic effects of alcohol compared with healthy peers. This study used a randomized, placebo-controlled, cross-over, within-subject alcohol administration design to investigate neurobiological mechanisms within ventral prefrontal cortical (vPFC) systems that may underlie altered sensitivity to alcohol in bipolar disorder (NCT04063384). Forty-seven young adults (n&#8201;=&#8201;23 with bipolar disorder, 64% women) completed clinical assessment and two beverage administration sessions (alcohol and placebo, counter-balanced). Participants were dosed to 0.08&#8201;g% breath alcohol concentration during the alcohol condition and completed measures of subjective response to alcohol and an emotional processing fMRI task during the ascending limb. Timing during the placebo condition mirrored the alcohol session. Acute alcohol was associated with reduced functional connectivity between the insula - subcallosal cingulate cortex, and increased connectivity between the left nucleus accumbens - ventromedial PFC in bipolar disorder, but with no change in functional connectivity between these regions in healthy peers. Alcohol-related increases in nucleus accumbens - ventromedial PFC functional connectivity was associated with greater positive stimulating effects of alcohol in bipolar disorder and heavier recent alcohol use. Results suggest vPFC brain systems respond differently to acute alcohol during emotional processing in young adults with bipolar disorder compared with healthy peers, and that vPFC system responses relate to the subjective experience of intoxication and recent alcohol use.</AbstractText>
					<CopyrightInformation>&#169; 2023. American College of Neuropsychopharmacology.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kirsch</LastName>
						<ForeName>Dylan E</ForeName>
						<Initials>DE</Initials>
						<Identifier Source="ORCID">0000-0001-9935-9635</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas, Austin, TX, USA. dylankirsch@psych.ucla.edu.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Waggoner Center for Alcohol and Addiction Research, University of Texas, Austin, TX, USA. dylankirsch@psych.ucla.edu.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Institute for Neuroscience, University of Texas, Austin, TX, USA. dylankirsch@psych.ucla.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kosted</LastName>
						<ForeName>Raquel</ForeName>
						<Initials>R</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Le</LastName>
						<ForeName>Vanessa</ForeName>
						<Initials>V</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Almeida</LastName>
						<ForeName>Jorge R C</ForeName>
						<Initials>JRC</Initials>
						<Identifier Source="ORCID">0000-0002-1213-1986</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fromme</LastName>
						<ForeName>Kim</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Institute for Neuroscience, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Strakowski</LastName>
						<ForeName>Stephen M</ForeName>
						<Initials>SM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Waggoner Center for Alcohol and Addiction Research, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Institute for Neuroscience, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, University of Texas, Austin, TX, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lippard</LastName>
						<ForeName>Elizabeth T C</ForeName>
						<Initials>ETC</Initials>
						<Identifier Source="ORCID">0000-0002-0528-3308</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, University of Texas, Austin, TX, USA. elizabeth.lippard@austin.utexas.edu.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Waggoner Center for Alcohol and Addiction Research, University of Texas, Austin, TX, USA. elizabeth.lippard@austin.utexas.edu.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Institute for Neuroscience, University of Texas, Austin, TX, USA. elizabeth.lippard@austin.utexas.edu.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, University of Texas, Austin, TX, USA. elizabeth.lippard@austin.utexas.edu.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Institute of Early Life Adversity Research, University of Texas, Austin, TX, USA. elizabeth.lippard@austin.utexas.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>R21 AA027884</GrantID>
						<Acronym>AA</Acronym>
						<Agency>NIAAA NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>K01 AA027573</GrantID>
						<Acronym>AA</Acronym>
						<Agency>NIAAA NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>R01 AA020637</GrantID>
						<Acronym>AA</Acronym>
						<Agency>NIAAA NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>F31 AA029005</GrantID>
						<Acronym>AA</Acronym>
						<Agency>NIAAA NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2023</Year>
					<Month>07</Month>
					<Day>20</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Neuropsychopharmacology</MedlineTA>
				<NlmUniqueID>8904907</NlmUniqueID>
				<ISSNLinking>0893-133X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>3K9958V90M</RegistryNumber>
					<NameOfSubstance UI="D000431">Ethanol</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000000981">diagnostic imaging</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D017397">Prefrontal Cortex</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000000981">diagnostic imaging</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D009714">Nucleus Accumbens</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000431">Ethanol</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
			<CoiStatement>We do not believe any of these relationships could influence the reported results, but we report them for transparency. SMS serves as DSMB chair for Sunovion and served recently on a DMC for Otsuka. He is also a contributor to Medscape. ETCL, JRCA, and SMS received funding for a Janssen-sponsored study through University of Texas at Austin. All other authors report no conflicts of interest.</CoiStatement>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2023</Year>
					<Month>3</Month>
					<Day>16</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2023</Year>
					<Month>7</Month>
					<Day>9</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="revised">
					<Year>2023</Year>
					<Month>6</Month>
					<Day>12</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2024</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2023</Year>
					<Month>10</Month>
					<Day>23</Day>
					<Hour>0</Hour>
					<Minute>44</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2023</Year>
					<Month>7</Month>
					<Day>21</Day>
					<Hour>1</Hour>
					<Minute>12</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2023</Year>
					<Month>7</Month>
					<Day>20</Day>
					<Hour>23</Hour>
					<Minute>32</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">37474761</ArticleId>
				<ArticleId IdType="pmc">PMC10584851</ArticleId>
				<ArticleId IdType="doi">10.1038/s41386-023-01657-6</ArticleId>
				<ArticleId IdType="pii">10.1038/s41386-023-01657-6</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511&#8211;8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2232018</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Goldberg JF. Bipolar disorder with comorbid substance abuse: diagnosis, prognosis, and treatment. J Psychiatr Pr. 2001;7:109&#8211;22.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15990511</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Fleck DE, Arndt S, DelBello MP, Strakowski SM. Concurrent tracking of alcohol use and bipolar disorder symptoms. Bipolar Disord. 2006;8:338&#8211;44.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16879134</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE, Jr, et al. Effects of Co-occurring Alcohol Abuse on the Course of Bipolar Disorder Following a First Hospitalization for Mania. Arch Gen Psychiatry. 2005;62:851&#8211;858.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16061762</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ray LA, Mackillop J, Monti PM. Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. Subst Use Misuse. 2010;45:1742&#8211;65.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4703313</ArticleId>
						<ArticleId IdType="pubmed">20590398</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Quinn PD, Fromme K. Subjective response to alcohol challenge: a quantitative review. Alcohol Clin Exp Res. 2011;35:1759&#8211;70.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3183255</ArticleId>
						<ArticleId IdType="pubmed">21777258</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>King A, Vena A, Hasin DS, deWit H, O'Connor SJ, Cao D. Subjective Responses to Alcohol in the Development and Maintenance of Alcohol Use Disorder. Am J Psychiatry. 2021;178:560&#8211;571.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8222099</ArticleId>
						<ArticleId IdType="pubmed">33397141</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>King AC, McNamara PJ, Hasin DS, Cao D. Alcohol challenge responses predict future alcohol use disorder symptoms: a 6-year prospective study. Biol Psychiatry. 2014;75:798&#8211;806.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4280017</ArticleId>
						<ArticleId IdType="pubmed">24094754</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>King AC, de Wit H, McNamara PJ, Cao D. Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch Gen Psychiatry. 2011;68:389&#8211;99.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4633413</ArticleId>
						<ArticleId IdType="pubmed">21464363</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Yip SW, Doherty J, Wakeley J, Saunders K, Tzagarakis C, de Wit H, et al. Reduced subjective response to acute ethanol administration among young men with a broad bipolar phenotype. Neuropsychopharmacology. 2012;37:1808&#8211;15.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3376329</ArticleId>
						<ArticleId IdType="pubmed">22491350</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lippard ETC, Kirsch DE, Kosted R, Le V, Almeida J, Fromme K, et al. Subjective response to alcohol in young adults with bipolar disorder and recent alcohol use: a within-subject randomized placebo-controlled alcohol administration study. Psychopharmacol (Berl) 2023;240:739&#8211;753.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC10084816</ArticleId>
						<ArticleId IdType="pubmed">36695842</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Tretyak V, Kirsch DE, Radpour S, Weber WA, Fromme K, Strakowski SM, et al. Subjective Response to Alcohol: Associated Alcohol Use and Orbitofrontal Gray Matter Volume in Bipolar Disorder. J Affect Disord. 2020;279:671&#8211;679.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7812664</ArticleId>
						<ArticleId IdType="pubmed">33190118</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bjork JM, Gilman JM. The effects of acute alcohol administration on the human brain: insights from neuroimaging. Neuropharmacology. 2014;84:101&#8211;10.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3971012</ArticleId>
						<ArticleId IdType="pubmed">23978384</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gilman JM, Ramchandani VA, Davis MB, Bjork JM, Hommer DW. Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J Neurosci. 2008;28:4583&#8211;91.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2730732</ArticleId>
						<ArticleId IdType="pubmed">18448634</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Padula CB, Simmons AN, Matthews SC, Robinson SK, Tapert SF, Schuckit MA, et al. Alcohol attenuates activation in the bilateral anterior insula during an emotional processing task: a pilot study. Alcohol Alcohol. 2011;46:547&#8211;52.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3201697</ArticleId>
						<ArticleId IdType="pubmed">21665869</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gorka SM, Fitzgerald DA, King AC, Phan KL. Alcohol attenuates amygdala-frontal connectivity during processing social signals in heavy social drinkers: a preliminary pharmaco-fMRI study. Psychopharmacol (Berl) 2013;229:141&#8211;54.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3740023</ArticleId>
						<ArticleId IdType="pubmed">23584670</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Han J, Keedy S, Murray CH, Foxley S, de Wit H. Acute effects of alcohol on resting-state functional connectivity in healthy young men. Addict Behav. 2021;115:106786.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8693384</ArticleId>
						<ArticleId IdType="pubmed">33421747</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Boissoneault J, Stennett B, Robinson ME. Acute alcohol intake alters resting state functional connectivity of nucleus accumbens with pain-related corticolimbic structures. Drug Alcohol Depend. 2020;207:107811.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6981011</ArticleId>
						<ArticleId IdType="pubmed">31891860</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gorka SM, Phan KL, Childs E. Acute calming effects of alcohol are associated with disruption of the salience network. Addict Biol. 2018;23:921&#8211;930.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">28791789</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gilman JM, Ramchandani VA, Crouss T, Hommer DW. Subjective and neural responses to intravenous alcohol in young adults with light and heavy drinking patterns. Neuropsychopharmacology. 2012;37:467&#8211;77.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3242308</ArticleId>
						<ArticleId IdType="pubmed">21956438</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Paulus MP, Schuckit MA, Tapert SF, Tolentino NJ, Matthews SC, Smith TL, et al. High versus low level of response to alcohol: evidence of differential reactivity to emotional stimuli. Biol Psychiatry. 2012;72:848&#8211;55.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3433640</ArticleId>
						<ArticleId IdType="pubmed">22608014</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Weafer J, Ross TJ, O'Connor S, Stein EA, de Wit H, Childs E. Striatal activity correlates with stimulant-like effects of alcohol in healthy volunteers. Neuropsychopharmacology. 2018;43:2532&#8211;2538.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6224577</ArticleId>
						<ArticleId IdType="pubmed">30093699</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>McKenna BS, Anthenelli RM, Smith TL, Schuckit MA. Low versus high level of response to alcohol affects amygdala functional connectivity during processing of emotional stimuli. Alcohol Clin Exp Res. 2022;46:66&#8211;76.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8820383</ArticleId>
						<ArticleId IdType="pubmed">35064942</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Strakowski SM, Adler CM, Almeida J, Altshuler LL, Blumberg HP, Chang KD, et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 2012;14:313&#8211;25.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3874804</ArticleId>
						<ArticleId IdType="pubmed">22631617</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lippard ET, Mazure CM, Johnston JA, Spencer L, Weathers J, Pittman B, et al. Brain circuitry associated with the development of substance use in bipolar disorder and preliminary evidence for sexual dimorphism in adolescents. J Neurosci Res. 2017;95:777&#8211;791.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5123602</ArticleId>
						<ArticleId IdType="pubmed">27870392</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev. 2004;111:33&#8211;51.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">14756584</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>First MB, Williams JBW, Karg RS, Spitzer RL. Structured Clinical Interview for DSM-5&#8212;Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). 2015.</Citation>
				</Reference>
				<Reference>
					<Citation>Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50&#8211;5.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">13638508</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;25:56&#8211;61.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC495331</ArticleId>
						<ArticleId IdType="pubmed">14399272</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429&#8211;35.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Andreasen NC, Endicott J, Spitzer RL, Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry. 1977;34:1229&#8211;35.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">911222</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Corporation, P. Wechsler Abbreviated Scale of Intelligence Manual. 1999, San Antonio: TXHarcourt Brace and Company.</Citation>
				</Reference>
				<Reference>
					<Citation>Curtin JJ, Fairchild BA. Alcohol and cognitive control: implications for regulation of behavior during response conflict. J Abnorm Psychol. 2003;112:424&#8211;36.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12943021</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Watson PE. Total body water and blood alcohol levels: Updating the fundamentals. Hum Metab Alcohol. 1989;1:41&#8211;58.</Citation>
				</Reference>
				<Reference>
					<Citation>Patrica E, Watson IanD, Watson RDB. Prediction of Blood Alcohol Concentration in Human Subjects. J Stud Alcohol. 1981;42:547&#8211;556.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7289599</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Quinn PD, Fromme K. Individual differences in subjective alcohol responses and alcohol-related disinhibition. Exp Clin Psychopharmacol. 2016;24:90&#8211;9.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4795977</ArticleId>
						<ArticleId IdType="pubmed">26867000</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cofres&#237; RU, Bartholow BD, Fromme K. Female drinkers are more sensitive than male drinkers to alcohol-induced heart rate increase. Exp Clin Psychopharmacol. 2020;28:540&#8211;552.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7263942</ArticleId>
						<ArticleId IdType="pubmed">31789554</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Corbin WR, Hartman JD, Bruening AB, Fromme K. Contextual influences on subjective alcohol response. Exp Clin Psychopharmacol. 2021;29:48&#8211;58.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8405099</ArticleId>
						<ArticleId IdType="pubmed">32673048</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacol (Berl) 2013;227:177&#8211;92.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3624068</ArticleId>
						<ArticleId IdType="pubmed">23271193</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Yamasaki H, LaBar KS, McCarthy G. Dissociable prefrontal brain systems for attention and emotion. Proc Natl Acad Sci USA. 2002;99:11447&#8211;51.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC123276</ArticleId>
						<ArticleId IdType="pubmed">12177452</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Strakowski SM, Eliassen JC, Lamy M, Cerullo MA, Allendorfer JB, Madore M, et al. Functional magnetic resonance imaging brain activation in bipolar mania: evidence for disruption of the ventrolateral prefrontal-amygdala emotional pathway. Biol Psychiatry. 2011;69:381&#8211;8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3058900</ArticleId>
						<ArticleId IdType="pubmed">21051038</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Strakowski SM, Fleck DE, Welge J, Eliassen JC, Norris M, Durling M, et al. fMRI brain activation changes following treatment of a first bipolar manic episode. Bipolar Disord. 2016;18:490&#8211;501.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5951160</ArticleId>
						<ArticleId IdType="pubmed">27647671</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lippard ETC, Weber W, Welge J, Adler CM, Fleck DE, Almeida J, et al. Variation in Rostral Anterior Cingulate Functional Connectivity with Amygdala and Caudate during First-Manic Episode Distinguish Bipolar Young Adults who do not Remit Following Treatment. Bipolar Disord. 2021;23:500&#8211;8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC8060357</ArticleId>
						<ArticleId IdType="pubmed">33089593</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sobell LC, and Sobell MB. Timeline follow-back: A technique for assessing self-reported alcohol consumption, in Measuring alcohol consumption: Psychosocial and biochemical methods. 1992, Humana Press: Totowa, NJ, US. p. 41&#8211;72.</Citation>
				</Reference>
				<Reference>
					<Citation>Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51:768&#8211;74.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">8778124</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Whitfield-Gabrieli S, Nieto-Castanon A. Conn: A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks. Brain Connectivity. 2012;2:125&#8211;141.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">22642651</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Poldrack RA, Mumford JA, Nichols TE. Handbook of Functional MRI Data Analysis, Handbook of Functional MRI Data Analysis. 2011, Cambridge: Cambridge University Press.</Citation>
				</Reference>
				<Reference>
					<Citation>Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage. 2007;37:90&#8211;101.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2214855</ArticleId>
						<ArticleId IdType="pubmed">17560126</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cumming, G. The New Statistics &#8211; Effect Sizes, Confidence Intervals, and Meta-Analysis. 2012.</Citation>
				</Reference>
				<Reference>
					<Citation>Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods. 2008;11:364&#8211;386.</Citation>
				</Reference>
				<Reference>
					<Citation>Lenhard A, Lenhard W. Calculation of effect sizes. 2015.</Citation>
				</Reference>
				<Reference>
					<Citation>Townsend J, Altshuler LL. Emotion processing and regulation in bipolar disorder: a review. Bipolar Disord. 2012;14:326&#8211;39.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">22631618</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Strakowski, S. The Bipolar Brain: Integrating Neuroimaging and Genetics, The bipolar brain: integrating neuroimaging and genetics. 2022: Oxford University Press.</Citation>
				</Reference>
				<Reference>
					<Citation>Margulies DS, Kelly AM, Uddin LQ, Biswal BB, Castellanos FX, Milham MP. Mapping the functional connectivity of anterior cingulate cortex. Neuroimage. 2007;37:579&#8211;88.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17604651</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Johnson SL, Edge MD, Holmes MK, Carver CS. The behavioral activation system and mania. Annu Rev Clin Psychol. 2012;8:243&#8211;67.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3409638</ArticleId>
						<ArticleId IdType="pubmed">22077912</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217&#8211;38.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2805560</ArticleId>
						<ArticleId IdType="pubmed">19710631</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357&#8211;381.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3085570</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Pizzagalli DA, Goetz E, Ostacher M, Iosifescu DV, Perlis RH. Euthymic patients with bipolar disorder show decreased reward learning in a probabilistic reward task. Biol Psychiatry. 2008;64:162&#8211;8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2464620</ArticleId>
						<ArticleId IdType="pubmed">18242583</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Yip SW, Worhunsky PD, Rogers RD, Goodwin GM. Hypoactivation of the ventral and dorsal striatum during reward and loss anticipation in antipsychotic and mood stabilizer-naive bipolar disorder. Neuropsychopharmacology. 2015;40:658&#8211;66.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4289954</ArticleId>
						<ArticleId IdType="pubmed">25139065</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Schreiter S, Spengler S, Willert A, Mohnke S, Herold D, Erk S, et al. Neural alterations of fronto-striatal circuitry during reward anticipation in euthymic bipolar disorder. Psychol Med. 2016;46:3187&#8211;3198.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">27573157</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Johnson SL, Mehta H, Ketter TA, Gotlib IH, Knutson B. Neural responses to monetary incentives in bipolar disorder. NeuroImage: Clin. 2019;24:102018.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6831914</ArticleId>
						<ArticleId IdType="pubmed">31670069</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Liu R, Wang Y, Chen X, Zhang Z, Xiao L, Zhou Y. Anhedonia correlates with functional connectivity of the nucleus accumbens subregions in patients with major depressive disorder. Neuroimage Clin. 2021;30:102599.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7930634</ArticleId>
						<ArticleId IdType="pubmed">33662708</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Satterthwaite TD, Kable JW, Vandekar L, Katchmar N, Bassett DS, Baldassano CF, et al. Common and Dissociable Dysfunction of the Reward System in Bipolar and Unipolar Depression. Neuropsychopharmacology. 2015;40:2258&#8211;68.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4613620</ArticleId>
						<ArticleId IdType="pubmed">25767910</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kroemer NB, Opel N, Teckentrup V, Li M, Grotegerd D, Meinert S, et al. Functional Connectivity of the Nucleus Accumbens and Changes in Appetite in Patients With Depression. JAMA Psychiatry. 2022;79:993&#8211;1003.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC9403857</ArticleId>
						<ArticleId IdType="pubmed">36001327</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Stanton CH, Holmes AJ, Chang S, Joormann J. From Stress to Anhedonia: Molecular Processes through Functional Circuits. Trends Neurosci. 2019;42:23&#8211;42.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6344037</ArticleId>
						<ArticleId IdType="pubmed">30327143</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Dimick MK, Hird MA, Fiksenbaum LM, Mitchell R, Goldstein BI. Severe anhedonia among adolescents with bipolar disorder is common and associated with increased psychiatric symptom burden. J Psychiatr Res. 2021;134:200&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">33412423</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Heller AS, Johnstone T, Light SN, Peterson MJ, Kolden GG, Kalin NH, et al. Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment. Am J Psychiatry. 2013;170:197&#8211;206.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3563751</ArticleId>
						<ArticleId IdType="pubmed">23223803</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4350513</ArticleId>
						<ArticleId IdType="pubmed">25313512</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, et al. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord. 2014;16:119&#8211;28.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3949142</ArticleId>
						<ArticleId IdType="pubmed">24103187</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kirsch DE, Le V, Kosted R, Fromme K, Lippard E. Neural Underpinnings of Expecting Alcohol: Placebo Alcohol Administration Alters Nucleus Accumbens Resting State Functional Connectivity. Behavioural Brain Res. 2022;437:114148.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">36206822</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2011;188:361&#8211;5.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4750381</ArticleId>
						<ArticleId IdType="pubmed">21641663</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760&#8211;73.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6135092</ArticleId>
						<ArticleId IdType="pubmed">27475769</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Schuckit MA, Smith TL, Kalmijn J, Danko GP. A cross-generational comparison of alcohol challenges at about age 20 in 40 father-offspring pairs. Alcohol Clin Exp Res. 2005;29:1921&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16340447</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Carmiol N, Peralta JM, Almasy L, Contreras J, Pacheco A, Escamilla MA, et al. Shared genetic factors influence risk for bipolar disorder and alcohol use disorders. Eur Psychiatry. 2014;29:282&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4160878</ArticleId>
						<ArticleId IdType="pubmed">24321773</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rosa AR, Reinares M, Franco C, Comes M, Torrent C, S&#225;nchez-Moreno J, et al. Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord. 2009;11:401&#8211;9.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19500093</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord. 2003;5:349&#8211;55.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">14525555</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, et al. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry. 2006;67:1721&#8211;8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17196051</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bonn&#237;n CM, Mart&#237;nez-Ar&#225;n A, Torrent C, Pacchiarotti I, Rosa AR, Franco C, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord. 2010;121:156&#8211;60.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19505727</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">34118638</PMID>
			<DateCompleted>
				<Year>2021</Year>
				<Month>08</Month>
				<Day>05</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>08</Month>
				<Day>02</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1879-1379</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>140</Volume>
						<PubDate>
							<Year>2021</Year>
							<Month>Aug</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of psychiatric research</Title>
					<ISOAbbreviation>J Psychiatr Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome.</ArticleTitle>
				<Pagination>
					<StartPage>205</StartPage>
					<EndPage>213</EndPage>
					<MedlinePgn>205-213</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2021.05.082</ELocationID>
				<ELocationID EIdType="pii" ValidYN="Y">S0022-3956(21)00358-7</ELocationID>
				<Abstract>
					<AbstractText>Bipolar disorder often follows a set progression best described in stages where advanced stages are associated with poorer outcomes. Bipolar disorder is also often characterized by a predominance of episode polarity, where some individuals experience more depressive episodes (termed predominant depressive polarity) while others experience more hypo/manic episodes (termed predominant hypo/manic polarity). We examined the associations between staging and predominant polarity with measures of illness burden and treatment outcome utilizing data from a six-month comparative effectiveness trial of lithium and quetiapine in bipolar disorder (Bipolar CHOICE). We used number of self-reported lifetime mood (depressive and hypo/manic) episodes as a proxy for staging and ratio of depressive to manic episodes to define predominant polarity. Polarity and staging were correlated with several measures of burden of illness. Childhood abuse was correlated with more lifetime mood episodes, while more depressive episodes and depressive polarity were correlated with more anxiety disorder comorbidity. Depressive polarity was also correlated with more past trials of psychotropics, particularly antidepressants. However, neither staging nor predominant polarity moderated the randomized treatment effect of lithium vs. quetiapine. Number of depressive episodes in the past year was identified as a potential predictor of overall worse treatment outcome, regardless of medication condition. In conclusion, though staging and predominant episode polarity correlated with several measures of illness burden, they were not associated with differential treatment outcomes. This could be because many of our patients presented for treatment at advanced stages of illness and further highlights the need for early intervention in bipolar disorder.</AbstractText>
					<CopyrightInformation>Copyright &#169; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kamali</LastName>
						<ForeName>Masoud</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA, 02114, United States; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, United States. Electronic address: mkamali@mgh.harvard.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Pegg</LastName>
						<ForeName>Samantha</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology and Human Development, Vanderbilt University, 230 Appleton Place, Nashville, TN, 37203, United States. Electronic address: samantha.l.pegg@vanderbilt.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Janos</LastName>
						<ForeName>Jessica A</ForeName>
						<Initials>JA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, 235 East Cameron Avenue, Chapel Hill, NC, 27599, United States. Electronic address: jjanos@live.unc.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bobo</LastName>
						<ForeName>William V</ForeName>
						<Initials>WV</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, United States. Electronic address: Bobo.William@mayo.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Brody</LastName>
						<ForeName>Benjamin</ForeName>
						<Initials>B</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Weill Cornell Medical College, 525 East 68th Street, New York, NY, 10065, United States. Electronic address: jeb9083@med.cornell.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gao</LastName>
						<ForeName>Keming</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, 10524 Euclid Avenue, Cleveland, OH, 44106, United States. Electronic address: Keming.Gao@uhhospitals.org.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ketter</LastName>
						<ForeName>Terence A</ForeName>
						<Initials>TA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA, 94305, United States. Electronic address: tketter@stanford.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>McElroy</LastName>
						<ForeName>Susan L</ForeName>
						<Initials>SL</Initials>
						<AffiliationInfo>
							<Affiliation>Lindner Center of HOPE, University of Cincinnati Department of Psychiatry and Behavioral Neuroscience, 260 Stetson Street, Cincinnati, OH, 45219, United States. Electronic address: susan.mcelroy@lindnercenter.org.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>McInnis</LastName>
						<ForeName>Melvin G</ForeName>
						<Initials>MG</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Michigan, 4250 Plymouth Road, Ann Arbor, MI, 48109, United States. Electronic address: mmcinnis@med.umich.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rabideau</LastName>
						<ForeName>Dustin J</ForeName>
						<Initials>DJ</Initials>
						<AffiliationInfo>
							<Affiliation>Biostatistics Center, Massachusetts General Hospital, 50 Staniford Street, Suite 560, Boston, MA, 02114, United States; Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, United States. Electronic address: drabideau@mgh.harvard.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Reilly-Harrington</LastName>
						<ForeName>Noreen A</ForeName>
						<Initials>NA</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA, 02114, United States; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, United States. Electronic address: nharrington11@mgh.harvard.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Shelton</LastName>
						<ForeName>Richard C</ForeName>
						<Initials>RC</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Alabama at Birmingham School of Medicine, 1720 2nd Avenue S, Birmingham, AL, 35294, United States. Electronic address: rshelton@uab.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sylvia</LastName>
						<ForeName>Louisa G</ForeName>
						<Initials>LG</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA, 02114, United States; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, United States. Electronic address: lsylvia2@partners.org.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tohen</LastName>
						<ForeName>Mauricio</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of New Mexico Health Sciences Center, 2400 Tucker Avenue NE, Albuquerque, NM, 87106, United States. Electronic address: mtohen@salud.unm.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nierenberg</LastName>
						<ForeName>Andrew</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA, 02114, United States; Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, United States. Electronic address: anierenberg@mgh.harvard.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>R01 HS019371</GrantID>
						<Acronym>HS</Acronym>
						<Agency>AHRQ HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>T32 MH018921</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2021</Year>
					<Month>06</Month>
					<Day>02</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>J Psychiatr Res</MedlineTA>
				<NlmUniqueID>0376331</NlmUniqueID>
				<ISSNLinking>0022-3956</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000339">Affect</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001008">Anxiety Disorders</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D017281">Cost of Illness</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">Lithium</Keyword>
				<Keyword MajorTopicYN="N">Predominant polarity</Keyword>
				<Keyword MajorTopicYN="N">Quetiapine</Keyword>
				<Keyword MajorTopicYN="N">Staging</Keyword>
			</KeywordList>
			<CoiStatement>Conflict of Interest. 
				<b>Dr. Kamali</b> has received research grant support from Assurex Health, Janssen Pharmaceutica, and AFSP. 
				<b>Dr. Bobo</b> has been supported by NIMH, NSF, the Myocarditis Foundation, and the Mayo Foundation for Medical Education and Research. 
				<b>Dr. Ketter</b> has received: grant/research support from Agency for Healthcare Research and Quality, AstraZeneca Pharmaceuticals LP, Cephalon Inc. (now Teva Pharmaceuticals), Eli Lilly and Company, Pfizer, Inc., Merck &amp; Co., Inc., and Sunovion Pharmaceuticals; consultant/advisory board fees from Acadia Pharmaceuticals, Allergan, Inc., Avanir Pharmaceuticals, Depotmed, Forest Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Merck &amp; Co., Inc., ProPhase, Sunovion Pharmaceuticals, Teva Pharmaceuticals, Bristol-Myers Squibb Company and Cephalon, Inc; lecture honoraria from Abbott Laboratories, Inc., GlaxoSmithKline, Otsuka Pharmaceuticals, Pfizer, Inc., and AstraZeneca Pharmaceuticals LP; and royalties from American Psychiatric Publishing, Inc. 
				<b>Dr. McElroy</b> has been a consultant to or member of the scientific advisory boards of F. Hoffmann-La Roche Ltd. Idorsia, Myriad, Novo Nordisk, Otsuka, Sipnose, Sunovion and Takeda. She has been a principal or co-investigator on studies sponsored by Brainsway, Idorsia, Janssen, Marriott Foundation, Myriad, National Institute of Mental Health, Novo Nordisk, Otsuka, Sunovion. She is also an inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and along with the patent&#8217;s assignee, University of Cincinnati, Cincinnati, Ohio, has received payments from Johnson &amp; Johnson, which has exclusive rights under the patent. 
				<b>Dr. McInnis</b> has received consulting fees from Janssen and Otsuka Pharmaceuticals and research support from Janssen; he acknowledges the support of the Prechter Bipolar Research Program and the Richard Tam Foundation. 
				<b>Dr. Reilly-Harrington</b> has received royalties from New Harbinger and Oxford University Press and has served as a consultant for Guidepoint. 
				<b>Dr. Shelton</b> has received grants from Acadia Pharmaceuticals, Allergan plc, Boehringer Ingelheim, INmuneBIO, Intracellular Therapies, Neurorx, Inc., Novartis International AG, LivaNova plc, Myriad Genetics, Inc., and Otsuka Pharmaceuticals. He has served as a consultant for Acadia Pharmaceuticals, Allergan plc, Neurorx, Inc., Novartis International AG, Evecxia Therapeutics, and Seelos Therapeutics. 
				<b>Dr. Sylvia</b> has served as a consultant for United Biosource Corporation, Clintara, Bracket, and Clinical Trials Network and Institute. She receives royalties from New Harbinger. She has received grant/research support from NIMH, PCORI, AFSP, and Takeda. 
				<b>Dr. Tohen</b> is a former full-time employee at Lilly (1997&#8211;2008). He has been a consultant for AstraZeneca, Abbott, BMS, Lilly, GSK, J&amp;J, Otsuka, Roche, Lundbeck, Elan, Alkermes, Allergan, Intracellular Therapies, Merck, Minerva, Neurocrine, Pamlab, Alexza, Forest, Teva, Sunovion, and Gedeon Richter. His spouse is a former employee at Lilly (1998&#8211;2013). 
				<b>Dr. Nierenberg</b> has served on the Scientific Ad Board for Alkermes, Jazz Pharma, Sage Pharma, Otsuka, and Neuronetics. He has served as a consultant for Acadia Pharm, Esai, Myriad, Merck, Ginger, and Protogenics. He has received honoraria from Sunovion and Neurostar. 
				<b>Dr. Brody</b>, 
				<b>Dr. Gao</b>, 
				<b>Dr. Rabideau</b>, 
				<b>Ms. Pegg</b>, and 
				<b>Ms. Janos</b> declare no conflict of interest.
			</CoiStatement>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2021</Year>
					<Month>3</Month>
					<Day>11</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="revised">
					<Year>2021</Year>
					<Month>5</Month>
					<Day>25</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2021</Year>
					<Month>5</Month>
					<Day>29</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2021</Year>
					<Month>6</Month>
					<Day>13</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2021</Year>
					<Month>8</Month>
					<Day>6</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2021</Year>
					<Month>6</Month>
					<Day>12</Day>
					<Hour>20</Hour>
					<Minute>18</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2022</Year>
					<Month>8</Month>
					<Day>1</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">34118638</ArticleId>
				<ArticleId IdType="mid">NIHMS1711013</ArticleId>
				<ArticleId IdType="pmc">PMC8319086</ArticleId>
				<ArticleId IdType="doi">10.1016/j.jpsychires.2021.05.082</ArticleId>
				<ArticleId IdType="pii">S0022-3956(21)00358-7</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Baldessarini RJ, Undurraga J, V&#225;zquez GH, Tondo L, Salvatore P, Ha K, Khalsa HMK, Lepri B, Ha TH, Chang JS, Tohen M, Vieta E, 2012. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr. Scand 125, 293&#8211;302. 10.1111/j.1600-0447.2011.01818.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1600-0447.2011.01818.x</ArticleId>
						<ArticleId IdType="pubmed">22188017</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, Berk L, Conus P, McGorry PD, 2011. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 13, 87&#8211;98. 10.1111/j.1399-5618.2011.00889.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2011.00889.x</ArticleId>
						<ArticleId IdType="pubmed">21320256</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, Yatham LN, Yung A, Mcgorry P, 2007a. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 9, 671&#8211;678. 10.1111/j.1399-5618.2007.00484.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2007.00484.x</ArticleId>
						<ArticleId IdType="pubmed">17988356</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Daglas R, Dandash O, Y&#252;cel M, Henry L, Hallam K, Macneil C, Hasty M, Pantelis C, Murphy BP, Kader L, Damodaran S, Wong MTH, Conus P, Ratheesh A, McGorry PD, Cotton SM, 2017a. Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br. J. Psychiatry 210, 413&#8211;421. 10.1192/bjp.bp.116.186833</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.bp.116.186833</ArticleId>
						<ArticleId IdType="pubmed">28254958</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Dandash O, Daglas R, Cotton SM, Allott K, Fornito A, Suo C, Klauser P, Liberg B, Henry L, Macneil C, Hasty M, McGorry P, Pantelis CS, Y&#246;cel M, 2017b. Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Transl. Psychiatry 7, e1011. 10.1038/tp.2016.281</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1038/tp.2016.281</ArticleId>
						<ArticleId IdType="pmc">PMC5545739</ArticleId>
						<ArticleId IdType="pubmed">28117843</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Hallam KT, Mcgorry PD, 2007b. The potential utility of a staging model as a course specifier: A bipolar disorder perspective. J. Affect. Disord 100, 279&#8211;281. 10.1016/j.jad.2007.03.007</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2007.03.007</ArticleId>
						<ArticleId IdType="pubmed">17433450</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Post R, Ratheesh A, Gliddon E, Singh A, Vieta E, Carvalho AF, Ashton MM, Berk L, Cotton SM, McGorry PD, Fernandes BS, Yatham LN, Dodd S, 2017c. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry 16, 236&#8211;244. 10.1002/wps.20441</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1002/wps.20441</ArticleId>
						<ArticleId IdType="pmc">PMC5608827</ArticleId>
						<ArticleId IdType="pubmed">28941093</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bowden CL, Singh V, Thompson P, Gonzalez JM, Katz MM, Dahl M, Prihoda TJ, Chang X, 2007. Development of the bipolar inventory of symptoms scale. Acta Psychiatr. Scand 116, 189&#8211;194. 10.1111/j.1600-0447.2006.00955.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1600-0447.2006.00955.x</ArticleId>
						<ArticleId IdType="pubmed">17655560</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Colom F, Vieta E, Daban C, Pacchiarotti I, S&#225;nchez-Moreno J, 2006. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J. Affect. Disord 93, 13&#8211;17. 10.1016/j.jad.2006.01.032</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2006.01.032</ArticleId>
						<ArticleId IdType="pubmed">16650901</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cosci F, Fava GA, 2012. Staging of mental disorders: Systematic Review. Psychother. Psychosom 82, 20&#8211;34. 10.1159/000342243</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1159/000342243</ArticleId>
						<ArticleId IdType="pubmed">23147126</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endicott J, Nee J, Harrison W, Blumenthal R, 1993. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 29, 321&#8211;326.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">8290681</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Feighner JP, Jacobs RS, Jackson RE, Hendrickson G, Merideth CH, O&#8217;Meara PD, 1983. A double-blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders. Br. J. Clin. Pharmacol 15 Suppl 2, 227S&#8211;237S. 10.1111/j.1365-2125.1983.tb05870.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1365-2125.1983.tb05870.x</ArticleId>
						<ArticleId IdType="pmc">PMC1427892</ArticleId>
						<ArticleId IdType="pubmed">6337610</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Frank E, Nimgaonkar VL, Phillips ML, Kupfer DJ, 2015. All the world&#8217;s a (clinical) stage: rethinking bipolar disorder from a longitudinal perspective. Mol. Psychiatry 20, 23&#8211;31. 10.1038/mp.2014.71</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1038/mp.2014.71</ArticleId>
						<ArticleId IdType="pmc">PMC4303542</ArticleId>
						<ArticleId IdType="pubmed">25048003</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gonz&#225;lez-Pinto A, Alberich S, Barbeito S, Alonso M, Vieta E, Mart&#237;nez-Ar&#225;n A, Saenz M, L&#243;pez P, 2010. Different profile of substance abuse in relation to predominant polarity in bipolar disorder. The Vitoria long-term follow-up study. J. Affect. Disord 124, 250&#8211;255. 10.1016/j.jad.2009.11.005</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2009.11.005</ArticleId>
						<ArticleId IdType="pubmed">19959240</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gonzalez JM, Bowden CL, Katz MM, Thompson P, Singh V, Prihoda TJ, Dahl M, 2008. Development of the Bipolar Inventory of Symptoms Scale: concurrent validity, discriminant validity and retest reliability. Int. J. Methods Psychiatr. Res 17, 198&#8211;209. 10.1002/mpr.262</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1002/mpr.262</ArticleId>
						<ArticleId IdType="pmc">PMC6878587</ArticleId>
						<ArticleId IdType="pubmed">18792087</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, MacMillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munaf&#242; M, Paton C, Saharkian BJ, Saunders KEA, Sinclair JMA, Taylor D, Vieta E, Young AH, 2016. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J. Psychopharmacol 30, 495&#8211;553. 10.1177/0269881116636545</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1177/0269881116636545</ArticleId>
						<ArticleId IdType="pmc">PMC4922419</ArticleId>
						<ArticleId IdType="pubmed">26979387</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Grande I, Magalh&#227;es PV, Chendo I, Stertz L, Panizutti B, Colpo GD, Rosa AR, Gama CS, Kapczinski F, Vieta E, 2014. Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatr. Scand 129, 437&#8211;444. 10.1111/acps.12268</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/acps.12268</ArticleId>
						<ArticleId IdType="pubmed">24628576</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Guy W, 1976. ECDEU Assessment Manuel for Psychopharmacology, Revised. US Government Printing Office, Washington, DC.</Citation>
				</Reference>
				<Reference>
					<Citation>Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB, 2003. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60, 261&#8211;269. 10.1001/archpsyc.60.3.261</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.60.3.261</ArticleId>
						<ArticleId IdType="pubmed">12622659</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB, 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59, 530&#8211;537. 10.1001/archpsyc.59.6.530</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.59.6.530</ArticleId>
						<ArticleId IdType="pubmed">12044195</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kapczinski F, Magalhaes PVS, Balanza-Martinez V, Dias VV, Frangou S, Gama CS, Gonzalez-Pinto A, Grande I, Ha K, Kauer-Sant&#8217;Anna M, Kunz M, Kupka R, Leboyer M, Lopez-Jaramillo C, Post RM, Rybakowski JK, Scott J, Strejilevitch S, Tohen M, Vazquez G, Yatham L, Vieta E, Berk M, 2014. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr. Scand 130, 354&#8211;363. 10.1111/acps.12305</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/acps.12305</ArticleId>
						<ArticleId IdType="pubmed">24961757</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kessing LV, Gonz&#225;lez-Pinto A, Fagiolini A, Bechdolf A, Reif A, Yildiz A, Etain B, Henry C, Severus E, Reininghaus EZ, Morken G, Goodwin GM, Scott J, Geddes JR, Rietschel M, Land&#233;n M, Manchia M, Bauer M, Martinez-Cengotitabengoa M, Andreassen OA, &#8230; Vieta E, 2021. DSM-5 and ICD-11 criteria for bipolar disorder: Implications for the prevalence of bipolar disorder and validity of the diagnosis - a narrative review from the ECNP bipolar disorders network. Eur. Neuropsychopharmacol S0924&#8211;977X(21)00113&#8211;9. Advance online publication. 10.1016/j.euroneuro.2021.01.097</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.euroneuro.2021.01.097</ArticleId>
						<ArticleId IdType="pubmed">33541809</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Leon AC, Solomon DA, Mueller TI, Endicott J, Posternak M, Judd LL, Schettler PJ, Akiskal HS, Keller MB, 2000. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. J. Nerv. Ment. Dis 188, 805&#8211;812. 10.1097/00005053-200012000-00003</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1097/00005053-200012000-00003</ArticleId>
						<ArticleId IdType="pubmed">11191580</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Magalh&#227;es PV, Dodd S, Nierenberg AA, Berk M, 2012. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Aust. New Zeal. J. Psychiatry 46, 1058&#8211;1067. 10.1177/0004867412460593</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1177/0004867412460593</ArticleId>
						<ArticleId IdType="pubmed">23015748</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Manchia M, Vieta E, Smeland OB, Altimus C, Bechdolf A, Bellivier F, Bergink V, Fagiolini A, Geddes JR, Hajek T, Henry C, Kupka R, Lagerberg TV, Licht RW, Martinez-Cengotitabengoa M, Morken G, Nielsen RE, Pinto AG, Reif A, Rietschel M, &#8230; European College of Neuropsychopharmacology (ECNP) Bipolar Disorders Network, 2020. Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action. Eur. Neuropsychopharmacol 36, 121&#8211;136. 10.1016/j.euroneuro.2020.05.006</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.euroneuro.2020.05.006</ArticleId>
						<ArticleId IdType="pubmed">32536571</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mcgorry P, Keshavan M, Goldstone S, Amminger P, Allott K, Berk M, Lavoie S, Pantelis C, Yung A, Wood S, Hickie I, 2014. Biomarkers and clinical staging in psychiatry. World Psychiatry. 13, 211&#8211;223. 10.1002/wps.20144</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1002/wps.20144</ArticleId>
						<ArticleId IdType="pmc">PMC4219053</ArticleId>
						<ArticleId IdType="pubmed">25273285</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Montgomery SA, Asberg M, 1979. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382&#8211;389. 10.1192/bjp.134.4.382</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.134.4.382</ArticleId>
						<ArticleId IdType="pubmed">444788</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nierenberg AA, McElroy SL, Friedman ES, Ketter TA, Shelton RC, Deckersbach T, McInnis MG, Bowden CL, Tohen M, Kocsis JH, Calabrese JR, Kinrys G, Bobo WV, Singh V, KAMALI M, Kemp D, Brody B, Reilly-Harrington NA, Sylvia LG, Shesler LW, Bernstein EE, Schoenfeld D, Rabideau DJ, Leon AC, Faraone S, Thase ME, 2016. Bipolar CHOICE (clinical health outcomes initiative in comparative effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J. Clin. Psychiatry 77, 90&#8211;99. 10.4088/JCP.14m09349</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.4088/JCP.14m09349</ArticleId>
						<ArticleId IdType="pubmed">26845264</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Shesler LW, McElroy SL, Friedman ES, Thase ME, Shelton RC, Bowden CL, Tohen M, Singh V, Deckersbach T, Ketter TA, Kocsis JH, McInnis MG, Schoenfeld D, Bobo WV, Calabrese JR, 2014. Clinical and health outcomes initiative in comparative effectiveness for bipolar disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Clin. Trials 11, 114&#8211;127. 10.1177/1740774513512184</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1177/1740774513512184</ArticleId>
						<ArticleId IdType="pmc">PMC4495881</ArticleId>
						<ArticleId IdType="pubmed">24346608</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ortiz BB, Eden FDM, de Souza ASR, Teciano CA, de Lima DM, Noto C, Higuchi CH, Cogo-Moreira H, Bressan RA, Gadelha A, 2017. New evidence in support of staging approaches in schizophrenia: differences in clinical profiles between first episode, early stage, and late stage. Compr. Psychiatry 73, 93&#8211;96. 10.1016/j.comppsych.2016.11.006</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.comppsych.2016.11.006</ArticleId>
						<ArticleId IdType="pubmed">27923116</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Peters A, Sylvia LG, da Silva Magalh&#227;es PV, Miklowitz DJ, Frank E, Otto MW, Hansen NS, Dougherty DD, Berk M, Nierenberg AA, Deckersbach T, 2014. Age at onset, course of illness and response to psychotherapy in bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Psychol. Med 44, 3455&#8211;3467. 10.1017/S0033291714000804</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1017/S0033291714000804</ArticleId>
						<ArticleId IdType="pmc">PMC4620042</ArticleId>
						<ArticleId IdType="pubmed">25066366</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Popovic D, Torrent C, Goikolea JM, Cruz N, S&#225;nchez-Moreno J, Gonz&#225;lez-Pinto A, Vieta E, 2014. Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr. Scand 129, 366&#8211;374. 10.1111/acps.12179</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/acps.12179</ArticleId>
						<ArticleId IdType="pubmed">23865756</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Reinares M, Colom F, Rosa AR, Bonn&#237;n CM, Franco C, Sol&#233; B, Kapczinski F, Vieta E, 2010. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J. Affect. Disord 123, 81&#8211;86. 10.1016/j.jad.2009.09.009</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2009.09.009</ArticleId>
						<ArticleId IdType="pubmed">19853922</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rodriguez V, Alameda L, Trotta G, Spinazzola E, Marino P, Matheson SL, Laurens KR, Murray RM, Vassos E, 2021. Environmental risk factors in bipolar disorder and psychotic depression: a systematic review and meta-analysis of prospective studies. Schizophr. Bull sbaa197. Advance online publication. 10.1093/schbul/sbaa197</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1093/schbul/sbaa197</ArticleId>
						<ArticleId IdType="pmc">PMC8266635</ArticleId>
						<ArticleId IdType="pubmed">33479726</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rosa AR, Gonz&#225;lez-Ortega I, Gonz&#225;lez-Pinto A, Echebur&#250;a E, Comes M, Mart&#237;nez-&#192;ran A, Ugarte A, Fern&#225;ndez M, Vieta E, 2012. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr. Scand 125, 335&#8211;341. 10.1111/j.1600-0447.2011.01830.x</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1600-0447.2011.01830.x</ArticleId>
						<ArticleId IdType="pubmed">22283440</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Shah N, Grover S, Rao GP, 2017. Clinical practice guidelines for management of bipolar disorder. Indian J. Psychiatry 59, S51&#8211;S66. 10.4103/0019-5545.196974</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.4103/0019-5545.196974</ArticleId>
						<ArticleId IdType="pmc">PMC5310104</ArticleId>
						<ArticleId IdType="pubmed">28216785</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC, 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 Suppl 20, 22&#8211;33.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9881538</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Siwek M, Sowa-Ku&#263;ma M, Stycze&#324; K, Misztak P, Nowak RJ, Szewczyk B, Dudek D, Rybakowski JK, Nowak G, Maes M, 2017. Associations of serum cytokine receptor levels with melancholia, staging of illness, depressive and manic phases, and severity of depression in bipolar disorder. Mol. Neurobiol 54, 5883&#8211;5893. 10.1007/s12035-016-0124-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1007/s12035-016-0124-8</ArticleId>
						<ArticleId IdType="pubmed">27660275</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sobin LH, 2003. TNM: evolution and relation to other prognostic factors. Semin. Surg. Oncol 21, 3&#8211;7. 10.1002/ssu.10014</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1002/ssu.10014</ArticleId>
						<ArticleId IdType="pubmed">12923909</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W, 1997. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73, 159&#8211;171. 10.1016/s0165-1781(97)00123-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/s0165-1781(97)00123-6</ArticleId>
						<ArticleId IdType="pubmed">9481807</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD, 1999. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am. J. Psychiatry 156, 1264&#8211;1266. 10.1176/ajp.156.8.1264</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/ajp.156.8.1264</ArticleId>
						<ArticleId IdType="pubmed">10450271</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Vieta E, Salagre E, Grande I, Carvalho AF, Fernandes BS, Berk M, Birmaher B, Tohen M, Suppes T, 2018. Early intervention in bipolar disorder. Am. J. Psychiatry 175, 411&#8211;426. 10.1176/appi.ajp.2017.17090972</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.2017.17090972</ArticleId>
						<ArticleId IdType="pubmed">29361850</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O&#8217;Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M, 2018. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 20, 97&#8211;170. 10.1111/bdi.12609</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/bdi.12609</ArticleId>
						<ArticleId IdType="pmc">PMC5947163</ArticleId>
						<ArticleId IdType="pubmed">29536616</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA, 1978. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133, 429&#8211;435. 10.1192/bjp.133.5.429</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.133.5.429</ArticleId>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">31735057</PMID>
			<DateCompleted>
				<Year>2021</Year>
				<Month>03</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>03</Month>
				<Day>29</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1440-1614</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>54</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>2020</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Australian and New Zealand journal of psychiatry</Title>
					<ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Improvement in cognitive function in young people with bipolar disorder: Results from participants in an 18-month randomised controlled trial of adjunctive psychotherapy.</ArticleTitle>
				<Pagination>
					<StartPage>272</StartPage>
					<EndPage>281</EndPage>
					<MedlinePgn>272-281</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867419887794</ELocationID>
				<Abstract>
					<AbstractText Label="OBJECTIVE">To examine the effects of 18&#8201;months of intensive stabilisation with medication management and Interpersonal and Social Rhythm Therapy or Non-specific Supportive Clinical Management on cognitive function in young people with bipolar disorder. Determinants of change in cognitive function over the 18&#8201;months of the trial were also examined.</AbstractText>
					<AbstractText Label="METHOD">Patients aged 15-36&#8201;years with Bipolar I Disorder, Bipolar II Disorder and Bipolar Not Otherwise Specified were recruited. From a battery of cognitive tests, change scores for pre-defined domains of cognitive function were created based on performance at baseline and follow-up. Change was compared between the two therapy groups. Regression analysis was used to determine the impact of a range of clinical variables on change in cognitive performance between baseline and follow-up.</AbstractText>
					<AbstractText Label="RESULTS">One hundred participants were randomised to Interpersonal and Social Rhythm Therapy (
						<i>n</i>&#8201;=&#8201;49) or Non-specific Supportive Clinical Management (
						<i>n</i>&#8201;=&#8201;51). Seventy-eight patients underwent cognitive testing at baseline and 18&#8201;months. Across both groups, there were significant improvements in a Global Cognitive Composite score, Executive Function and Psychomotor Speed domains from baseline to 18&#8201;months. Lower scores at baseline on all domains were associated with greater improvement over 18&#8201;months. Overall, there was no difference between therapies in change in cognitive function, either in a global composite score or change in domains.
					</AbstractText>
					<AbstractText Label="CONCLUSION">While there was no difference between therapy groups, intensive stabilisation with psychological therapy was associated with improved cognitive function, particularly in those patients with poorer cognitive function at baseline. However, this was not compared with treatment as usual so cannot be attributed necessarily to the therapies.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Porter</LastName>
						<ForeName>Richard J</ForeName>
						<Initials>RJ</Initials>
						<Identifier Source="ORCID">0000-0002-8695-3966</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Canterbury District Health Board, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Inder</LastName>
						<ForeName>Maree</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Douglas</LastName>
						<ForeName>Katie M</ForeName>
						<Initials>KM</Initials>
						<Identifier Source="ORCID">0000-0002-5344-2959</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Moor</LastName>
						<ForeName>Stephanie</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Canterbury District Health Board, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Carter</LastName>
						<ForeName>Janet D</ForeName>
						<Initials>JD</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, University of Canterbury, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Frampton</LastName>
						<ForeName>Christopher Ma</ForeName>
						<Initials>CM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Crowe</LastName>
						<ForeName>Marie</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, Christchurch, New Zealand.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2019</Year>
					<Month>11</Month>
					<Day>16</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Aust N Z J Psychiatry</MedlineTA>
				<NlmUniqueID>0111052</NlmUniqueID>
				<ISSNLinking>0004-8674</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D003071">Cognition</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D007398">Interpersonal Relations</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009520">New Zealand</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011613">Psychotherapy</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D012044">Regression Analysis</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D012917">Social Adjustment</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">bipolar depression</Keyword>
				<Keyword MajorTopicYN="N">interpersonal and social rhythm therapy</Keyword>
				<Keyword MajorTopicYN="N">mania</Keyword>
				<Keyword MajorTopicYN="N">neuropsychological function</Keyword>
				<Keyword MajorTopicYN="N">psychotherapy</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2019</Year>
					<Month>11</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2021</Year>
					<Month>3</Month>
					<Day>30</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2019</Year>
					<Month>11</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">31735057</ArticleId>
				<ArticleId IdType="doi">10.1177/0004867419887794</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">33753882</PMID>
			<DateCompleted>
				<Year>2021</Year>
				<Month>06</Month>
				<Day>23</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2024</Year>
				<Month>04</Month>
				<Day>02</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1740-634X</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>46</Volume>
						<Issue>7</Issue>
						<PubDate>
							<Year>2021</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title>
					<ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Changes in the brain structural connectome after a prospective randomized clinical trial of lithium and quetiapine treatment in youth with bipolar disorder.</ArticleTitle>
				<Pagination>
					<StartPage>1315</StartPage>
					<EndPage>1323</EndPage>
					<MedlinePgn>1315-1323</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1038/s41386-021-00989-5</ELocationID>
				<Abstract>
					<AbstractText>The goals of the current study were to determine whether topological organization of brain structural networks is altered in youth with bipolar disorder, whether such alterations predict treatment outcomes, and whether they are normalized by treatment. Youth with bipolar disorder were randomized to double-blind treatment with quetiapine or lithium and assessed weekly. High-resolution MRI images were collected from children and adolescents with bipolar disorder who were experiencing a mixed or manic episode (n&#8201;=&#8201;100) and healthy youth (n&#8201;=&#8201;63). Brain networks were constructed based on the similarity of morphological features across regions and analyzed using graph theory approaches. We tested for pretreatment anatomical differences between bipolar and healthy youth and for changes in neuroanatomic network metrics following treatment in the youth with bipolar disorder. Youth with bipolar disorder showed significantly increased clustering coefficient (C
						<sub>p</sub>) (p&#8201;=&#8201;0.009) and characteristic path length (L
						<sub>p</sub>) (p&#8201;=&#8201;0.04) at baseline, and altered nodal centralities in insula, inferior frontal gyrus, and supplementary motor area. C
						<sub>p</sub>, L
						<sub>p</sub>, and nodal centrality of the insula exhibited normalization in patients following treatment. Changes in these neuroanatomic parameters were correlated with improvement in manic symptoms but did not differ between the two drug therapies. Baseline structural network matrices significantly differentiated medication responders and non-responders with 80% accuracy. These findings demonstrate that both global and nodal structural network features are altered in early course bipolar disorder, and that pretreatment alterations in neuroanatomic features predicted treatment outcome and were reduced by treatment. Similar connectome normalization with lithium and quetiapine suggests that the connectome changes are a downstream effect of both therapies that is related to their clinical efficacy.
					</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author EqualContrib="Y" ValidYN="Y">
						<LastName>Lei</LastName>
						<ForeName>Du</ForeName>
						<Initials>D</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA. leidu@ucmail.uc.edu.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author EqualContrib="Y" ValidYN="Y">
						<LastName>Li</LastName>
						<ForeName>Wenbin</ForeName>
						<Initials>W</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tallman</LastName>
						<ForeName>Maxwell J</ForeName>
						<Initials>MJ</Initials>
						<Identifier Source="ORCID">0000-0003-3036-561X</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Patino</LastName>
						<ForeName>L Rodrigo</ForeName>
						<Initials>LR</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>McNamara</LastName>
						<ForeName>Robert K</ForeName>
						<Initials>RK</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Strawn</LastName>
						<ForeName>Jeffrey R</ForeName>
						<Initials>JR</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Klein</LastName>
						<ForeName>Christina C</ForeName>
						<Initials>CC</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nery</LastName>
						<ForeName>Fabiano G</ForeName>
						<Initials>FG</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fleck</LastName>
						<ForeName>David E</ForeName>
						<Initials>DE</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Qin</LastName>
						<ForeName>Kun</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ai</LastName>
						<ForeName>Yuan</ForeName>
						<Initials>Y</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yang</LastName>
						<ForeName>Jing</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Zhang</LastName>
						<ForeName>Wenjing</ForeName>
						<Initials>W</Initials>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lui</LastName>
						<ForeName>Su</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gong</LastName>
						<ForeName>Qiyong</ForeName>
						<Initials>Q</Initials>
						<Identifier Source="ORCID">0000-0002-5912-4871</Identifier>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China. qiyonggong@hmrrc.org.cn.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Adler</LastName>
						<ForeName>Caleb M</ForeName>
						<Initials>CM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sweeney</LastName>
						<ForeName>John A</ForeName>
						<Initials>JA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Huaxi MR Research Center (HMRRC), Department of Radiology, The Center for Medical Imaging, West China Hospital of Sichuan University, Chengdu, P. R. China.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>DelBello</LastName>
						<ForeName>Melissa P</ForeName>
						<Initials>MP</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>R01 MH080973</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2021</Year>
					<Month>03</Month>
					<Day>22</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Neuropsychopharmacology</MedlineTA>
				<NlmUniqueID>8904907</NlmUniqueID>
				<ISSNLinking>0893-133X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>2S3PL1B6UJ</RegistryNumber>
					<NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9FN79X2M3F</RegistryNumber>
					<NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000000981">diagnostic imaging</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000000981">diagnostic imaging</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D063132">Connectome</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000069348">Quetiapine Fumarate</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2020</Year>
					<Month>11</Month>
					<Day>9</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2021</Year>
					<Month>2</Month>
					<Day>16</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="revised">
					<Year>2021</Year>
					<Month>2</Month>
					<Day>2</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2021</Year>
					<Month>3</Month>
					<Day>24</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2021</Year>
					<Month>6</Month>
					<Day>24</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2021</Year>
					<Month>3</Month>
					<Day>23</Day>
					<Hour>6</Hour>
					<Minute>49</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2021</Year>
					<Month>3</Month>
					<Day>22</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">33753882</ArticleId>
				<ArticleId IdType="pmc">PMC8134458</ArticleId>
				<ArticleId IdType="doi">10.1038/s41386-021-00989-5</ArticleId>
				<ArticleId IdType="pii">10.1038/s41386-021-00989-5</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD) Biol Psychiatry. 2004;55:875&#8211;81.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15110730</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lewinsohn PM, Seeley JR, Buckley ME, Klein DN. Bipolar disorder in adolescence and young adulthood. Child Adolesc Psychiatr Clin N. Am. 2002;11:461&#8211;75.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12222078</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorder during adolescence and young adulthood in a community sample. Bipolar Disord. 2000;2(3 Pt 2):281&#8211;93.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11249806</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ketter TA, Wang PW. Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. J Clin Psychiatry. 2002;63(Suppl 3):21&#8211;5.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11908918</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci Biobehav Rev. 2013;37:418&#8211;35.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23318228</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Passarotti AM, Sweeney JA, Pavuluri MN. Fronto-limbic dysfunction in mania pre-treatment and persistent amygdala over-activity post-treatment in pediatric bipolar disorder. Psychopharmacology (Berl) 2011;216:485&#8211;99.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3174733</ArticleId>
						<ArticleId IdType="pubmed">21390505</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lui S, Li T, Deng W, Jiang L, Wu Q, Tang H, et al. Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by &#8220;resting state&#8221; functional magnetic resonance imaging. Arch Gen Psychiatry. 2010;67:783&#8211;92.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">20679586</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW. Changes in caudate volume with neuroleptic treatment. Lancet. 1994;344:1434.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7968091</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Wegbreit E, Ellis JA, Nandam A, Fitzgerald JM, Passarotti AM, Pavuluri MN, et al. Amygdala functional connectivity predicts pharmacotherapy outcome in pediatric bipolar disorder. Brain Connect. 2011;1:411&#8211;22.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3604767</ArticleId>
						<ArticleId IdType="pubmed">22432455</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Collin G, van den Heuvel MP, Abramovic L, Vreeker A, de Reus MA, van Haren NE, et al. Brain network analysis reveals affected connectome structure in bipolar I disorder. Hum Brain Mapp. 2016;37:122&#8211;34.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5597048</ArticleId>
						<ArticleId IdType="pubmed">26454006</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sk&#229;tun KC, Kaufmann T, Brandt CL, Doan NT, Aln&#230;s D, T&#248;nnesen S, et al. Thalamo-cortical functional connectivity in schizophrenia and bipolar disorder. Brain Imaging Behav. 2018;12:640&#8211;52.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">28444556</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Wei Y, Chang M, Womer FY, Zhou Q, Yin Z, Wei S, et al. Local functional connectivity alterations in schizophrenia, bipolar disorder, and major depressive disorder. J Affect Disord. 2018;236:266&#8211;73.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">29751242</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10:186&#8211;98.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19190637</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, et al. Toward discovery science of human brain function. Proc Natl Acad Sci USA. 2010;107:4734&#8211;9.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2842060</ArticleId>
						<ArticleId IdType="pubmed">20176931</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Suo X, Lei D, Li L, Li W, Dai J, Wang S, et al. Psychoradiological patterns of small-world properties and a systematic review of connectome studies of patients with 6 major psychiatric disorders. J Psychiatry Neurosci. 2018;43:170214.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6203546</ArticleId>
						<ArticleId IdType="pubmed">30375837</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cao M, Wang Z, He Y. Connectomics in psychiatric research: advances and applications. Neuropsychiatr Dis Treat. 2015;11:2801&#8211;10.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4631424</ArticleId>
						<ArticleId IdType="pubmed">26604764</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Alexander-Bloch A, Giedd JN, Bullmore E. Imaging structural co-variance between human brain regions. Nat Rev Neurosci. 2013;14:322&#8211;36.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4043276</ArticleId>
						<ArticleId IdType="pubmed">23531697</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Chen T, Kendrick KM, Wang J, Wu M, Li K, Huang X, et al. Anomalous single-subject based morphological cortical networks in drug-naive, first-episode major depressive disorder. Hum Brain Mapp. 2017;38:2482&#8211;94.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6866860</ArticleId>
						<ArticleId IdType="pubmed">28176413</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Niu R, Lei D, Chen F, Chen Y, Suo X, Li L, et al. Disrupted grey matter network morphology in pediatric posttraumatic stress disorder. NeuroImage Clin. 2018;18:943&#8211;51.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5988464</ArticleId>
						<ArticleId IdType="pubmed">29876279</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Zhang W, Lei D, Keedy SK, Ivleva EI, Eum S, Yao L, et al. Brain gray matter network organization in psychotic disorders. Neuropsychopharmacology. 2020;45:666&#8211;74.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7021697</ArticleId>
						<ArticleId IdType="pubmed">31812151</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sporns O, Tononi G, Kotter R. The human connectome: a structural description of the human brain. PLoS computational Biol. 2005;1:e42.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC1239902</ArticleId>
						<ArticleId IdType="pubmed">16201007</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Qi S, Meesters S, Nicolay K, Ter Haar Romeny BM, Ossenblok P. Structural brain network: what is the effect of LiFE optimization of whole brain tractography? Front Computational Neurosci. 2016;10:12.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4754446</ArticleId>
						<ArticleId IdType="pubmed">26909034</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Poolsup N, Li Wan PoA, de Oliveira IR. Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther. 2000;25:139&#8211;56.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">10849192</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cade JF. Lithium salts in the treatment of psychotic excitement. 1949. Bull World Health Organ. 2000;78:518&#8211;20.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2560740</ArticleId>
						<ArticleId IdType="pubmed">10885180</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Delbello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45:305&#8211;13.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16540815</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:1216&#8211;23.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12364843</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Silverstone PH, Bell EC, Willson MC, Dave S, Wilman AH. Lithium alters brain activation in bipolar disorder in a task- and state-dependent manner: an fMRI study. Ann Gen Psychiatry. 2005;4:14.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC1188051</ArticleId>
						<ArticleId IdType="pubmed">16029502</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Silverstone PH, McGrath BM, Kim H. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord. 2005;7:1&#8211;10.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15654927</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>O&#8217;Donnell T, Rotzinger S, Ulrich M, Hanstock CC, Nakashima TT, Silverstone PH. Effects of chronic lithium and sodium valproate on concentrations of brain amino acids. Eur Neuropsychopharmacol. 2003;13:220&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12888180</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Glitz DA, Manji HK, Moore GJ. Mood disorders: treatment-induced changes in brain neurochemistry and structure. Semin Clin Neuropsychiatry. 2002;7:269&#8211;80.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12382209</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Manji HK, Moore GJ, Chen G. Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry Suppl. 2001;41:s107&#8211;19.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11450170</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet. 2000;356:1241&#8211;2.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11072948</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry. 2000;48:740&#8211;54.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11063971</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gong J, Chen G, Jia Y, Zhong S, Zhao L, Luo X, et al. Disrupted functional connectivity within the default mode network and salience network in unmedicated bipolar II disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:11&#8211;18.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">29958116</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Dandash O, Daglas R, Cotton SM, Allott K, Fornito A, et al. Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Transl Psychiatry. 2017;7:e1011.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5545739</ArticleId>
						<ArticleId IdType="pubmed">28117843</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Giakoumatos CI, Nanda P, Mathew IT, Tandon N, Shah J, Bishop JR, et al. Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder. J Psychiatr Res. 2015;61:180&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4859940</ArticleId>
						<ArticleId IdType="pubmed">25563516</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Zhang W, Xiao Y, Sun H, Patino LR, Tallman MJ, Weber WA, et al. Discrete patterns of cortical thickness in youth with bipolar disorder differentially predict treatment response to quetiapine but not lithium. Neuropsychopharmacology. 2018;43:2256&#8211;63.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6135862</ArticleId>
						<ArticleId IdType="pubmed">29946107</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Geller B, Zimerman B, Williams M, Bolhofner K, Craney JL, DelBello MP, et al. Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections. J Am Acad Child Adolesc Psychiatry. 2001;40:450&#8211;5.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11314571</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry: J Ment Sci. 1978;133:429&#8211;35.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Poznanski EO, Mokros HB. Children&#8217;s depression rating scale, revised (CDRS-R). Western Psychological Services, Los Angeles; 1996.</Citation>
				</Reference>
				<Reference>
					<Citation>Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children&#8217;s global assessment scale (CGAS) Arch Gen Psychiatry. 1983;40:1228&#8211;31.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6639293</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hollingshead AB, Redlich FC Social class and mental illness: community study. John Wiley &amp; Sons Inc.; 1958.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC1994199</ArticleId>
						<ArticleId IdType="pubmed">17895405</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Duke PM, Litt IF, Gross RT. Adolescents&#8217; self-assessment of sexual maturation. Pediatrics. 1980;66:918&#8211;20.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7454482</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blakemore SJ, Burnett S, Dahl RE. The role of puberty in the developing adolescent brain. Hum Brain Mapp. 2010;31:926&#8211;33.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3410522</ArticleId>
						<ArticleId IdType="pubmed">20496383</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Stano J. Wechsler abbreviated scale of intelligence. San Antonio, TX: The Psychological Corporation; 1999.</Citation>
				</Reference>
				<Reference>
					<Citation>Schneider MR, Adler CM, Whitsel R, Weber W, Mills NP, Bitter SM, et al. The effects of ziprasidone on prefrontal and amygdalar activation in manic youth with bipolar disorder. Isr J Psychiatry Relat Sci. 2012;49:112&#8211;20.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">22801290</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839&#8211;51.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15955494</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#8211;89.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">11771995</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kong XZ, Wang X, Huang L, Pu Y, Yang Z, Dang X, et al. Measuring individual morphological relationship of cortical regions. J Neurosci Methods. 2014;237:103&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">25220868</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Li X, Lei D, Niu R, Li L, Suo X, Li W, et al. Disruption of gray matter morphological networks in patients with paroxysmal kinesigenic dyskinesia. Hum Brain Mapp. 2020;42:398&#8211;411.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7776009</ArticleId>
						<ArticleId IdType="pubmed">33058379</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Watts DJ, Strogatz SH. Collective dynamics of &#8216;small-world&#8217; networks. Nature. 1998;393:440&#8211;2.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9623998</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>He Y, Dagher A, Chen Z, Charil A, Zijdenbos A, Worsley K, et al. Impaired small-world efficiency in structural cortical networks in multiple sclerosis associated with white matter lesion load. Brain: J Neurol. 2009;132(Pt 12):3366&#8211;79.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2792366</ArticleId>
						<ArticleId IdType="pubmed">19439423</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Zhang J, Wang J, Wu Q, Kuang W, Huang X, He Y, et al. Disrupted brain connectivity networks in drug-naive, first-episode major depressive disorder. Biol Psychiatry. 2011;70:334&#8211;42.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">21791259</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. PLoS Comput Biol. 2007;3:e17.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC1794324</ArticleId>
						<ArticleId IdType="pubmed">17274684</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychological Assess. 1994;6:284.</Citation>
				</Reference>
				<Reference>
					<Citation>Manelis A, Almeida JR, Stiffler R, Lockovich JC, Aslam HA, Phillips ML. Anticipation-related brain connectivity in bipolar and unipolar depression: a graph theory approach. Brain. 2016;139(Pt 9):2554&#8211;66.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4995358</ArticleId>
						<ArticleId IdType="pubmed">27368345</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Spielberg JM, Beall EB, Hulvershorn LA, Altinay M, Karne H, Anand A. Resting state brain network disturbances related to hypomania and depression in medication-free bipolar disorder. Neuropsychopharmacology. 2016;41:3016&#8211;24.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5101549</ArticleId>
						<ArticleId IdType="pubmed">27356764</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Suo X, Lei D, Li K, Chen F, Li F, Li L, et al. Disrupted brain network topology in pediatric posttraumatic stress disorder: A resting-state fMRI study. Hum Brain Mapp. 2015;36:3677&#8211;86.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6869652</ArticleId>
						<ArticleId IdType="pubmed">26096541</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hadley JA, Kraguljac NV, White DM, Ver Hoef L, Tabora J, Lahti AC. Change in brain network topology as a function of treatment response in schizophrenia: a longitudinal resting-state fMRI study using graph theory. NPJ schizophrenia. 2016;2:16014.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4898893</ArticleId>
						<ArticleId IdType="pubmed">27336056</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Meng C, Brandl F, Tahmasian M, Shao J, Manoliu A, Scherr M, et al. Aberrant topology of striatum&#8217;s connectivity is associated with the number of episodes in depression. Brain. 2014;137(Pt 2):598&#8211;609.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">24163276</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mcauley JJ, Costa LDF, Caetano TS. Rich-club phenomena across complex network hierachies. Appl Phys Lett. 2007;91:084103.</Citation>
				</Reference>
				<Reference>
					<Citation>Goulden N, Khusnulina A, Davis NJ, Bracewell RM, Bokde AL, McNulty JP, et al. The salience network is responsible for switching between the default mode network and the central executive network: replication from DCM. Neuroimage. 2014;99:180&#8211;90.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">24862074</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function. Brain Struct Funct. 2010;214:655&#8211;67.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2899886</ArticleId>
						<ArticleId IdType="pubmed">20512370</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rodigari A, Oliveri M. Disrupting SMA activity modulates explicit and implicit emotional responses: an rTMS study. Neurosci Lett. 2014;579:30&#8211;4.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">25038415</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Oliveri M, Babiloni C, Filippi MM, Caltagirone C, Babiloni F, Cicinelli P, et al. Influence of the supplementary motor area on primary motor cortex excitability during movements triggered by neutral or emotionally unpleasant visual cues. Exp Brain Res. 2003;149:214&#8211;21.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12610690</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mazzola V, Vuilleumier P, Latorre V, Petito A, Gallese V, Popolizio T, et al. Effects of emotional contexts on cerebello-thalamo-cortical activity during action observation. PLoS ONE. 2013;8:e75912.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3784399</ArticleId>
						<ArticleId IdType="pubmed">24086664</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson&#8217;s disease. Lancet Neurol. 2018;17:629&#8211;40.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">29914708</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Wen H, Liu Y, Rekik I, Wang S, Zhang J, Zhang Y, et al. Disrupted topological organization of structural networks revealed by probabilistic diffusion tractography in Tourette syndrome children. Hum brain Mapp. 2017;38:3988&#8211;4008.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6866946</ArticleId>
						<ArticleId IdType="pubmed">28474385</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lei D, Pinaya WHL, van Amelsvoort T, Marcelis M, Donohoe G, Mothersill DO, et al. Detecting schizophrenia at the level of the individual: relative diagnostic value of whole-brain images, connectome-wide functional connectivity and graph-based metrics. Psychol Med. 2020;50:1852&#8211;61.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7477363</ArticleId>
						<ArticleId IdType="pubmed">31391132</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Roberts G, Lord A, Frankland A, Wright A, Lau P, Levy F, et al. Functional dysconnection of the inferior frontal gyrus in young people with bipolar disorder or at genetic high risk. Biol Psychiatry. 2017;81:718&#8211;27.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">28031150</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>German&#225; C, Kempton MJ, Sarnicola A, Christodoulou T, Haldane M, Hadjulis M, et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatr Scand. 2010;122:481&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">20560901</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ketter TA, Miller S, Dell&#8217;Osso B, Wang PW. Treatment of bipolar disorder: review of evidence regarding quetiapine and lithium. J Affect Disord. 2016;191:256&#8211;73.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">26688495</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Wang J, Wang L, Zang Y, Yang H, Tang H, Gong Q, et al. Parcellation-dependent small-world brain functional networks: a resting-state fMRI study. Hum Brain Mapp. 2009;30:1511&#8211;23.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6870680</ArticleId>
						<ArticleId IdType="pubmed">18649353</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">3312180</PMID>
			<DateCompleted>
				<Year>1987</Year>
				<Month>11</Month>
				<Day>27</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0160-6689</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>48 Suppl</Volume>
						<PubDate>
							<Year>1987</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of clinical psychiatry</Title>
					<ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Clonazepam in acute and maintenance treatment of bipolar affective disorder.</ArticleTitle>
				<Pagination>
					<StartPage>29</StartPage>
					<EndPage>37</EndPage>
					<MedlinePgn>29-37</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>This is a report on the efficacy of clonazepam in the treatment of acute mania. The advantages of clonazepam over standard neuroleptics are its rapidity of action, its lack of toxicity, and, particularly important, the fact that it does not cause tardive dyskinesia, a potentially disabling neurological side effect of neuroleptic treatment. Results are reported of double-blind, controlled studies comparing clonazepam with lithium and with haloperidol in the treatment of acutely manic patients who were newly admitted through an emergency room. For the maintenance treatment of patients with bipolar illness, a combined approach is outlined that involves medications with different mechanisms of action. Treatment is initiated with lithium, and, if necessary, tryptophan is added to enhance lithium response; drug-resistant patients who fail to respond satisfactorily to lithium or lithium plus tryptophan are given adjunctive clonazepam therapy.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Chouinard</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
						<AffiliationInfo>
							<Affiliation>Allan Memorial Institute, Royal Victoria Hospital, Montreal, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016454">Review</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Psychiatry</MedlineTA>
				<NlmUniqueID>7801243</NlmUniqueID>
				<ISSNLinking>0160-6689</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>5PE9FDE8GB</RegistryNumber>
					<NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>8DUH1N11BX</RegistryNumber>
					<NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9FN79X2M3F</RegistryNumber>
					<NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>J6292F8L3D</RegistryNumber>
					<NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002998">Clonazepam</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D014364">Tryptophan</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
			<NumberOfReferences>66</NumberOfReferences>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1987</Year>
					<Month>10</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1987</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1987</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">3312180</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">35561011</PMID>
			<DateCompleted>
				<Year>2022</Year>
				<Month>11</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>11</Month>
				<Day>29</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1744-6163</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>58</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>2022</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>Perspectives in psychiatric care</Title>
					<ISOAbbreviation>Perspect Psychiatr Care</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Impact of nurse-led medication adherence therapy on bipolar affective disorder: A randomized controlled trial.</ArticleTitle>
				<Pagination>
					<StartPage>2676</StartPage>
					<EndPage>2686</EndPage>
					<MedlinePgn>2676-2686</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1111/ppc.13108</ELocationID>
				<Abstract>
					<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study evaluated the impact of nurse-led medication adherence therapy (MAT) on medication adherence behavior and symptom severity of inpatients with bipolar disorder.</AbstractText>
					<AbstractText Label="METHOD" NlmCategory="METHODS">Two arms, single-blind, randomized controlled trial on individuals with bipolar disorder was conducted at inpatient department of mental healthcare setting, India. Eighty-five participants were randomly allocated to MAT group and Treatment as usual group. Standard measures were used to assess medication adherence and symptom severity of both groups at baseline and follow-up time points.</AbstractText>
					<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MAT improved medication adherence behavior resulting in marked decrease in symptom severity of participants with bipolar disorders.</AbstractText>
					<AbstractText Label="IMPLICATIONS FOR NURSING PRACTICE" NlmCategory="CONCLUSIONS">Psychiatric nurses can effectively implement MAT for bipolar inpatients, which improves better clinical outcomes, prevent relapse, and readmissions.</AbstractText>
					<CopyrightInformation>&#169; 2022 Wiley Periodicals LLC.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Balikai</LastName>
						<ForeName>Shreedevi I</ForeName>
						<Initials>SI</Initials>
						<Identifier Source="ORCID">0000-0003-4556-9922</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatric Nursing, District Hospital, Vijayapura, Karnataka, India.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rentala</LastName>
						<ForeName>Sreevani</ForeName>
						<Initials>S</Initials>
						<Identifier Source="ORCID">0000-0001-6700-8398</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatric Nursing, Dharwad Institute of Mental Health and Neuroscience (DIMHANS), Dharwad, Karnataka, India.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mudakavi</LastName>
						<ForeName>Irasangappa Basavaraj</ForeName>
						<Initials>IB</Initials>
						<Identifier Source="ORCID">0000-0002-7649-2473</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatric Nursing, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nayak</LastName>
						<ForeName>Raghavendra Bheemappa</ForeName>
						<Initials>RB</Initials>
						<Identifier Source="ORCID">0000-0002-8162-5736</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Dharwad Institute of Mental Health and Neuroscience, Dharwad, Karnataka, India.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2022</Year>
					<Month>05</Month>
					<Day>13</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Perspect Psychiatr Care</MedlineTA>
				<NlmUniqueID>0401133</NlmUniqueID>
				<ISSNLinking>0031-5990</ISSNLinking>
			</MedlineJournalInfo>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016037">Single-Blind Method</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D024802">Nurse's Role</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D055118">Medication Adherence</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D019964">Mood Disorders</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">medication adherence therapy</Keyword>
				<Keyword MajorTopicYN="N">nurse-led</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="revised">
					<Year>2022</Year>
					<Month>4</Month>
					<Day>13</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="received">
					<Year>2022</Year>
					<Month>2</Month>
					<Day>8</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2022</Year>
					<Month>4</Month>
					<Day>29</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2022</Year>
					<Month>5</Month>
					<Day>14</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2022</Year>
					<Month>11</Month>
					<Day>30</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2022</Year>
					<Month>5</Month>
					<Day>13</Day>
					<Hour>19</Hour>
					<Minute>33</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">35561011</ArticleId>
				<ArticleId IdType="doi">10.1111/ppc.13108</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Title>REFERENCES</Title>
				<Reference>
					<Citation>American Medical Association.&#160;(2020). Patient support and advocacy. Eight reasons patients don't take their medications. Retrieved August 13, 2021 from https://www.ama-assn.org/delivering-care/patient-support-advocacy/8-reasons-patients-dont-take-their-medications</Citation>
				</Reference>
				<Reference>
					<Citation>Anbazhagan, S., Fathima, F., Agrawal, T., &amp; Misquith, D. (2016). Psychometric properties of Morisky Medication Adherence Scale (MMAS) in known diabetic and hypertensive patients in a rural population of Kolar District, Karnataka. Indian Journal of Public Health Research and Development, 7(2), 250. https://doi.org/10.5958/0976-5506.2016.00102.9</Citation>
				</Reference>
				<Reference>
					<Citation>Bahredar, M. J., Asgharnejad Farid, A. A., Ghanizadeh, A., &amp; Birashk, B. (2014). The efficacy of psycho-educational group program on medication adherence and global functioning of patients with bipolar disorder type I. International Journal of Community-Based Nursing and Midwifery, 2(1), 12-19.</Citation>
				</Reference>
				<Reference>
					<Citation>Bauer, M., Glenn, T., Alda, M., Bauer, R., Grof, P., Marsh, W., Monteith, S., Munoz, R., Rasgon, N., Sagduyu, K., &amp; Whybrow, P. C. (2019). Trajectories of adherence to mood stabilizers in patients with bipolar disorder. International Journal of Bipolar Disorders, 7(19), 5283. https://doi.org/10.1186/s40345-019-0154-z</Citation>
				</Reference>
				<Reference>
					<Citation>Bowskill, R., Clatworthy, J., Parham, R., Rank, T., &amp; Horne, R. (2007). Patients' perceptions of information received about medication prescribed for bipolar disorder: Implications for informed choice. Journal of Affective Disorders, 100(1&#8722;3), 253-257. https://doi.org/10.1016/j.jad.2006.10.018</Citation>
				</Reference>
				<Reference>
					<Citation>Chakrabarti, S. (2016). Treatment-adherence in bipolar disorder: A patient-centered approach. World Journal of Psychiatry, 6(4), 399-409. https://doi.org/10.5498/wjp.v6.i4.399</Citation>
				</Reference>
				<Reference>
					<Citation>Eker, F., &amp; Hark&#305;n, S. (2012). Effectiveness of six-week psychoeducation program on adherence of patients with bipolar affective disorder. Journal of Affective Disorders, 138(3), 409-416. https://doi.org/10.1016/j.jad.2012.01.004</Citation>
				</Reference>
				<Reference>
					<Citation>GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#8722;2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392(10159), 1789-1858. https://doi.org/10.1016/S0140-6736(18)32279-7</Citation>
				</Reference>
				<Reference>
					<Citation>George, L. S., Sharma, P. S. V. N., &amp; Nair, S. (2013). Effect of psycho-educative intervention on adherence to treatment, knowledge, and attitude among persons with bipolar affective disorder (BPAD)-Randomized controlled trial. IOSR Journal of Nursing and Health Science, 1(5), 12-17.</Citation>
				</Reference>
				<Reference>
					<Citation>Ghatwal, H., Joseph, J., &amp; Jangid, P. (2021). Effect of nurse-led screening linked brief psycho-education for improving adherence to antipsychotic medications among clients with mental illness: A quasi-experimental study. Journal of Mental Health Human Behaviour, 26(1), 28-35. https://doi.org/10.4103/jmhhb.jmhhb_175_20</Citation>
				</Reference>
				<Reference>
					<Citation>Greenhalgh, T. (2018). Challenges psychiatrists face in treating patients with bipolar disorder. Bipolar Disorder Advisor,&#160;15, 2021.</Citation>
				</Reference>
				<Reference>
					<Citation>Hong, J., Reed, C., Novick, D., Haro, J. M., &amp; Aguado, J. (2011). Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Research, 190(1), 110-114. https://doi.org/10.1016/j.psychres.2011.04.016. https://www.psychiatryadvisor.com/home/bipolar-disorder-advisor/challenges-psychiatrists-face-in-treating-patients-with-bipolar-disorder/</Citation>
				</Reference>
				<Reference>
					<Citation>Javadpour, A., Hedayati, A., Dehbozorgi, G. R., &amp; Azizi, A. (2013). The impact of a simple individual psycho-education program on quality of life, rate of relapse, and medication adherence in bipolar disorder patients. Asian Journal of Psychiatry, 6(3), 208-213. https://doi.org/10.1016/j.ajp.2012.12.005</Citation>
				</Reference>
				<Reference>
					<Citation>Jawad, I., Watson, S., Haddad, P. M., Talbot, P. S., &amp; McAllister-Williams, R. H. (2018). Medication nonadherence in bipolar disorder: A narrative review. Therapeutic Advances in Psychopharmacology, 8(12), 349-363. https://doi.org/10.1177/2045125318804364</Citation>
				</Reference>
				<Reference>
					<Citation>Johnson, F. R., Ozdemir, S., Manjunath, R., Hauber, A. B., Burch, S. P., &amp; Thompson, T. R. (2007). Factors that affect adherence to bipolar disorder treatments: A stated-preference approach. Medical Care, 45(6), 545-552. https://doi.org/10.1097/MLR.0b013e318040ad90</Citation>
				</Reference>
				<Reference>
					<Citation>J&#243;nsd&#243;ttir, H., Opjordsmoen, S., Birkenaes, A. B., Simonsen, C., Engh, J. A., Ringen, P. A., Vaskinn, A., Friis, S., Sundet, K., &amp; Andreassen, O. A. (2013). Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatrica Scandinavica, 127(1), 23-33. https://doi.org/10.1111/j.1600-0447.2012.01911.x</Citation>
				</Reference>
				<Reference>
					<Citation>Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., &amp; Keller, M. B. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry, 60(3), 261-269. https://doi.org/10.1001/archpsyc.60.3.261</Citation>
				</Reference>
				<Reference>
					<Citation>Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., &amp; Keller, M. B. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry, 59(6), 530-537. https://doi.org/10.1001/archpsyc.59.6.530</Citation>
				</Reference>
				<Reference>
					<Citation>Karada&#287;, H., Kokurcan, A., G&#252;riz, S. O., Atmar, M., &amp; &#214;rsel, S. (2019). Assessing the treatment adherence and clinical correlates of low adherence among bipolar disorder outpatients: A cross-sectional study. Psychiatry and Clinical Psychopharmacology, 29(4), 558-564. https://doi.org/10.1080/24750573.2018.1480082</Citation>
				</Reference>
				<Reference>
					<Citation>Lam, D. H., Watkins, E. R., Hayward, P., Bright, J., Wright, K., Kerr, N., Parr-Davis, G., &amp; Sham, P. (2003). A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: Outcome of the first year. Archives of General Psychiatry, 60(2), 145-152. https://doi.org/10.1001/archpsyc.60.2.145</Citation>
				</Reference>
				<Reference>
					<Citation>Levin, J. B., Sajatovic, M., Rahman, M., Aebi, M. E., Tatsuoka, C., Depp, C., Cushman, C., Johnston, E., Cassidy, K. A., Blixen, C., Eskew, L., Klein, P. J., Fuentes-Casiano, E., &amp; Moore, D. J. (2019). Outcomes of psychoeducation and a text messaging adherence intervention among individuals with hypertension and bipolar disorder. Psychiatric Services (Washington, D.C.), 70(7), 608-612. https://doi.org/10.1176/appi.ps.201800482</Citation>
				</Reference>
				<Reference>
					<Citation>Lin, E. C. L., Berk, M., Hsu, P. C., &amp; Lu, R. B. (2017). A nurse-led psychoeducational program balancing my swing improves medication adherence among Taiwanese Han-Chinese with bipolar II disorder. Neuropsychiatry, 7(4), 302-309. https://www.jneuropsychiatry.org/peer-review/a-nurseled-psychoeducational-program-balancingmyswing-improves-medication-adherence-among-taiwanese-hanchinese-with-bipolar-ii-dis.html</Citation>
				</Reference>
				<Reference>
					<Citation>McKenzie, K., &amp; Chang, Y. P. (2015). The effect of nurse-led motivational interviewing on medication adherence in patients with bipolar disorder. Perspectives in Psychiatric Care, 51(1), 36-44. https://doi.org/10.1111/ppc.12060</Citation>
				</Reference>
				<Reference>
					<Citation>Mishra, A., Krishna, G. S., Alla, S., Kurian, T. D., Kurian, J., Ramesh, M., &amp; Kishor, M. (2017). Impact of pharmacist-psychiatrist collaborative patient education on medication adherence and quality of life (QOL) of bipolar affective disorder (BPAD) patients. Frontiers in Pharmacology, 8, 722. https://doi.org/10.3389/fphar.2017.00722</Citation>
				</Reference>
				<Reference>
					<Citation>MoHFW Government of India. (2016). National Mental Health Survey of India, 2015&#8722;16 prevalence, pattern and outcomes. http://indianmhs.nimhans.ac.in/Docs/Report2.pdf</Citation>
				</Reference>
				<Reference>
					<Citation>Morisky, D. E., Green, L. W., &amp; Levine, D. M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 24(1), 67-74. https://doi.org/10.1097/00005650-198601000-00007</Citation>
				</Reference>
				<Reference>
					<Citation>Narayanan, D., Jith, A., &amp; Bansal, R. (2020). Nonadherence in bipolar disorder patients: A 14-year retrospective study. Indian Journal of Psychiatry, 62(3), 290-294. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_357_19</Citation>
				</Reference>
				<Reference>
					<Citation>National Alliance on Mental Illness. (2021). Bipolar disorder. Retrieved December 12, 2021 from https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Bipolar-Disorder</Citation>
				</Reference>
				<Reference>
					<Citation>National Institute of Mental Health.&#160;(2021). Bipolar disorder: Transforming the understanding and treatment of mental illnesses. Retrieved November 22, 2021 from&#160;https://www.nimh.nih.gov/health/topics/bipolar-disorder</Citation>
				</Reference>
				<Reference>
					<Citation>Okasha, T. A., Radwan, D. N., Elkholy, H., Hendawy, H., Shourab, E., Teama, R., &amp; Abdelgawad, A. S. (2020). Psycho-demographic and clinical predictors of medication adherence in patients with bipolar I disorder in a university hospital in Egypt. The South African Journal of Psychiatry: SAJP: The Journal of the Society of Psychiatrists of South Africa, 26, 1437. https://doi.org/10.4102/sajpsychiatry.v26i0.1437</Citation>
				</Reference>
				<Reference>
					<Citation>Patel, J. S., &amp; Kiran, M. (2020). Psychoeducation, improving medication adherence among individuals with bipolar affective disorder. Indian Journal of Applied Research, 10(3), 9848.</Citation>
				</Reference>
				<Reference>
					<Citation>Peet, M., &amp; Harvey, N. S. (1991). Lithium maintenance: 1. A standard education program for patients. The British Journal of Psychiatry: The Journal of Mental Science, 158, 197-200. https://doi.org/10.1192/bjp.158.2.197</Citation>
				</Reference>
				<Reference>
					<Citation>Pozza, A., Coluccia, A., Gualtieri, G., &amp; Ferretti, F. (2020). Enhancing adherence to antipsychotic treatment for bipolar disorders. Comparison of mobile app-based psychoeducation, group psychoeducation, and the combination of both: Protocol of a three-arm single-blinded parallel-group multi-centre randomized trial. La Clinica Terapeutica, 171(2), e7-e93. https://doi.org/10.7417/CT.2020.2194</Citation>
				</Reference>
				<Reference>
					<Citation>Rosa, A. R., Marco, M., Fachel, J. M., Kapczinski, F., Stein, A. T., &amp; Barros, H. M. (2007). Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients. Progress in Neuro-psychopharmacology &amp; Biological Psychiatry, 31(1), 217-224. https://doi.org/10.1016/j.pnpbp.2006.08.007</Citation>
				</Reference>
				<Reference>
					<Citation>Rowland, T. A., &amp; Marwaha, S. (2018). Epidemiology and risk factors for bipolar disorder. Therapeutic Advances in Psychopharmacology, 8(9), 251-269. https://doi.org/10.1177/2045125318769235</Citation>
				</Reference>
				<Reference>
					<Citation>Schaffer, A., Isomets&#228;, E. T., Tondo, L., Moreno, D. H., Sinyor, M., Kessing, L. V., Turecki, G., Weizman, A., Azorin, J. M., Ha, K., Reis, C., Cassidy, F., Goldstein, T., Rihmer, Z., Beautrais, A., Chou, Y. H., Diazgranados, N., Levitt, A. J., Zarate, C. A., Jr., &amp; Yatham, L. (2015). Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on suicide in bipolar disorder. The Australian and New Zealand Journal of Psychiatry, 49(9), 785-802. https://doi.org/10.1177/0004867415594427</Citation>
				</Reference>
				<Reference>
					<Citation>Scott, J., &amp; Tacchi, M. J. (2002). A pilot study of concordance therapy for individuals with bipolar disorders who are non-adherent with lithium prophylaxis. Bipolar Disorders, 4(6), 386-392. https://doi.org/10.1034/j.1399-5618.2002.02242.x</Citation>
				</Reference>
				<Reference>
					<Citation>Semahegn, A., Torpey, K., Manu, A., Assefa, N., Tesfaye, G., &amp; Ankomah, A. (2020). Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis. Systematic Reviews, 9(1), 17. https://doi.org/10.1186/s13643-020-1274-3</Citation>
				</Reference>
				<Reference>
					<Citation>Sharma, S., Kumar, N., Chakraborti, S., Sinha, S., Kumari, S., &amp; Gajendragad, J. M. (2012). Prevalence and factors associated with medication compliance in Indian patients suffering from mental disorders. Tropical Doctor, 42(1), 28-31. https://doi.org/10.1258/td.2011.110009</Citation>
				</Reference>
				<Reference>
					<Citation>Thase, M. E. (2012). Strategies for increasing treatment adherence in bipolar disorder. The Journal of Clinical Psychiatry, 73(2), e08. https://doi.org/10.4088/JCP.10060tx3cc</Citation>
				</Reference>
				<Reference>
					<Citation>Velligan, D. I., Sajatovic, M., Hatch, A., Kramata, P., &amp; Docherty, J. P. (2017). Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for non-adherence to medication in patients with serious mental illness. Patient Preference and Adherence, 11, 449-468. https://doi.org/10.2147/PPA.S124658</Citation>
				</Reference>
				<Reference>
					<Citation>World Health Organization. 2019. Mental disorders: Key facts. Retrieved November 20, 2021 from&#160;https://www.who.int/news-room/fact-sheets/detail/mental-disorders</Citation>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">33797828</PMID>
			<DateCompleted>
				<Year>2022</Year>
				<Month>04</Month>
				<Day>19</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>05</Month>
				<Day>31</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1399-5618</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>23</Volume>
						<Issue>8</Issue>
						<PubDate>
							<Year>2021</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Bipolar disorders</Title>
					<ISOAbbreviation>Bipolar Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Clinical predictors of non-response to lithium treatment in the Pharmacogenomics of Bipolar Disorder (PGBD) study.</ArticleTitle>
				<Pagination>
					<StartPage>821</StartPage>
					<EndPage>831</EndPage>
					<MedlinePgn>821-831</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.13078</ELocationID>
				<Abstract>
					<AbstractText Label="BACKGROUND">Lithium is regarded as a first-line treatment for bipolar disorder (BD), but partial response and non-response commonly occurs. There exists a need to identify lithium non-responders prior to initiating treatment. The Pharmacogenomics of Bipolar Disorder (PGBD) Study was designed to identify predictors of lithium response.</AbstractText>
					<AbstractText Label="METHODS">The PGBD Study was an eleven site prospective trial of lithium treatment in bipolar I disorder. Subjects were stabilized on lithium monotherapy over 4 months and gradually discontinued from all other psychotropic medications. After ensuring a sustained clinical remission (defined by a score of &#8804;3 on the CGI for 4 weeks) had been achieved, subjects were followed for up to 2&#160;years to monitor clinical response. Cox proportional hazard models were used to examine the relationship between clinical measures and time until failure to remit or relapse.</AbstractText>
					<AbstractText Label="RESULTS">A total of 345 individuals were enrolled into the study and included in the analysis. Of these, 101 subjects failed to remit or relapsed, 88 achieved remission and continued to study completion, and 156 were terminated from the study for other reasons. Significant clinical predictors of treatment failure (p&#160;&lt;&#160;0.05) included baseline anxiety symptoms, functional impairments, negative life events and lifetime clinical features such as a history of migraine, suicidal ideation/attempts, and mixed episodes, as well as a chronic course of illness.</AbstractText>
					<AbstractText Label="CONCLUSIONS">In this PGBD Study of lithium response, several clinical features were found to be associated with failure to respond to lithium. Future validation is needed to confirm these clinical predictors of treatment failure and their use clinically to distinguish who will do well on lithium before starting pharmacotherapy.</AbstractText>
					<CopyrightInformation>&#169; 2021 The Authors. Bipolar Disorders published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Lin</LastName>
						<ForeName>Yian</ForeName>
						<Initials>Y</Initials>
						<Identifier Source="ORCID">0000-0002-6343-7942</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Maihofer</LastName>
						<ForeName>Adam X</ForeName>
						<Initials>AX</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stapp</LastName>
						<ForeName>Emma</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ritchey</LastName>
						<ForeName>Megan</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Alliey-Rodriguez</LastName>
						<ForeName>Ney</ForeName>
						<Initials>N</Initials>
						<AffiliationInfo>
							<Affiliation>University of Chicago, Chicago, IL, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Anand</LastName>
						<ForeName>Amit</ForeName>
						<Initials>A</Initials>
						<Identifier Source="ORCID">0000-0003-1016-6904</Identifier>
						<AffiliationInfo>
							<Affiliation>Center for Behavioral Health, Cleveland Clinic, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Balaraman</LastName>
						<ForeName>Yokesh</ForeName>
						<Initials>Y</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Indiana University, Indianapolis, IN, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Berrettini</LastName>
						<ForeName>Wade H</ForeName>
						<Initials>WH</Initials>
						<AffiliationInfo>
							<Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bertram</LastName>
						<ForeName>Holli</ForeName>
						<Initials>H</Initials>
						<AffiliationInfo>
							<Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bhattacharjee</LastName>
						<ForeName>Abesh</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Calkin</LastName>
						<ForeName>Cynthia V</ForeName>
						<Initials>CV</Initials>
						<AffiliationInfo>
							<Affiliation>Dalhousie University, Halifax, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Conroy</LastName>
						<ForeName>Carla</ForeName>
						<Initials>C</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Coryell</LastName>
						<ForeName>William</ForeName>
						<Initials>W</Initials>
						<Identifier Source="ORCID">0000-0003-3989-7276</Identifier>
						<AffiliationInfo>
							<Affiliation>University of Iowa, Iowa City, IA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>D'Arcangelo</LastName>
						<ForeName>Nicole</ForeName>
						<Initials>N</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>DeModena</LastName>
						<ForeName>Anna</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Biernacka</LastName>
						<ForeName>Joanna M</ForeName>
						<Initials>JM</Initials>
						<Identifier Source="ORCID">0000-0001-9350-4440</Identifier>
						<AffiliationInfo>
							<Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fisher</LastName>
						<ForeName>Carrie</ForeName>
						<Initials>C</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Indiana University, Indianapolis, IN, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Frazier</LastName>
						<ForeName>Nicole</ForeName>
						<Initials>N</Initials>
						<AffiliationInfo>
							<Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Frye</LastName>
						<ForeName>Mark</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gao</LastName>
						<ForeName>Keming</ForeName>
						<Initials>K</Initials>
						<Identifier Source="ORCID">0000-0003-1130-2461</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Garnham</LastName>
						<ForeName>Julie</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Dalhousie University, Halifax, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gershon</LastName>
						<ForeName>Elliot</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>University of Chicago, Chicago, IL, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Glazer</LastName>
						<ForeName>Kara</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Goes</LastName>
						<ForeName>Fernando S</ForeName>
						<Initials>FS</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Goto</LastName>
						<ForeName>Toyomi</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Karberg</LastName>
						<ForeName>Elizabeth</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Harrington</LastName>
						<ForeName>Gloria</ForeName>
						<Initials>G</Initials>
						<AffiliationInfo>
							<Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jakobsen</LastName>
						<ForeName>Petter</ForeName>
						<Initials>P</Initials>
						<AffiliationInfo>
							<Affiliation>Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kamali</LastName>
						<ForeName>Masoud</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Massachusetts General Hospital and Harvard University, Boston, MA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kelly</LastName>
						<ForeName>Marisa</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Leckband</LastName>
						<ForeName>Susan G</ForeName>
						<Initials>SG</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lohoff</LastName>
						<ForeName>Falk W</ForeName>
						<Initials>FW</Initials>
						<AffiliationInfo>
							<Affiliation>National Institute of Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stautland</LastName>
						<ForeName>Andrea</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen and Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>McCarthy</LastName>
						<ForeName>Michael J</ForeName>
						<Initials>MJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, VA San Diego Healthcare System, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>McInnis</LastName>
						<ForeName>Melvin G</ForeName>
						<Initials>MG</Initials>
						<AffiliationInfo>
							<Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mondimore</LastName>
						<ForeName>Francis</ForeName>
						<Initials>F</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Morken</LastName>
						<ForeName>Gunnar</ForeName>
						<Initials>G</Initials>
						<AffiliationInfo>
							<Affiliation>Division of Psychiatry, St. Olav University Hospital of Trondheim and Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nurnberger</LastName>
						<ForeName>John I</ForeName>
						<Initials>JI</Initials>
						<Identifier Source="ORCID">0000-0002-7674-1767</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Indiana University, Indianapolis, IN, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Oedegaard</LastName>
						<ForeName>Ketil J</ForeName>
						<Initials>KJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen and Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Syrstad</LastName>
						<ForeName>Vigdis Elin Giever</ForeName>
						<Initials>VEG</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen and Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ryan</LastName>
						<ForeName>Kelly</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schinagle</LastName>
						<ForeName>Martha</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schoeyen</LastName>
						<ForeName>Helle</ForeName>
						<Initials>H</Initials>
						<AffiliationInfo>
							<Affiliation>Division of Psychiatry, Faculty of Medicine and Dentistry, Stavanger University Hospital, University of Bergen, Stavanger, Norway.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Andreassen</LastName>
						<ForeName>Ole A</ForeName>
						<Initials>OA</Initials>
						<AffiliationInfo>
							<Affiliation>Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Shaw</LastName>
						<ForeName>Marth</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>University of Iowa, Iowa City, IA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Shilling</LastName>
						<ForeName>Paul D</ForeName>
						<Initials>PD</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Slaney</LastName>
						<ForeName>Claire</ForeName>
						<Initials>C</Initials>
						<AffiliationInfo>
							<Affiliation>Dalhousie University, Halifax, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tarwater</LastName>
						<ForeName>Bruce</ForeName>
						<Initials>B</Initials>
						<AffiliationInfo>
							<Affiliation>University of Iowa, Iowa City, IA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Calabrese</LastName>
						<ForeName>Joseph R</ForeName>
						<Initials>JR</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Alda</LastName>
						<ForeName>Martin</ForeName>
						<Initials>M</Initials>
						<Identifier Source="ORCID">0000-0001-9544-3944</Identifier>
						<AffiliationInfo>
							<Affiliation>Dalhousie University, Halifax, Canada.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>National Institute of Mental Health, Klecany, Czech Republic.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nievergelt</LastName>
						<ForeName>Caroline M</ForeName>
						<Initials>CM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Zandi</LastName>
						<ForeName>Peter P</ForeName>
						<Initials>PP</Initials>
						<Identifier Source="ORCID">0000-0001-8423-2623</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kelsoe</LastName>
						<ForeName>John R</ForeName>
						<Initials>JR</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>#64410</GrantID>
						<Agency>The Canadian Institutes of Health Research</Agency>
						<Country />
					</Grant>
					<Grant>
						<GrantID>I01 BX003431</GrantID>
						<Acronym>BX</Acronym>
						<Agency>BLRD VA</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>U01 MH092758</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016448">Multicenter Study</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2021</Year>
					<Month>05</Month>
					<Day>05</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>Denmark</Country>
				<MedlineTA>Bipolar Disord</MedlineTA>
				<NlmUniqueID>100883596</NlmUniqueID>
				<ISSNLinking>1398-5647</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9FN79X2M3F</RegistryNumber>
					<NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D018020">Lithium Compounds</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D010597">Pharmacogenetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">clinical predictor</Keyword>
				<Keyword MajorTopicYN="N">lithium</Keyword>
				<Keyword MajorTopicYN="N">treatment response</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2021</Year>
					<Month>4</Month>
					<Day>3</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2022</Year>
					<Month>4</Month>
					<Day>20</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2021</Year>
					<Month>4</Month>
					<Day>2</Day>
					<Hour>12</Hour>
					<Minute>28</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">33797828</ArticleId>
				<ArticleId IdType="doi">10.1111/bdi.13078</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Title>REFERENCES</Title>
				<Reference>
					<Citation>Berghofer A. Lithium and suicide. BMJ. 2013;347:f4449.</Citation>
				</Reference>
				<Reference>
					<Citation>Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord. 2009;11:77-83.</Citation>
				</Reference>
				<Reference>
					<Citation>Grof P, M&#252;ller-Oerlinghausen B. A critical appraisal of lithium&#8217;s efficacy and effectiveness: the last 60 years. Bipolar Disord. 2009;11:10-19.</Citation>
				</Reference>
				<Reference>
					<Citation>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97-170.</Citation>
				</Reference>
				<Reference>
					<Citation>Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1:351-359.</Citation>
				</Reference>
				<Reference>
					<Citation>Malhi GS, Bell E, Boyce P, et al. The 2020 royal australian and new zealand college of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. Bipolar Disord. 2020;22:805-821.</Citation>
				</Reference>
				<Reference>
					<Citation>Sakurai H, Kato M, Yasui-Furukori N, et al. Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology: pharmacological management of bipolar disorder: Japanese expert consensus. Bipolar Disord. 2020;22:822-830.</Citation>
				</Reference>
				<Reference>
					<Citation>Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217-222.</Citation>
				</Reference>
				<Reference>
					<Citation>Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36:375-389.</Citation>
				</Reference>
				<Reference>
					<Citation>Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry. 2000;57:187-190.</Citation>
				</Reference>
				<Reference>
					<Citation>Garnham J, Munro A, Slaney C, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord. 2007;104:185-190.</Citation>
				</Reference>
				<Reference>
					<Citation>Rybakowski JK, Chlopocka-Wozniak M, Suwalska A. The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s. Bipolar Disord. 2001;3:63-67.</Citation>
				</Reference>
				<Reference>
					<Citation>Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-795.</Citation>
				</Reference>
				<Reference>
					<Citation>Baastrup PC, Mogens S. Lithium as a prophylactic agent: its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry. 1967;16:162-172.</Citation>
				</Reference>
				<Reference>
					<Citation>Kleindienst N, Engel RR, Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium. A systematic review for bipolar disorders. Psychol Med. 2005;35:1685-1694.</Citation>
				</Reference>
				<Reference>
					<Citation>Kleindienst N, Engel RR, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7:404-417.</Citation>
				</Reference>
				<Reference>
					<Citation>Hui TP, Kandola A, Shen L, et al. A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder. Acta Psychiatr Scand. 2019;140:94-115.</Citation>
				</Reference>
				<Reference>
					<Citation>Oedegaard KJ, Alda M, Anand A, et al. The pharmacogenomics of bipolar disorder study (PGBD): identification of genes for lithium response in a prospective sample. BMC Psychiatry. 2016;16:129.</Citation>
				</Reference>
				<Reference>
					<Citation>Nolen WA, Licht RW, Young AH, et al. ISBD/IGSLI Task Force on the treatment with lithium: what is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI task force on treatment with lithium. Bipolar Disord. 2019;21:394-409.</Citation>
				</Reference>
				<Reference>
					<Citation>Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005;61:92-105.</Citation>
				</Reference>
				<Reference>
					<Citation>Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337-344.</Citation>
				</Reference>
				<Reference>
					<Citation>Coryell W, Solomon DA, Fiedorowicz JG, Endicott J, Schettler PJ, Judd LL. Anxiety and outcome in bipolar disorder. Am J Psychiatry. 2009;166:1238-1243.</Citation>
				</Reference>
				<Reference>
					<Citation>Jacobsen KK, Nievergelt CM, Zayats T, et al. Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder. J Affect Disord. 2015;172:453-461.</Citation>
				</Reference>
				<Reference>
					<Citation>Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord. 2006;8:625-639.</Citation>
				</Reference>
				<Reference>
					<Citation>Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.</Citation>
				</Reference>
				<Reference>
					<Citation>Ahrens B, M&#252;ller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001;34:132-136.</Citation>
				</Reference>
				<Reference>
					<Citation>Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007;9:394-412.</Citation>
				</Reference>
				<Reference>
					<Citation>Sylvia LG, Reilly-Harrington NA, Leon AC, et al. Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder. Clin Trials. 2012;9:94-101.</Citation>
				</Reference>
				<Reference>
					<Citation>Nunes A, Ardau R, Berghofer A, et al. Prediction of lithium response using clinical data. Acta Psychiatr Scand. 2020;141:131-141.</Citation>
				</Reference>
				<Reference>
					<Citation>Kim TT, Dufour S, Xu C, et al. Predictive modeling for response to lithium and quetiapine in bipolar disorder. Bipolar Disord. 2019;21:428-436.</Citation>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">16449487</PMID>
			<DateCompleted>
				<Year>2006</Year>
				<Month>03</Month>
				<Day>20</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2016</Year>
				<Month>10</Month>
				<Day>25</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0002-953X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>163</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>2006</Year>
							<Month>Feb</Month>
						</PubDate>
					</JournalIssue>
					<Title>The American journal of psychiatry</Title>
					<ISOAbbreviation>Am J Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants.</ArticleTitle>
				<Pagination>
					<StartPage>313</StartPage>
					<EndPage>315</EndPage>
					<MedlinePgn>313-5</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The authors compared the switch rate into hypomania/mania in depressed patients treated with second-generation antidepressants who had either bipolar I or bipolar II disorder.</AbstractText>
					<AbstractText Label="METHOD" NlmCategory="METHODS">In a 10-week trial, 184 outpatients with bipolar depression (134 with bipolar I disorder, 48 with bipolar II disorder, two with bipolar disorder not otherwise specified) were treated with one of three antidepressants as an adjunct to mood stabilizers. The patients' switch rates were assessed. Switch was defined as a Young Mania Rating Scale (YMRS) score &gt;13 or a Clinical Global Impression (CGI) mania score &gt; or =3 (mildly ill).</AbstractText>
					<AbstractText Label="RESULTS" NlmCategory="RESULTS">Depressed subjects with bipolar II disorder had a significantly lower acute switch rate into hypomania/mania when either YMRS or CGI criteria were used to define switch.</AbstractText>
					<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest that depressed patients with bipolar II disorder are less vulnerable than those with bipolar I disorder to switch into hypomania/mania when treated with an antidepressant adjunctive to a mood stabilizer.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Altshuler</LastName>
						<ForeName>Lori L</ForeName>
						<Initials>LL</Initials>
						<AffiliationInfo>
							<Affiliation>Dept. of Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, 300 UCLA Medical Plaza, Suite 1544, Box 957057, Los Angeles, CA 90095-7057. laltshuler@mednet.ucla.edu</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Suppes</LastName>
						<ForeName>Trisha</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Black</LastName>
						<ForeName>David O</ForeName>
						<Initials>DO</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nolen</LastName>
						<ForeName>Willem A</ForeName>
						<Initials>WA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Leverich</LastName>
						<ForeName>Gabriele</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Keck</LastName>
						<ForeName>Paul E</ForeName>
						<Initials>PE</Initials>
						<Suffix>Jr</Suffix>
					</Author>
					<Author ValidYN="Y">
						<LastName>Frye</LastName>
						<ForeName>Mark A</ForeName>
						<Initials>MA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kupka</LastName>
						<ForeName>Ralph</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>McElroy</LastName>
						<ForeName>Susan L</ForeName>
						<Initials>SL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Grunze</LastName>
						<ForeName>Heinz</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kitchen</LastName>
						<ForeName>Christina M R</ForeName>
						<Initials>CM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Post</LastName>
						<ForeName>Robert</ForeName>
						<Initials>R</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>R01 MH079261</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Am J Psychiatry</MedlineTA>
				<NlmUniqueID>0370512</NlmUniqueID>
				<ISSNLinking>0002-953X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9FN79X2M3F</RegistryNumber>
					<NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000553">Ambulatory Care</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2006</Year>
					<Month>2</Month>
					<Day>2</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2006</Year>
					<Month>3</Month>
					<Day>21</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2006</Year>
					<Month>2</Month>
					<Day>2</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">16449487</ArticleId>
				<ArticleId IdType="doi">10.1176/appi.ajp.163.2.313</ArticleId>
				<ArticleId IdType="pii">163/2/313</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">25346391</PMID>
			<DateCompleted>
				<Year>2016</Year>
				<Month>04</Month>
				<Day>21</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>12</Month>
				<Day>02</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1399-5618</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>17</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>2015</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>Bipolar disorders</Title>
					<ISOAbbreviation>Bipolar Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Randomized, controlled trial of Interpersonal and Social Rhythm Therapy for young people with bipolar disorder.</ArticleTitle>
				<Pagination>
					<StartPage>128</StartPage>
					<EndPage>138</EndPage>
					<MedlinePgn>128-38</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12273</ELocationID>
				<Abstract>
					<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This randomized, controlled clinical trial compared the effect of interpersonal and social rhythm therapy (IPSRT) to that of specialist supportive care (SSC) on depressive outcomes (primary), social functioning, and mania outcomes over 26-78&#160;weeks in young people with bipolar disorder receiving psychopharmacological treatment.</AbstractText>
					<AbstractText Label="METHODS" NlmCategory="METHODS">Subjects were aged 15-36&#160;years, recruited from a range of sources, and the patient groups included bipolar I disorder, bipolar II disorder, and bipolar disorder not otherwise specified. Exclusion criteria were minimal. Outcome measures were the Longitudinal Interval Follow-up Evaluation and the Social Adjustment Scale. Paired-sample t-tests were used to determine the significance of change from baseline to outcome period. Analyses of covariance were used to determine the impact of therapy, impact of lifetime and current comorbidity, interaction between comorbidity and therapy, and impact of age at study entry on depression.</AbstractText>
					<AbstractText Label="RESULTS" NlmCategory="RESULTS">A group of 100 participants were randomized to IPSRT (n&#160;=&#160;49) or SSC (n&#160;=&#160;51). The majority had bipolar I disorder (78%) and were female (76%), with high levels of comorbidity. After treatment, both groups had improved depressive symptoms, social functioning, and manic symptoms. Contrary to our hypothesis, there was no significant difference between therapies. There was no impact of lifetime or current Axis I comorbidity or age at study entry. There was a relative impact of SSC for patients with current substance use disorder.</AbstractText>
					<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IPSRT and SSC used as an adjunct to pharmacotherapy appear to be effective in reducing depressive and manic symptoms and improving social functioning in adolescents and young adults with bipolar disorder and high rates of comorbidity. Identifying effective treatments that particularly address depressive symptoms is important in reducing the burden of bipolar disorder.</AbstractText>
					<CopyrightInformation>&#169; 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Inder</LastName>
						<ForeName>Maree L</ForeName>
						<Initials>ML</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, University of Otago, Christchurch.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Crowe</LastName>
						<ForeName>Marie T</ForeName>
						<Initials>MT</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Luty</LastName>
						<ForeName>Suzanne E</ForeName>
						<Initials>SE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Carter</LastName>
						<ForeName>Janet D</ForeName>
						<Initials>JD</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Moor</LastName>
						<ForeName>Stephanie</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Frampton</LastName>
						<ForeName>Christopher M</ForeName>
						<Initials>CM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Joyce</LastName>
						<ForeName>Peter R</ForeName>
						<Initials>PR</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2014</Year>
					<Month>10</Month>
					<Day>24</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>Denmark</Country>
				<MedlineTA>Bipolar Disord</MedlineTA>
				<NlmUniqueID>100883596</NlmUniqueID>
				<ISSNLinking>1398-5647</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D018692">Antimanic Agents</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003863">Depression</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D007398">Interpersonal Relations</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011613">Psychotherapy</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D012917">Social Adjustment</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D019966">Substance-Related Disorders</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Interpersonal and social rhythm therapy</Keyword>
				<Keyword MajorTopicYN="N">bipolar depression</Keyword>
				<Keyword MajorTopicYN="N">bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">mania</Keyword>
				<Keyword MajorTopicYN="N">psychotherapy</Keyword>
				<Keyword MajorTopicYN="N">social functioning</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2013</Year>
					<Month>10</Month>
					<Day>10</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2014</Year>
					<Month>8</Month>
					<Day>14</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2014</Year>
					<Month>10</Month>
					<Day>28</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2014</Year>
					<Month>10</Month>
					<Day>28</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2016</Year>
					<Month>4</Month>
					<Day>22</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">25346391</ArticleId>
				<ArticleId IdType="doi">10.1111/bdi.12273</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">21586996</PMID>
			<DateCompleted>
				<Year>2011</Year>
				<Month>09</Month>
				<Day>30</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2011</Year>
				<Month>05</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Electronic">1538-1145</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>17</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>2011</Year>
							<Month>May</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of psychiatric practice</Title>
					<ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Guidelines for treatment-resistant mania in children with bipolar disorder.</ArticleTitle>
				<Pagination>
					<StartPage>186</StartPage>
					<EndPage>193</EndPage>
					<MedlinePgn>186-93</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1097/01.pra.0000398411.59491.8c</ELocationID>
				<Abstract>
					<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To implement a treatment algorithm to operationalize treatment-resistance and improve patient outcomes in youth with pediatric bipolar disorder (PBD). The term "treatment resistance" was operationally defined as significant persistent symptoms following the application of a treatment algorithm.</AbstractText>
					<AbstractText Label="METHOD" NlmCategory="METHODS">Youth (6-17 years of age, n=120) with treatment-refractory bipolar I or II disorder, currently in a manic or mixed episode, were treated in accordance with the following 3 step algorithm: (1) removal of destabilizing agents (antidepressants, gamma aminobutyric acid [GABA]-agonists, and stimulants), (2) optimization of antimanic agents, and (3) use of a limited number (E 2) of mood stabilizers. The primary efficacy measure was change in scores on the Young Mania Rating Scale (YMRS) over the 6-month treatment course. Response was defined as repeated YMRS scores E 12.</AbstractText>
					<AbstractText Label="RESULTS" NlmCategory="RESULTS">The sample was dichotomized into responders and non-responders. Both responders and non-responders improved significantly, with responders improving by a greater margin (d=3.2). At the end of 6 months, 75.8% of subjects demonstrated a significant and stable decrease in manic symptoms consistent with symptomatic remission (YMRS E 12). None of the subjects withdrew from the clinical process due to adverse events.</AbstractText>
					<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The application of this proposed treatment algorithm allows for more accurate identification of true treatment resistance and can significantly reduce manic symptoms in patients previously described as having treatment-refractory bipolar disorder.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Scheffer</LastName>
						<ForeName>Russell E</ForeName>
						<Initials>RE</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Kansas School of Medicine-Wichita, 1010 N. Kansas, Wichita, KS 67214, USA. Rscheffer@kumc.edu</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tripathi</LastName>
						<ForeName>Aveekshit</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kirkpatrick</LastName>
						<ForeName>Forest G</ForeName>
						<Initials>FG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schultz</LastName>
						<ForeName>Tara</ForeName>
						<Initials>T</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Psychiatr Pract</MedlineTA>
				<NlmUniqueID>100901141</NlmUniqueID>
				<ISSNLinking>1527-4160</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000342">Affective Symptoms</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D018692">Antimanic Agents</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016903">Drug Monitoring</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004351">Drug Resistance</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D054539">Medication Therapy Management</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D010045">Outpatients</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D017410">Practice Guidelines as Topic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="entrez">
					<Year>2011</Year>
					<Month>5</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2011</Year>
					<Month>5</Month>
					<Day>19</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2011</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">21586996</ArticleId>
				<ArticleId IdType="doi">10.1097/01.pra.0000398411.59491.8c</ArticleId>
				<ArticleId IdType="pii">00131746-201105000-00004</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">17176206</PMID>
			<DateCompleted>
				<Year>2007</Year>
				<Month>02</Month>
				<Day>06</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2007</Year>
				<Month>11</Month>
				<Day>15</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0893-3200</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>20</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>2006</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of family psychology : JFP : journal of the Division of Family Psychology of the American Psychological Association (Division 43)</Title>
					<ISOAbbreviation>J Fam Psychol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Family functioning in bipolar I disorder.</ArticleTitle>
				<Pagination>
					<StartPage>701</StartPage>
					<EndPage>704</EndPage>
					<MedlinePgn>701-4</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>In a sample of 62 patients with Bipolar I disorder, the authors used a repeated measures longitudinal design to examine whether global family functioning was associated with the presence of a concurrent bipolar episode as well as whether global family functioning was associated with the presence of manic and depressive episodes in the following 3 months. Participants were recruited for a randomized clinical trial examining the efficacy of family treatments combined with pharmacotherapy for bipolar disorder. Global family functioning was repeatedly measured with both clinician-rated and patient-rated assessment instruments over the 28-month study period. Results indicated that mood episodes were associated with concurrent global family functioning within individuals, but global family functioning was not associated with episode status in the subsequent 3 months. The repeated measures nature of these results suggests that global family functioning and bipolar episodes may fluctuate in concert with each other but that global family functioning is not associated with subsequent change in episode status.</AbstractText>
					<CopyrightInformation>(c) 2006 APA, all rights reserved.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Uebelacker</LastName>
						<ForeName>Lisa A</ForeName>
						<Initials>LA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Human Behavior, Brown University and Psychosocial Research Program, Butler Hospital, Providence, RI, USA. Lisa_Uebelacker@brown.edu</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Beevers</LastName>
						<ForeName>Christopher G</ForeName>
						<Initials>CG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Battle</LastName>
						<ForeName>Cynthia L</ForeName>
						<Initials>CL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Strong</LastName>
						<ForeName>David</ForeName>
						<Initials>D</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Keitner</LastName>
						<ForeName>Gabor I</ForeName>
						<Initials>GI</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ryan</LastName>
						<ForeName>Christine E</ForeName>
						<Initials>CE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Solomon</LastName>
						<ForeName>David A</ForeName>
						<Initials>DA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Miller</LastName>
						<ForeName>Ivan W</ForeName>
						<Initials>IW</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>MH58866</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Fam Psychol</MedlineTA>
				<NlmUniqueID>8802265</NlmUniqueID>
				<ISSNLinking>0893-3200</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D018692">Antimanic Agents</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D019260">Expressed Emotion</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005190">Family</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D005196">Family Therapy</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D009341">Negativism</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D010353">Patient Education as Topic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011614">Psychotherapy, Brief</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D011615">Psychotherapy, Group</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2006</Year>
					<Month>12</Month>
					<Day>21</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2007</Year>
					<Month>2</Month>
					<Day>7</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2006</Year>
					<Month>12</Month>
					<Day>21</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">17176206</ArticleId>
				<ArticleId IdType="doi">10.1037/0893-3200.20.4.701</ArticleId>
				<ArticleId IdType="pii">2006-22333-020</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">35724496</PMID>
			<DateCompleted>
				<Year>2022</Year>
				<Month>07</Month>
				<Day>26</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>09</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1879-1379</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>152</Volume>
						<PubDate>
							<Year>2022</Year>
							<Month>Aug</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of psychiatric research</Title>
					<ISOAbbreviation>J Psychiatr Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Cognitive remediation for people with bipolar disorder: The contribution of session attendance and therapy components to cognitive and functional outcomes.</ArticleTitle>
				<Pagination>
					<StartPage>144</StartPage>
					<EndPage>151</EndPage>
					<MedlinePgn>144-151</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2022.06.021</ELocationID>
				<ELocationID EIdType="pii" ValidYN="Y">S0022-3956(22)00327-2</ELocationID>
				<Abstract>
					<AbstractText Label="BACKGROUND">Cognitive remediation (CR) can reduce cognitive and functional difficulties in people with bipolar disorder (BD). To date, there is limited evidence on the contribution of session attendance and therapy components to treatment outcomes. This study explores whether attendance and core CR components contribute to treatment outcomes.</AbstractText>
					<AbstractText Label="METHODS">This is a secondary analysis using data from a randomized controlled trial comparing CR plus treatment-as-usual (TAU; n&#160;=&#160;40) to TAU only (n&#160;=&#160;40) in euthymic people with BD. Session attendance was measured by number of sessions and by achieving therapy completion, pre-defined as attending &#8805;20 sessions. We used instrumental variable analysis to examine the effect of attendance on treatment outcomes. We then considered the association between core therapy components (i.e., massed practice, errorless learning, strategy use, therapist contact) and post-treatment outcome changes using correlation.</AbstractText>
					<AbstractText Label="RESULTS">The CR group improved significantly in measure of global cognition, psychosocial functioning, and goal attainment. Therapy recipients attended 27.1 sessions on average, with 32 (80%) completing the minimum number of 20 sessions. Attending more sessions and achieving therapy completion were associated with improved treatment outcomes, but this relationship was not significant within the subgroup of CR completers. Improvement in psychosocial functioning was associated with therapist contact and goal attainment with selecting useful strategies during therapy.</AbstractText>
					<AbstractText Label="CONCLUSIONS">Our findings highlight the relevance of session attendance, specifically the importance of achieving a minimum threshold of CR sessions, for outcome improvement. Strategy use and therapist contact might facilitate improvements in psychosocial functioning and personal recovery goals.</AbstractText>
					<CopyrightInformation>Copyright &#169; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Tsapekos</LastName>
						<ForeName>Dimosthenis</ForeName>
						<Initials>D</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: dimosthenis.tsapekos@kcl.ac.uk.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Strawbridge</LastName>
						<ForeName>Rebecca</ForeName>
						<Initials>R</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wykes</LastName>
						<ForeName>Til</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; South London &amp; Maudsley NHS Foundation Trust, Maudsley Hospital, London, UK.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Young</LastName>
						<ForeName>Allan H</ForeName>
						<Initials>AH</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; South London &amp; Maudsley NHS Foundation Trust, Maudsley Hospital, London, UK.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cella</LastName>
						<ForeName>Matteo</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; South London &amp; Maudsley NHS Foundation Trust, Maudsley Hospital, London, UK.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2022</Year>
					<Month>06</Month>
					<Day>11</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>J Psychiatr Res</MedlineTA>
				<NlmUniqueID>0376331</NlmUniqueID>
				<ISSNLinking>0022-3956</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D000072466">Cognitive Remediation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">Cognition</Keyword>
				<Keyword MajorTopicYN="N">Cognitive remediation</Keyword>
				<Keyword MajorTopicYN="N">Functioning</Keyword>
				<Keyword MajorTopicYN="N">Session attendance</Keyword>
				<Keyword MajorTopicYN="N">Therapy components</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2021</Year>
					<Month>10</Month>
					<Day>19</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="revised">
					<Year>2022</Year>
					<Month>5</Month>
					<Day>19</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2022</Year>
					<Month>6</Month>
					<Day>10</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2022</Year>
					<Month>6</Month>
					<Day>21</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2022</Year>
					<Month>7</Month>
					<Day>27</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2022</Year>
					<Month>6</Month>
					<Day>20</Day>
					<Hour>18</Hour>
					<Minute>15</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">35724496</ArticleId>
				<ArticleId IdType="doi">10.1016/j.jpsychires.2022.06.021</ArticleId>
				<ArticleId IdType="pii">S0022-3956(22)00327-2</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">30383333</PMID>
			<DateCompleted>
				<Year>2019</Year>
				<Month>12</Month>
				<Day>06</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>12</Month>
				<Day>17</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1399-5618</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>21</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>2019</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>Bipolar disorders</Title>
					<ISOAbbreviation>Bipolar Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder.</ArticleTitle>
				<Pagination>
					<StartPage>350</StartPage>
					<EndPage>360</EndPage>
					<MedlinePgn>350-360</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12715</ELocationID>
				<Abstract>
					<AbstractText Label="INTRODUCTION">Depressive episodes are often prevalent among patients with bipolar disorder, but little is known regarding the differential patterns of development over time. We aimed to determine and characterize trajectories of depressive symptoms among adults with bipolar disorder during 6&#160;months of systematic treatment.</AbstractText>
					<AbstractText Label="METHODS">The pragmatic clinical trial, Bipolar Clinical Health Outcomes Initiative in Comparative Effectiveness (CHOICE), randomized 482 outpatients with bipolar disorder to lithium or quetiapine. Depressive symptoms were rated at up to 9 visits using the Montgomery-Asberg Depression Rating Scale (MADRS). Growth mixture modeling was utilized to identify trajectories and multinomial regression analysis estimated associations with potential predictors.</AbstractText>
					<AbstractText Label="RESULTS">Four distinct trajectories of depressive symptoms were identified. The responding class (60.3%) with a rapid reduction and subsequent low level; the partial-responding class (18.4%) with an initial reduction followed by an increase during the remaining weeks; the fluctuating class (11.6%) with a fluctuation in depressive symptoms; and the non-responding class (9.7%) with sustained moderate-severe depressive symptoms. Bipolar type I predicted membership of the non-responding class and randomization to quetiapine predicted membership of either the responding or the non-responding class.</AbstractText>
					<AbstractText Label="CONCLUSION">Approximately 30% experienced a partial or fluctuating course, and almost 10% had a chronic course with moderate-severe depression during 6&#160;months. Patients diagnosed with bipolar type 1 had higher risk of being categorized into a class with a worse outcome. While no differences in average overall outcomes occurred between the lithium and quetiapine groups, trajectory analysis revealed that the lithium group had more variable courses.</AbstractText>
					<CopyrightInformation>&#169; 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Behrendt-M&#248;ller</LastName>
						<ForeName>Ida</ForeName>
						<Initials>I</Initials>
						<Identifier Source="ORCID">0000-0001-9716-720X</Identifier>
						<AffiliationInfo>
							<Affiliation>Mental Health Centre Copenhagen, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Madsen</LastName>
						<ForeName>Trine</ForeName>
						<Initials>T</Initials>
						<Identifier Source="ORCID">0000-0003-4918-5862</Identifier>
						<AffiliationInfo>
							<Affiliation>Mental Health Centre Copenhagen, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>S&#248;rensen</LastName>
						<ForeName>Holger Jelling</ForeName>
						<Initials>HJ</Initials>
						<AffiliationInfo>
							<Affiliation>Mental Health Centre Copenhagen, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sylvia</LastName>
						<ForeName>Louisa</ForeName>
						<Initials>L</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Friedman</LastName>
						<ForeName>Edward S</ForeName>
						<Initials>ES</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Shelton</LastName>
						<ForeName>Richard C</ForeName>
						<Initials>RC</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bowden</LastName>
						<ForeName>Charles L</ForeName>
						<Initials>CL</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Texas Health Science Center, San Antonio, Texas.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Calabrese</LastName>
						<ForeName>Joseph R</ForeName>
						<Initials>JR</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>McElroy</LastName>
						<ForeName>Susan L</ForeName>
						<Initials>SL</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Lindner Center of HOPE, Mason, Ohio.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ketter</LastName>
						<ForeName>Terence A</ForeName>
						<Initials>TA</Initials>
						<Identifier Source="ORCID">0000-0001-5132-453X</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Reilly-Harrington</LastName>
						<ForeName>Noreen A</ForeName>
						<Initials>NA</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gao</LastName>
						<ForeName>Keming</ForeName>
						<Initials>K</Initials>
						<Identifier Source="ORCID">0000-0003-1130-2461</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Thase</LastName>
						<ForeName>Michael</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>V Bobo</LastName>
						<ForeName>William</ForeName>
						<Initials>W</Initials>
						<Identifier Source="ORCID">0000-0002-5674-3079</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tohen</LastName>
						<ForeName>Mauricio</ForeName>
						<Initials>M</Initials>
						<Identifier Source="ORCID">0000-0001-8049-4351</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of New Mexico Health Science Center, Albuquerque, New Mexico.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>McInnis</LastName>
						<ForeName>Melvin</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kamali</LastName>
						<ForeName>Masoud</ForeName>
						<Initials>M</Initials>
						<Identifier Source="ORCID">0000-0003-1453-5201</Identifier>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kocsis</LastName>
						<ForeName>James H</ForeName>
						<Initials>JH</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Weill Cornell Medical College, New York, New York.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Deckersbach</LastName>
						<ForeName>Thilo</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>K&#246;hler-Forsberg</LastName>
						<ForeName>Ole</ForeName>
						<Initials>O</Initials>
						<Identifier Source="ORCID">0000-0003-1453-5201</Identifier>
						<AffiliationInfo>
							<Affiliation>Mental Health Centre Copenhagen, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nierenberg</LastName>
						<ForeName>Andrew A</ForeName>
						<Initials>AA</Initials>
						<AffiliationInfo>
							<Affiliation>Dauten Family Center for Bipolar Treatment Innovation, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Harvard Medical School, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2018</Year>
					<Month>12</Month>
					<Day>01</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>Denmark</Country>
				<MedlineTA>Bipolar Disord</MedlineTA>
				<NlmUniqueID>100883596</NlmUniqueID>
				<ISSNLinking>1398-5647</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>2S3PL1B6UJ</RegistryNumber>
					<NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D003863">Depression</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016903">Drug Monitoring</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D018020">Lithium Compounds</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000069348">Quetiapine Fumarate</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">depressive symptoms</Keyword>
				<Keyword MajorTopicYN="N">growth mixture modeling</Keyword>
				<Keyword MajorTopicYN="N">trajectories</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2018</Year>
					<Month>11</Month>
					<Day>2</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2019</Year>
					<Month>12</Month>
					<Day>18</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2018</Year>
					<Month>11</Month>
					<Day>2</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">30383333</ArticleId>
				<ArticleId IdType="doi">10.1111/bdi.12715</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">25310199</PMID>
			<DateCompleted>
				<Year>2015</Year>
				<Month>07</Month>
				<Day>28</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2014</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Electronic">1533-712X</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>34</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>2014</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of clinical psychopharmacology</Title>
					<ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study.</ArticleTitle>
				<Pagination>
					<StartPage>749</StartPage>
					<EndPage>751</EndPage>
					<MedlinePgn>749-51</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000000222</ELocationID>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Murphy</LastName>
						<ForeName>Beth L</ForeName>
						<Initials>BL</Initials>
						<AffiliationInfo>
							<Affiliation>Frazier Research Institute McLean Hospital Belmont, MA and Harvard Medical School Boston, MA BMurphy5@partners.org Harvard Medical School Boston, MA and Laboratory for Psychiatric Biostatistics McLean Hospital Belmont, MA Frazier Research Institute McLean Hospital Belmont, MA and Harvard Medical School Boston, MA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ravichandran</LastName>
						<ForeName>Caitlin</ForeName>
						<Initials>C</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Babb</LastName>
						<ForeName>Suzann M</ForeName>
						<Initials>SM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cohen</LastName>
						<ForeName>Bruce M</ForeName>
						<Initials>BM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
					<PublicationType UI="D016422">Letter</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Psychopharmacol</MedlineTA>
				<NlmUniqueID>8109496</NlmUniqueID>
				<ISSNLinking>0271-0749</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>5S6W795CQM</RegistryNumber>
					<NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003866">Depressive Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D009271">Naltrexone</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D009292">Narcotic Antagonists</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="entrez">
					<Year>2014</Year>
					<Month>10</Month>
					<Day>14</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2014</Year>
					<Month>10</Month>
					<Day>14</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2015</Year>
					<Month>7</Month>
					<Day>29</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">25310199</ArticleId>
				<ArticleId IdType="doi">10.1097/JCP.0000000000000222</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">12479659</PMID>
			<DateCompleted>
				<Year>2003</Year>
				<Month>04</Month>
				<Day>02</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>11</Month>
				<Day>06</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1398-5647</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>4</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>2002</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>Bipolar disorders</Title>
					<ISOAbbreviation>Bipolar Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tiagabine in treatment refractory bipolar disorder: a clinical case series.</ArticleTitle>
				<Pagination>
					<StartPage>283</StartPage>
					<EndPage>289</EndPage>
					<MedlinePgn>283-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Anticonvulsants have provided major treatment advances for patients with bipolar disorder. Many of these drugs, including several with proven efficacy in bipolar mania or depression, enhance the activity of the gamma-amino butyric acid (GABA) neurotransmitter system. A new anticonvulsant, tiagabine, has selective GABAergic activity and is approved for patients with partial epilepsy. Few reports of its potential effectiveness in bipolar disorder, however, have been published. We sought to evaluate the effectiveness of tiagabine added to ongoing medication regimens in patients with bipolar disorder inadequately responsive to or intolerant of usual treatments.</AbstractText>
					<AbstractText Label="METHODS" NlmCategory="METHODS">Seventeen treatment-refractory patients participating in the Stanley Foundation Bipolar Network (SFBN) long-term follow-up study were offered open treatment with add-on tiagabine after discussion of the risks, benefits, other treatment options and giving informed consent. Patients' clinical symptoms and somatic complaints were closely monitored with SFBN longitudinal and cross-sectional ratings. Four patients discontinued low-dose tiagabine prior to the second visit and were excluded from data analysis.</AbstractText>
					<AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirteen patients received a mean of 38 days of treatment at a mean dose of 8.7 mg/day of tiagabine. On the Clinical Global Impression Scale for Bipolar Disorder Overall category, three (23%) patients showed much or very much improvement and 10 (77%) patients showed no change or worsening. Three significant adverse events were noted, including two presumptive seizures.</AbstractText>
					<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Open add-on tiagabine for treatment-refractory patients with bipolar disorder demonstrated limited efficacy with the majority of patients showing no change or worsening of clinical symptoms. In addition, patients experienced serious side-effects attributed as likely due to the medication, which resolved without lasting consequence when tiagabine was discontinued.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Suppes</LastName>
						<ForeName>Trisha</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9070, USA. trisha.suppes@utsouthwestern.edu</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Chisholm</LastName>
						<ForeName>Karrie A</ForeName>
						<Initials>KA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dhavale</LastName>
						<ForeName>Dawn</ForeName>
						<Initials>D</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Frye</LastName>
						<ForeName>Mark A</ForeName>
						<Initials>MA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Altshuler</LastName>
						<ForeName>Lori L</ForeName>
						<Initials>LL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>McElroy</LastName>
						<ForeName>Susan L</ForeName>
						<Initials>SL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Keck</LastName>
						<ForeName>Paul E</ForeName>
						<Initials>PE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nolen</LastName>
						<ForeName>Willem A</ForeName>
						<Initials>WA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kupka</LastName>
						<ForeName>Ralph</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Denicoff</LastName>
						<ForeName>Kirk D</ForeName>
						<Initials>KD</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Leverich</LastName>
						<ForeName>Gabrielle S</ForeName>
						<Initials>GS</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rush</LastName>
						<ForeName>A John</ForeName>
						<Initials>AJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Post</LastName>
						<ForeName>Robert M</ForeName>
						<Initials>RM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Denmark</Country>
				<MedlineTA>Bipolar Disord</MedlineTA>
				<NlmUniqueID>100883596</NlmUniqueID>
				<ISSNLinking>1398-5647</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D009557">Nipecotic Acids</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>Z80I64HMNP</RegistryNumber>
					<NameOfSubstance UI="D000078308">Tiagabine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000928">Antidepressive Agents</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D039721">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D009557">Nipecotic Acids</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000078308">Tiagabine</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2002</Year>
					<Month>12</Month>
					<Day>14</Day>
					<Hour>4</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2003</Year>
					<Month>4</Month>
					<Day>4</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2002</Year>
					<Month>12</Month>
					<Day>14</Day>
					<Hour>4</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">12479659</ArticleId>
				<ArticleId IdType="doi">10.1034/j.1399-5618.2002.01201.x</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">34218509</PMID>
			<DateCompleted>
				<Year>2022</Year>
				<Month>04</Month>
				<Day>05</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2023</Year>
				<Month>03</Month>
				<Day>02</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1399-5618</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>24</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>2022</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>Bipolar disorders</Title>
					<ISOAbbreviation>Bipolar Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Adjunctive dietary intervention for bipolar disorder: a randomized, controlled, parallel-group, modified double-blinded trial of a high n-3 plus low n-6 diet.</ArticleTitle>
				<Pagination>
					<StartPage>171</StartPage>
					<EndPage>184</EndPage>
					<MedlinePgn>171-184</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.13112</ELocationID>
				<Abstract>
					<AbstractText Label="OBJECTIVE">To investigate the preliminary efficacy of a high n-3 plus low n-6 (H3-L6) dietary intervention in improving mood stability in Bipolar Disorder (BD) when compared to dietary intervention with usual U.S. levels of n-6 and n-3 polyunsaturated fatty acid (PUFA) intakes (control diet, CD).</AbstractText>
					<AbstractText Label="METHODS">This 2-arm, parallel-group, randomized, modified double-blind, controlled 48-week study of 12-week intensive diet intervention in subjects with BD was conducted at a single suburban-rural site in the mid-Atlantic region. Participants with DSM-IV TR BD I or II with hypomanic or depressive symptoms were randomized, stratified on gender (N&#160;=&#160;82). The intervention included the provision of group-specific study foods and dietary counseling. Variability of mood symptoms was measured by a twice-daily, 12-week ecological momentary analysis (EMA) paradigm, and group differences were analyzed using multilevel models. Circulating n-3 and n-6 fatty acids were measured at baseline and after 4, 8, and 12&#160;weeks of diet exposure.</AbstractText>
					<AbstractText Label="RESULTS">All 82 randomized participants were included in biochemical analyses. Seventy participants completed at least 2 EMA surveys and were included in primary EMA analyses. Variability in mood, energy, irritability, and pain as measured using EMA was reduced in the H3-L6&#160;group compared to the CD group. No significant differences in mean ratings of mood symptoms, or any other symptom measures, were detected. The dietary intervention effect on target PUFAs significantly differed by the group over time.</AbstractText>
					<AbstractText Label="CONCLUSIONS">A dietary intervention adjunctive to usual care showed preliminary efficacy in improving variability in mood symptoms in participants with BD.</AbstractText>
					<AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.Gov NCT02272010.</AbstractText>
					<CopyrightInformation>&#169; 2021 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Saunders</LastName>
						<ForeName>Erika F H</ForeName>
						<Initials>EFH</Initials>
						<Identifier Source="ORCID">0000-0001-7222-0828</Identifier>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Health, Penn State University College of Medicine, Hershey, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mukherjee</LastName>
						<ForeName>Dahlia</ForeName>
						<Initials>D</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Health, Penn State University College of Medicine, Hershey, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Myers</LastName>
						<ForeName>Tiffany</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Health, Penn State University College of Medicine, Hershey, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wasserman</LastName>
						<ForeName>Emily</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hameed</LastName>
						<ForeName>Ahmad</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Health, Penn State University College of Medicine, Hershey, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bassappa Krishnamurthy</LastName>
						<ForeName>Venkatesh</ForeName>
						<Initials>V</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry and Behavioral Health, Penn State University College of Medicine, Hershey, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>MacIntosh</LastName>
						<ForeName>Beth</ForeName>
						<Initials>B</Initials>
						<AffiliationInfo>
							<Affiliation>Metabolic and Nutrition Research Core, University of North Carolina, Chapel Hill, NC, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Domenichiello</LastName>
						<ForeName>Anthony</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ramsden</LastName>
						<ForeName>Christopher E</ForeName>
						<Initials>CE</Initials>
						<AffiliationInfo>
							<Affiliation>National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wang</LastName>
						<ForeName>Ming</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<DataBankList CompleteYN="Y">
					<DataBank>
						<DataBankName>ClinicalTrials.gov</DataBankName>
						<AccessionNumberList>
							<AccessionNumber>NCT02272010</AccessionNumber>
						</AccessionNumberList>
					</DataBank>
				</DataBankList>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>UL1 TR000127</GrantID>
						<Acronym>TR</Acronym>
						<Agency>NCATS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>UL1 TR002014</GrantID>
						<Acronym>TR</Acronym>
						<Agency>NCATS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>Z99 AG999999</GrantID>
						<Acronym>ImNIH</Acronym>
						<Agency>Intramural NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2021</Year>
					<Month>08</Month>
					<Day>02</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>Denmark</Country>
				<MedlineTA>Bipolar Disord</MedlineTA>
				<NlmUniqueID>100883596</NlmUniqueID>
				<ISSNLinking>1398-5647</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D043371">Fatty Acids, Omega-6</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004032">Diet</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D015525">Fatty Acids, Omega-3</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D043371">Fatty Acids, Omega-6</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">depression</Keyword>
				<Keyword MajorTopicYN="N">diet</Keyword>
				<Keyword MajorTopicYN="N">fatty acids</Keyword>
				<Keyword MajorTopicYN="N">food</Keyword>
				<Keyword MajorTopicYN="N">omega-3</Keyword>
				<Keyword MajorTopicYN="N">omega-6</Keyword>
				<Keyword MajorTopicYN="N">unsaturated</Keyword>
			</KeywordList>
			<CoiStatement>CONFLICT OF INTEREST. ES reports having received a stipend for work as an associate editor from the 
				<i>Journal of Clinical Psychiatry</i> and past participation in an advisory board for Myriad Neuroscience. The other authors report no financial relationships with commercial interests.
			</CoiStatement>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2021</Year>
					<Month>7</Month>
					<Day>5</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2022</Year>
					<Month>4</Month>
					<Day>6</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2021</Year>
					<Month>7</Month>
					<Day>4</Day>
					<Hour>21</Hour>
					<Minute>15</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2023</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">34218509</ArticleId>
				<ArticleId IdType="mid">NIHMS1807007</ArticleId>
				<ArticleId IdType="pmc">PMC9157563</ArticleId>
				<ArticleId IdType="doi">10.1111/bdi.13112</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. Washington, DC: American Psychiatric Association; 2013.</Citation>
				</Reference>
				<Reference>
					<Citation>Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543&#8211;552.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC1931566</ArticleId>
						<ArticleId IdType="pubmed">17485606</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990&#8211;2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743&#8211;800.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4561509</ArticleId>
						<ArticleId IdType="pubmed">26063472</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385&#8211;395.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">20092882</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nierenberg AA, McElroy SL, Friedman ES, et al. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry. 2016;77(1):90&#8211;99.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">26845264</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bauer M, Glenn T, Alda M, et al. Comparison of pre-episode and pre-remission states using mood ratings from patients with bipolar disorder. Pharmacopsychiatry. 2011;44(Suppl 1):S49&#8211;53.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">21544745</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bauer M, Glenn T, Keil M, et al. Brief depressive symptoms in patients with bipolar disorder: analysis of long-term self-reported data. Aust N Z J Psychiatry. 2012;46(11):1068&#8211;1078.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">22734088</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530&#8211;537.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12044195</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Liu JJ, Green P, John Mann J, Rapoport SI, Sublette ME. Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease. Brain Res. 2015;1597:220&#8211;246.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4339314</ArticleId>
						<ArticleId IdType="pubmed">25498862</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry. 2003;160(12):2222&#8211;2227.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">14638594</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr. 2006;83(6 Suppl):1483S&#8211;1493S.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16841858</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Freeman MP, Rapaport MH. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care. J Clin Psychiatry. 2011;72(2):258&#8211;259.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">21382308</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids. 1999;60(5&#8211; 6):329&#8211;337.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">10471117</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56(5):407&#8211;412.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">10232294</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Keck PE, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006;60(9):1020&#8211;1022.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16814257</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Murphy BL, Stoll AL, Harris PQ, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. 2012;32(5):699&#8211;703.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">22926607</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006;188:46&#8211;50.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16388069</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kraguljac NV, Montori VM, Pavuluri M, Chai HS, Wilson BS, Unal SS. Efficacy of omega-3 fatty acids in mood disorders -a systematic review and metaanalysis. Psychopharmacol Bull. 2009;42(3):39&#8211;54.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19752840</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Taha AY, Blanchard HC, Cheon Y, et al. Dietary linoleic acid lowering reduces lipopolysaccharide-induced increase in brain arachidonic acid metabolism. Mol Neurobiol. 2017;54(6):4303&#8211;4315.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5843819</ArticleId>
						<ArticleId IdType="pubmed">27339880</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Taha AY, Cheon Y, Faurot KF, et al. Dietary omega-6 fatty acid lowering increases bioavailability of omega-3 polyunsaturated fatty acids in human plasma lipid pools. Prostaglandins Leukot Essent Fatty Acids. 2014;90(5):151&#8211;157.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4035030</ArticleId>
						<ArticleId IdType="pubmed">24675168</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci. 2014;5(6):459&#8211;467.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4063504</ArticleId>
						<ArticleId IdType="pubmed">24786695</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Saunders EF, Ramsden CE, Sherazy MS, Gelenberg AJ, Davis JM, Rapoport SI. Reconsidering dietary polyunsaturated fatty acids in bipolar disorder: a translational picture. J Clin Psychiatry. 2016;77(10):e1342&#8211;e1347.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6093189</ArticleId>
						<ArticleId IdType="pubmed">27788314</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Myin-Germeys I, Peeters F, Havermans R, et al. Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatr Scand. 2003;107(2):124&#8211;131.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12534438</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Depp CA, Kim DH, de Dios LV, Wang V, Ceglowski J. A pilot study of mood ratings captured by mobile phone versus paper-and-pencil mood charts in bipolar disorder. J Dual Diagn. 2012;8(4):326&#8211;332.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3640573</ArticleId>
						<ArticleId IdType="pubmed">23646035</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Schwartz S, Schultz S, Reider A, Saunders EF. Daily mood monitoring of symptoms using smartphones in bipolar disorder: a pilot study assessing the feasibility of ecological momentary assessment. J Affect Disord. 2016;191:88&#8211;93.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4799837</ArticleId>
						<ArticleId IdType="pubmed">26655117</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Li H, Mukherjee D, Krishnamurthy VB, et al. Use of ecological momentary assessment to detect variability in mood, sleep and stress in bipolar disorder. BMC Res Notes. 2019;12(1):791.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6894147</ArticleId>
						<ArticleId IdType="pubmed">31801608</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Faurholt-Jepsen M, Munkholm K, Frost M, Bardram JE, Kessing LV. Electronic self-monitoring of mood using IT platforms in adult patients with bipolar disorder: a systematic review of the validity and evidence. BMC Psychiatry. 2016;16:7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4714425</ArticleId>
						<ArticleId IdType="pubmed">26769120</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mann JD, Faurot KR, MacIntosh B, et al. A sixteen-week three-armed, randomized, controlled trial investigating clinical and biochemical effects of targeted alterations in dietary linoleic acid and n-3 EPA+DHA in adults with episodic migraine: study protocol. Prostaglandins Leukot Essent Fatty Acids. 2018;128:41&#8211;52.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6269096</ArticleId>
						<ArticleId IdType="pubmed">29413360</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Altman EG, Hedeker DR, Janicak PG, Peterson JL, Davis JM. The Clinician-Administered Rating Scale for Mania (CARS-M): development, reliability, and validity. Biol Psychiatry. 1994;36(2):124&#8211;134.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7948445</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Davidson J, Turnbull CD, Strickland R, Miller R, Graves K. The Montgomery-Asberg Depression Scale: reliability and validity. Acta Psychiatr Scand. 1986;73(5):544&#8211;548.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3751660</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22&#8211;33;quiz 34&#8211;57.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9881538</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>MacIntosh BA, Ramsden CE, Faurot KR, et al. Low-n-6 and low-n-6 plus high-n-3 diets for use in clinical research. Br J Nutr. 2013;110(3):559&#8211;568.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4091836</ArticleId>
						<ArticleId IdType="pubmed">23328113</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Folch J, Lees M, Sloan Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497&#8211;509.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">13428781</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ramsden CE, Ringel A, Majchrzak-Hong SF, et al. Dietary linoleic acid-induced alterations in pro- and anti-nociceptive lipid autacoids: Implications for idiopathic pain syndromes? Mol Pain. 2016;12:174480691663638.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4955998</ArticleId>
						<ArticleId IdType="pubmed">27030719</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Domenichiello AF, Jensen JR, Zamora D, et al. Identifying oxidized lipid mediators as prognostic biomarkers of chronic post-traumatic headache. Pain. 2020;161(12):2775&#8211;2785.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7669546</ArticleId>
						<ArticleId IdType="pubmed">32694380</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Yuan ZX, Majchrzak-Hong S, Keyes GS, Iadarola MJ, Mannes AJ, Ramsden CE. Lipidomic profiling of targeted oxylipins with ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2018;410(23):6009&#8211;6029.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6314687</ArticleId>
						<ArticleId IdType="pubmed">30074088</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Jacka FN. Diet and depression-from confirmation to implementation. JAMA. 2019;321(9):842&#8211;843.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">30835294</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Jacka FN, O&#8217;Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the &#8216;SMILES&#8217; trial). BMC Med. 2017;15(1):23.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5282719</ArticleId>
						<ArticleId IdType="pubmed">28137247</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Chiu CC, Huang SY, Chen CC, Su KP. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry. 2005;66(12):1613&#8211;1614.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16401167</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Frangou S, Lewis M, Wollard J, Simmons A. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol. 2007;21(4):435&#8211;439.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16891338</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord. 2010;12(2):142&#8211;154.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3024033</ArticleId>
						<ArticleId IdType="pubmed">20402707</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81&#8211;86.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">21903025</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol. 2007;17(6&#8211;7):440&#8211;447.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17258897</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr. 2009;63(8):1037&#8211;1040.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19156158</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Fristad MA, Young AS, Vesco AT, et al. A Randomized controlled trial of individual family psychoeducational psychotherapy and omega-3 fatty acids in youth with subsyndromal bipolar disorder. J Child Adolesc Psychopharmacol. 2015;25(10):764&#8211;774.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4691654</ArticleId>
						<ArticleId IdType="pubmed">26682997</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol. 2009;2(2):207&#8211;214.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2825027</ArticleId>
						<ArticleId IdType="pubmed">20021459</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Reese EA, Cheon Y, Ramadan E, et al. Gabapentin&#8217;s minimal action on markers of rat brain arachidonic acid metabolism agrees with its inefficacy against bipolar disorder. Prostaglandins Leukot Essent Fatty Acids. 2012;87(2&#8211;3):71&#8211;77.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3431015</ArticleId>
						<ArticleId IdType="pubmed">22841517</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cheon Y, Park JY, Modi HR, et al. Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E&#8322; concentration in rat brain. J Neurochem. 2011;119(2):364&#8211;376.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3188676</ArticleId>
						<ArticleId IdType="pubmed">21812779</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Modi HR, Taha AY, Kim HW, Chang L, Rapoport SI, Cheon Y. Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability. J Neurochem. 2013;124(3):376&#8211;387.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3540173</ArticleId>
						<ArticleId IdType="pubmed">23121637</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Shimshoni JA, Basselin M, Li LO, Coleman RA, Rapoport SI, Modi HR. Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: relevance to valproate&#8217;s efficacy against bipolar disorder. Biochim Biophys Acta. 2011;1811(3):163&#8211;169.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3037030</ArticleId>
						<ArticleId IdType="pubmed">21184843</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lee HJ, Rao JS, Chang L, Rapoport SI, Kim HW. Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to &#8216;switching&#8217; in bipolar disorder? Mol Psychiatry. 2010;15(6):602&#8211;614.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2874651</ArticleId>
						<ArticleId IdType="pubmed">18982003</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kim HW, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry. 2011;16(4):419&#8211;428.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3190400</ArticleId>
						<ArticleId IdType="pubmed">20038946</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev. 2009;61(2):185&#8211;209.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2757443</ArticleId>
						<ArticleId IdType="pubmed">19555719</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804&#8211;817.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">20934453</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ramsden CE, Zamora D, Makriyannis A, et al. Diet-induced changes in n-3- and n-6-derived endocannabinoids and reductions in headache pain and psychological distress. J Pain. 2015;16(8):707&#8211;716.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4522350</ArticleId>
						<ArticleId IdType="pubmed">25958314</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Di Miceli M, Bosch-Bouju C, Lay&#233; S. PUFA and their derivatives in neurotransmission and synapses: a new hallmark of synaptopathies. Proc Nutr Soc. 2020;79(4):388&#8211;403.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">32299516</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Igarashi M, Ma K, Gao F, et al. Brain lipid concentrations in bipolar disorder. J Psychiatr Res. 2010;44(3):177&#8211;182.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2821962</ArticleId>
						<ArticleId IdType="pubmed">19767014</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hamazaki K, Maekawa M, Toyota T, Dean B, Hamazaki T, Yoshikawa T. Fatty acid composition of the postmortem prefrontal cortex of patients with schizophrenia, bipolar disorder, and major depressive disorder. Psychiatry Res. 2015;227(2&#8211;3):353&#8211;359.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">25858798</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hamazaki K, Choi KH, Kim HY. Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species. J Psychiatr Res. 2010;44(11):688&#8211;693.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2891352</ArticleId>
						<ArticleId IdType="pubmed">20056243</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bavaresco DV, Colonetti T, Grande AJ, et al. Efficacy of celecoxib adjunct treatment on bipolar disorder: systematic review and metaanalysis. CNS Neurol Disord Drug Targets. 2019;18(1):19&#8211;28.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">30398124</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Stolk P, Souverein PC, Wilting I, et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids. 2010;82(1):9&#8211;14.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2818404</ArticleId>
						<ArticleId IdType="pubmed">19939659</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Chiu C-C, Huang S-Y, Su K-P, et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol. 2003;13(2):99&#8211;103.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12650953</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sublette ME, Bosetti F, DeMar JC, et al. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord. 2007;9(7):759&#8211;765.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2238693</ArticleId>
						<ArticleId IdType="pubmed">17988367</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Pandey GN. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord. 2010;126(1&#8211;2):303&#8211;311.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2921578</ArticleId>
						<ArticleId IdType="pubmed">20413162</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Evans SJ, Kamali M, Prossin AR, et al. Association of plasma omega-3 and omega-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res. 2012;46(11):1435&#8211;1441.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3495133</ArticleId>
						<ArticleId IdType="pubmed">22884424</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Evans SJ, Prossin AR, Harrington GJ, et al. Fats and factors: lipid profiles associate with personality factors and suicidal history in bipolar subjects. PLoS One. 2012;7(1):e29297.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3258247</ArticleId>
						<ArticleId IdType="pubmed">22253709</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Evans SJ, Ringrose RN, Harrington GJ, Mancuso P, Burant CF, McInnis MG. Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism. J Psychiatr Res. 2014;57:58&#8211;64.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4127886</ArticleId>
						<ArticleId IdType="pubmed">24953860</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Saunders EF, Reider A, Singh G, Gelenberg AJ, Rapoport SI. Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment. Bipolar Disord. 2015;17(7):729&#8211;742.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4623957</ArticleId>
						<ArticleId IdType="pubmed">26424416</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Pomponi M, Janiri L, La Torre G, et al. Plasma levels of n-3 fatty acids in bipolar patients: deficit restricted to DHA. J Psychiatr Res. 2013;47(3):337&#8211;342.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23207113</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ramsden CE, Faurot KR, Zamora D, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain. 2013;154(11):2441&#8211;2451.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3850757</ArticleId>
						<ArticleId IdType="pubmed">23886520</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ramsden CE, Faurot KR, Zamora D, et al. Targeted alterations in dietary n-3 and n-6 fatty acids improve life functioning and reduce psychological distress among patients with chronic headache: a secondary analysis of a randomized trial. Pain. 2015;156(4):587&#8211;596.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5020375</ArticleId>
						<ArticleId IdType="pubmed">25790451</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Saunders EFH, Nazir R, Kamali M, et al. Gender differences, clinical correlates, and longitudinal outcome of bipolar disorder with co-morbid migraine. J Clin Psychiatry. 2014;75(5):512&#8211;519.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4211932</ArticleId>
						<ArticleId IdType="pubmed">24816075</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010611.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23797677</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry. 2007;68(8):1237&#8211;1245.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17854249</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bauer M, Glenn T, Grof P, et al. Frequency of subsyndromal symptoms and employment status in patients with bipolar disorder. Soc Psychiatry Psychiatr Epidemiol. 2009;44(7):515&#8211;522.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19011720</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bauer M, Glenn T, Grof P, Schmid R, Pfennig A, Whybrow PC. Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder? Psychopathology. 2010;43(1):1&#8211;7.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">19893338</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Faurholt-Jepsen M, Vinberg M, Christensen EM, et al. Differences in psychomotor activity during remission in unipolar disorder and bipolar disorder. Bipolar Disord. 2011;13:43.</Citation>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">15306144</PMID>
			<DateCompleted>
				<Year>2004</Year>
				<Month>11</Month>
				<Day>26</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2015</Year>
				<Month>11</Month>
				<Day>19</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0165-0327</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>81</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>2004</Year>
							<Month>Aug</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of affective disorders</Title>
					<ISOAbbreviation>J Affect Disord</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Sensitivity and specificity of the Mood Disorder Questionnaire for detecting bipolar disorder.</ArticleTitle>
				<Pagination>
					<StartPage>167</StartPage>
					<EndPage>171</EndPage>
					<MedlinePgn>167-71</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aims to replicate the sensitivity and specificity of the Mood Disorder Questionnaire (MDQ) for bipolar disorder and assess the impact of insight on the MDQ's sensitivity. Unlike prior telephone-based validation, this is the first clinical study to assess the validity of the MDQ.</AbstractText>
					<AbstractText Label="METHODS" NlmCategory="METHODS">37 consecutive patients with bipolar spectrum illness received the MDQ, as well as 36 consecutive patients with unipolar depression. MDQ diagnoses were compared to DSM-IV-based SCID diagnoses. A total of 16 bipolar patients also received the Scale to Assess Unawareness of Mental Disorder (SUMD) to measure insight.</AbstractText>
					<AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall sensitivity for the MDQ was 0.58, higher in bipolar I disorder (0.69) than in bipolar II/NOS (0.30, P=0.06). The sample was highly insightful, but the two patients with lowest insight both had false negative screens. Patients' low ratings of severity of mania (question 3 of the MDQ) explained almost half of all false negative results. Specificity was 0.67.</AbstractText>
					<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The MDQ demonstrates good sensitivity in insightful patients with bipolar I disorder, but may be less useful in patients with impaired insight or milder bipolar spectrum conditions.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Miller</LastName>
						<ForeName>Christopher J</ForeName>
						<Initials>CJ</Initials>
						<AffiliationInfo>
							<Affiliation>Bipolar Disorder Research Program, Cambridge Hospital, Cambridge, MA 02139, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Klugman</LastName>
						<ForeName>Jeffry</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Berv</LastName>
						<ForeName>Douglas A</ForeName>
						<Initials>DA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rosenquist</LastName>
						<ForeName>Klara J</ForeName>
						<Initials>KJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ghaemi</LastName>
						<ForeName>S Nassir</ForeName>
						<Initials>SN</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>MH-64189</GrantID>
						<Acronym>MH</Acronym>
						<Agency>NIMH NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>J Affect Disord</MedlineTA>
				<NlmUniqueID>7906073</NlmUniqueID>
				<ISSNLinking>0165-0327</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003951">Diagnostic Errors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005188">False Negative Reactions</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000592">standards</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011594">Psychometrics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D011795">Surveys and Questionnaires</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2002</Year>
					<Month>8</Month>
					<Day>23</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2003</Year>
					<Month>6</Month>
					<Day>3</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2004</Year>
					<Month>8</Month>
					<Day>13</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2004</Year>
					<Month>12</Month>
					<Day>16</Day>
					<Hour>9</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2004</Year>
					<Month>8</Month>
					<Day>13</Day>
					<Hour>5</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">15306144</ArticleId>
				<ArticleId IdType="doi">10.1016/S0165-0327(03)00156-3</ArticleId>
				<ArticleId IdType="pii">S0165032703001563</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">35219178</PMID>
			<DateCompleted>
				<Year>2022</Year>
				<Month>05</Month>
				<Day>09</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>05</Month>
				<Day>24</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1873-7862</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>58</Volume>
						<PubDate>
							<Year>2022</Year>
							<Month>May</Month>
						</PubDate>
					</JournalIssue>
					<Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title>
					<ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Mood instability - A new outcome measure in randomised trials of bipolar disorder?</ArticleTitle>
				<Pagination>
					<StartPage>39</StartPage>
					<EndPage>41</EndPage>
					<MedlinePgn>39-41</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2022.02.005</ELocationID>
				<ELocationID EIdType="pii" ValidYN="Y">S0924-977X(22)00131-6</ELocationID>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kessing</LastName>
						<ForeName>Lars Vedel</ForeName>
						<Initials>LV</Initials>
						<AffiliationInfo>
							<Affiliation>Copenhagen Affective disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address: lars.vedel.kessing@regionh.dk.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Faurholt-Jepsen</LastName>
						<ForeName>Maria</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Copenhagen Affective disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2022</Year>
					<Month>02</Month>
					<Day>23</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>Eur Neuropsychopharmacol</MedlineTA>
				<NlmUniqueID>9111390</NlmUniqueID>
				<ISSNLinking>0924-977X</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000339">Affect</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D017063">Outcome Assessment, Health Care</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">Digital monitoring</Keyword>
				<Keyword MajorTopicYN="N">Mood instability</Keyword>
			</KeywordList>
			<CoiStatement>Declaration of Competing Interest LVK has within the preceding three years been a consultant for Lundbeck and Teva.</CoiStatement>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2022</Year>
					<Month>1</Month>
					<Day>4</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="revised">
					<Year>2022</Year>
					<Month>2</Month>
					<Day>4</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2022</Year>
					<Month>2</Month>
					<Day>7</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2022</Year>
					<Month>2</Month>
					<Day>27</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2022</Year>
					<Month>5</Month>
					<Day>10</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2022</Year>
					<Month>2</Month>
					<Day>26</Day>
					<Hour>20</Hour>
					<Minute>16</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">35219178</ArticleId>
				<ArticleId IdType="doi">10.1016/j.euroneuro.2022.02.005</ArticleId>
				<ArticleId IdType="pii">S0924-977X(22)00131-6</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Owner="NLM" Status="MEDLINE">
			<PMID Version="1">2494152</PMID>
			<DateCompleted>
				<Year>1989</Year>
				<Month>04</Month>
				<Day>24</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0160-6689</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>50 Suppl</Volume>
						<PubDate>
							<Year>1989</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of clinical psychiatry</Title>
					<ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Valproate use in acute mania and bipolar disorder: an international perspective.</ArticleTitle>
				<Pagination>
					<StartPage>10</StartPage>
					<EndPage>12</EndPage>
					<MedlinePgn>10-2</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The author reviews European studies on the effect of the anticonvulsant agent valproate in the treatment of bipolar affective disorder. Since mania is associated with depletion of inhibitory transmitters in the central nervous system and gamma-aminobutyric acid (GABA) is one of the most important inhibitory transmitters, the GABAergic effects of valproate provide a theoretical basis for its use in affective disorders. The European studies, which have been both open and controlled, showed beneficial effects of valproate in acute and prophylactic treatment of bipolar illness, with particularly good results in mania. Side effects reported most often were mild and transient, and included gastrointestinal upset, lethargy, increased levels of hepatic transaminases, and mild alopecia.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Fawcett</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016430">Clinical Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016454">Review</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Psychiatry</MedlineTA>
				<NlmUniqueID>7801243</NlmUniqueID>
				<ISSNLinking>0160-6689</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>614OI1Z5WI</RegistryNumber>
					<NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D005060">Europe</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D014635">Valproic Acid</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
			<NumberOfReferences>25</NumberOfReferences>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1989</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1989</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1989</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">2494152</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Curated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">28007034</PMID>
			<DateCompleted>
				<Year>2017</Year>
				<Month>06</Month>
				<Day>09</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>12</Month>
				<Day>02</Day>
			</DateRevised>
			<Article PubModel="Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1471-244X</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>16</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>2016</Year>
							<Month>Dec</Month>
							<Day>22</Day>
						</PubDate>
					</JournalIssue>
					<Title>BMC psychiatry</Title>
					<ISOAbbreviation>BMC Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Online psycho-education to the treatment of bipolar disorder: protocol of a randomized controlled trial.</ArticleTitle>
				<Pagination>
					<StartPage>452</StartPage>
					<MedlinePgn>452</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="pii" ValidYN="Y">452</ELocationID>
				<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-016-1159-0</ELocationID>
				<Abstract>
					<AbstractText Label="BACKGROUND">Bipolar disorder patients frequently present recurrent episodes and often experience subsyndromal symptoms, cognitive impairment and difficulties in functioning, with a low quality of life, illness relapses and recurrent hospitalization. Early diagnosis and appropriate intervention may play a role in preventing neuroprogression in this disorder. New technologies represent an opportunity to develop standardized psychological treatments using internet-based tools that overcome some of the limitations of face-to-face treatments, in that they are readily accessible and the timing of therapy can be tailored to user needs and availability. However, although many psychological programs are offered through the web and mobile devices for bipolar disorder, there is a lack of high quality evidence concerning their efficacy and effectiveness due to the great variability in measures and methodology used.</AbstractText>
					<AbstractText Label="METHODS">This clinical trial is a simple-blind randomized trial within a European project to compare an internet-based intervention with treatment as usual. Bipolar disorder patients are to be included and randomly assigned to one of two groups: 1) the experimental group (tele-care support) and 2) the control group. Participants in both groups will be evaluated at baseline (pre-treatment) and post-treatment.</AbstractText>
					<AbstractText Label="DISCUSSION">This study describes the design of a clinical trial based on psychoeducation intervention that may have a significant impact on both prognosis and treatment in bipolar disorder. Specifically, bringing different services together (service aggregation), it is hoped that the approach proposed will significantly increase the impact of information and communication technologies on access and adherence to treatment, quality of the service, patient safety, patient and professional satisfaction, and quality of life of patients.</AbstractText>
					<AbstractText Label="TRIAL REGISTRATION">NCT02924415 . Retrospectively registered 27 September 2016.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Gonz&#225;lez-Ortega</LastName>
						<ForeName>Itxaso</ForeName>
						<Initials>I</Initials>
						<AffiliationInfo>
							<Affiliation>Center for Biomedical Research in the Mental Health Network (CIBERSAM), Department of Psychiatry, Araba University Hospital, University of the Basque Country, Olaguibel Street 29, 01004, Vitoria, Spain. itxaso.gonzalezortega@osakidetza.eus.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ugarte</LastName>
						<ForeName>Amaia</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Center for Biomedical Research in the Mental Health Network (CIBERSAM), Department of Psychiatry, Araba University Hospital, University of the Basque Country, Olaguibel Street 29, 01004, Vitoria, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ruiz de Az&#250;a</LastName>
						<ForeName>Sonia</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Center for Biomedical Research in the Mental Health Network (CIBERSAM), Department of Psychiatry, Araba University Hospital, University of the Basque Country, Olaguibel Street 29, 01004, Vitoria, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>N&#250;&#241;ez</LastName>
						<ForeName>Nuria</ForeName>
						<Initials>N</Initials>
						<AffiliationInfo>
							<Affiliation>Center for Biomedical Research in the Mental Health Network (CIBERSAM), Department of Psychiatry, Araba University Hospital, University of the Basque Country, Olaguibel Street 29, 01004, Vitoria, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Zubia</LastName>
						<ForeName>Marta</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Center for Biomedical Research in the Mental Health Network (CIBERSAM), Department of Psychiatry, Araba University Hospital, University of the Basque Country, Olaguibel Street 29, 01004, Vitoria, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ponce</LastName>
						<ForeName>Sara</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Centro de Investigaci&#243;n en Cronicidad-Kronikgune, Barakaldo, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Casla</LastName>
						<ForeName>Patricia</ForeName>
						<Initials>P</Initials>
						<AffiliationInfo>
							<Affiliation>IK4-Tekniker, Gipuzkoa, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Llano</LastName>
						<ForeName>Josu Xabier</ForeName>
						<Initials>JX</Initials>
						<AffiliationInfo>
							<Affiliation>Osatek, Bilbo, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Faria</LastName>
						<ForeName>&#193;ngel</ForeName>
						<Initials>&#193;</Initials>
						<AffiliationInfo>
							<Affiliation>Subdirecci&#243;n de Inform&#225;tica, Sistemas de Informaci&#243;n-Osakidetza, Vitoria, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gonz&#225;lez-Pinto</LastName>
						<ForeName>Ana</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Center for Biomedical Research in the Mental Health Network (CIBERSAM), Department of Psychiatry, Araba University Hospital, University of the Basque Country, Olaguibel Street 29, 01004, Vitoria, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<DataBankList CompleteYN="Y">
					<DataBank>
						<DataBankName>ClinicalTrials.gov</DataBankName>
						<AccessionNumberList>
							<AccessionNumber>NCT02924415</AccessionNumber>
						</AccessionNumberList>
					</DataBank>
				</DataBankList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2016</Year>
					<Month>12</Month>
					<Day>22</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>BMC Psychiatry</MedlineTA>
				<NlmUniqueID>100968559</NlmUniqueID>
				<ISSNLinking>1471-244X</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
					<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D002985">Clinical Protocols</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005060">Europe</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D020407">Internet</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D010353">Patient Education as Topic</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D012107">Research Design</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D012648">Self Care</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016037">Single-Blind Method</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D017216">Telemedicine</DescriptorName>
					<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">Psychoeducation</Keyword>
				<Keyword MajorTopicYN="N">Telemedicine</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2016</Year>
					<Month>11</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2016</Year>
					<Month>12</Month>
					<Day>7</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2016</Year>
					<Month>12</Month>
					<Day>24</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2016</Year>
					<Month>12</Month>
					<Day>23</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2017</Year>
					<Month>6</Month>
					<Day>10</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2016</Year>
					<Month>12</Month>
					<Day>22</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>epublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">28007034</ArticleId>
				<ArticleId IdType="pmc">PMC5178094</ArticleId>
				<ArticleId IdType="doi">10.1186/s12888-016-1159-0</ArticleId>
				<ArticleId IdType="pii">10.1186/s12888-016-1159-0</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Bonn&#237;n C, Del M, Gonz&#225;lez-Pinto A, Sol&#233; B, Reinares M, Gonz&#225;lez-Ortega I, Alberich S, et al. Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. J Affect Disord. 2014;160:50&#8211;54. doi: 10.1016/j.jad.2014.02.034.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2014.02.034</ArticleId>
						<ArticleId IdType="pubmed">24709022</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241&#8211;251. doi: 10.1001/archgenpsychiatry.2011.12.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.12</ArticleId>
						<ArticleId IdType="pmc">PMC3486639</ArticleId>
						<ArticleId IdType="pubmed">21383262</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rosa AR, Magalh&#227;es PV, Czepielewski L, Sulzbach MV, Goi PD, Vieta E, et al. Clinical staging in bipolar disorder: focus on cognition and functioning. J Clin Psychiatry. 2014;75:e450&#8211;e456. doi: 10.4088/JCP.13m08625.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.4088/JCP.13m08625</ArticleId>
						<ArticleId IdType="pubmed">24922497</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell&#8217;Osso MC, et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord. 2013;148:161&#8211;169. doi: 10.1016/j.jad.2013.02.001.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2013.02.001</ArticleId>
						<ArticleId IdType="pubmed">23477848</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Rosa AR, Gonz&#225;lez-Ortega I, Gonz&#225;lez-Pinto A, Echebur&#250;a E, Comes M, Mart&#237;nez-&#192;ran A, et al. One-year psychosocial functioning in patients in the early vs late stage of bipolar disorder. Acta Psychiatr Scand. 2012;125:335&#8211;341. doi: 10.1111/j.1600-0447.2011.01830.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1600-0447.2011.01830.x</ArticleId>
						<ArticleId IdType="pubmed">22283440</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2012;22:339&#8211;346. doi: 10.1016/j.euroneuro.2011.09.008.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.euroneuro.2011.09.008</ArticleId>
						<ArticleId IdType="pubmed">22000157</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Vieta E, Langosch JM, Figueira ML, Souery D, Blasco-Colmenares E, Medina E, et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd) Int J Neuropsychopharmacol. 2011;16:1719&#8211;1732. doi: 10.1017/S1461145713000278.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1017/S1461145713000278</ArticleId>
						<ArticleId IdType="pubmed">23663490</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Colom F, Vieta E, Tacchi MJ, S&#225;nchez-Moreno J, Scott J. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord. 2005;7(Suppl 5):24&#8211;31. doi: 10.1111/j.1399-5618.2005.00248.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2005.00248.x</ArticleId>
						<ArticleId IdType="pubmed">16225557</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Reinares M, S&#225;nchez-Moreno J, Fountoulakis KN. Psychosocial interventions in bipolar disorder: what, for whom, and when. J Affect Disord. 2014;156:46&#8211;55. doi: 10.1016/j.jad.2013.12.017.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2013.12.017</ArticleId>
						<ArticleId IdType="pubmed">24439829</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Colom F, Vieta E, S&#225;nchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009;194:260&#8211;265. doi: 10.1192/bjp.bp.107.040485.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.bp.107.040485</ArticleId>
						<ArticleId IdType="pubmed">19252157</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003;60:402&#8211;407. doi: 10.1001/archpsyc.60.4.402.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1001/archpsyc.60.4.402</ArticleId>
						<ArticleId IdType="pubmed">12695318</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Castle D, White C, Chamberlain J, Berk M, Berk L, Lauder S, et al. Group-based psychosocial intervention for bipolar disorder: randomised controlled trial. Br J Psychiatry. 2010;196:383&#8211;388. doi: 10.1192/bjp.bp.108.058263.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.bp.108.058263</ArticleId>
						<ArticleId IdType="pubmed">20435965</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ. Adjunctive psychotherapy for bipolar disorder: state of the evidence. Am J Psychiatry. 2008;165:1408&#8211;1419. doi: 10.1176/appi.ajp.2008.08040488.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.2008.08040488</ArticleId>
						<ArticleId IdType="pmc">PMC2613162</ArticleId>
						<ArticleId IdType="pubmed">18794208</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lauder S, Berk M, Castle DJ, Dodd S, Berk L. The role of psychotherapy in bipolar disorder. Med J Aust. 2010;193(4):S31&#8211;S35.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">20712559</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gonz&#225;lez-Isasi A, Echebur&#250;a E, Limi&#241;ana JM, Gonz&#225;lez-Pinto A. Predictors of good outcome in patients with refractory bipolar disorder after a drug or a drug and cognitive-behavioral treatment. Compr Psychiatry. 2012;53:224&#8211;229. doi: 10.1016/j.comppsych.2011.05.001.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.comppsych.2011.05.001</ArticleId>
						<ArticleId IdType="pubmed">21658693</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;1(36):427&#8211;440. doi: 10.1007/s10608-012-9476-1.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1007/s10608-012-9476-1</ArticleId>
						<ArticleId IdType="pmc">PMC3584580</ArticleId>
						<ArticleId IdType="pubmed">23459093</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mohr DC, Ho J, Duffecy J, Baron KG, Lehman KA, Jin L, et al. Perceived barriers to psychological treatments and their relationship to depression. J Clin Psychol. 2010;66:394&#8211;409.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2907887</ArticleId>
						<ArticleId IdType="pubmed">20127795</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Musiat P, Goldstone P, Tarrier N. Understanding the acceptability of e-mental health--attitudes and expectations towards computerised self-help treatments for mental health problems. BMC Psychiatry. 2014;14:109. doi: 10.1186/1471-244X-14-109.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1186/1471-244X-14-109</ArticleId>
						<ArticleId IdType="pmc">PMC3999507</ArticleId>
						<ArticleId IdType="pubmed">24725765</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Faurholt-Jepsen M, Vinberg M, Frost M, Christensen EM, Bardram J, et al. Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones-the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial. BMC Psychiatry. 2014;14:309. doi: 10.1186/s12888-014-0309-5.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1186/s12888-014-0309-5</ArticleId>
						<ArticleId IdType="pmc">PMC4247697</ArticleId>
						<ArticleId IdType="pubmed">25420431</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Faurholt-Jepsen M, Vinberg M, Frost M, Christensen EM, Bardram JE, Kessing LV. Smartphone data as an electronic biomarker of illness activity in bipolar disorder. Bipolar Disord. 2015;17:715&#8211;728. doi: 10.1111/bdi.12332.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/bdi.12332</ArticleId>
						<ArticleId IdType="pubmed">26395972</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Poole R, Simpson SA, Smith DJ. Internet-based psychoeducation for bipolar disorder: a qualitative analysis of feasibility, acceptability and impact. BMC Psychiatry. 2012;12:139. doi: 10.1186/1471-244X-12-139.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1186/1471-244X-12-139</ArticleId>
						<ArticleId IdType="pmc">PMC3527357</ArticleId>
						<ArticleId IdType="pubmed">22971042</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lauder S, Chester A, Castle D, Dodd S, Berk L, Klein B, et al. Development of an online intervention for bipolar disorder. Psychol Health Med. 2013;18:155&#8211;165. doi: 10.1080/13548506.2012.689840.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1080/13548506.2012.689840</ArticleId>
						<ArticleId IdType="pubmed">22712771</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lauder S, Chester A, Castle D, Dodd S, Gliddon E, Berk L, et al. A randomized head to head trial of MoodSwings.net.au: an Internet based self-help program for bipolar disorder. J Affect Disord. 2015;171:13&#8211;21. doi: 10.1016/j.jad.2014.08.008.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2014.08.008</ArticleId>
						<ArticleId IdType="pubmed">25282145</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Holl&#228;ndare F, Eriksson A, L&#246;vgren L, Humble MB, Boersma K. Internet-Based Cognitive Behavioral Therapy for Residual Symptoms in Bipolar Disorder Type II: A Single-Subject Design Pilot Study. JMIR Res Protoc. 2015;4 doi: 10.2196/resprot.3910.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.2196/resprot.3910</ArticleId>
						<ArticleId IdType="pmc">PMC4424320</ArticleId>
						<ArticleId IdType="pubmed">25908235</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Todd NJ, Solis-Trapala I, Jones SH, Lobban FA. An online randomised controlled trial to assess the feasibility, acceptability and potential effectiveness of &#8216;Living with Bipolar&#8217;: a web-based self-management intervention for bipolar disorder: trial design and protocol. Contemp Clin Trials. 2012;33:679&#8211;688. doi: 10.1016/j.cct.2012.02.011.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.cct.2012.02.011</ArticleId>
						<ArticleId IdType="pubmed">22387150</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Todd NJ, Jones SH, Lobban FA. What do service users with bipolar disorder want from a web-based self-management intervention? A qualitative focus group study. Clin Psychol Psychother. 2013;20:531&#8211;543. doi: 10.1002/cpp.1804.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1002/cpp.1804</ArticleId>
						<ArticleId IdType="pubmed">22715161</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Todd NJ, Jones SH, Hart A, Lobban FA. A web-based self-management intervention for Bipolar Disorder &#8216;living with bipolar&#8217;: a feasibility randomised controlled trial. J Affect Disord. 2014;169:21&#8211;29. doi: 10.1016/j.jad.2014.07.027.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2014.07.027</ArticleId>
						<ArticleId IdType="pubmed">25129531</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Barnes C, Harvey R, Smith M, Mitchel P, Wilhelm K. Evaluation of an online relapse prevention program for bipolar disorder: an overview of the aims and methodology of a randomized controlled trial. J Dis Manag Health Outcomes. 2007;15:215&#8211;224. doi: 10.2165/00115677-200715040-00003.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.2165/00115677-200715040-00003</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proudfoot J, Parker G, Manicavasagar V, Hadzi-Pavlovic D, Whitton A, Nicholas J, et al. Effects of adjunctive peer support on perceptions of illness control and understanding in an online psychoeducation program for bipolar disorder: a randomised controlled trial. J Affect Disord. 2012;15(142):98&#8211;105. doi: 10.1016/j.jad.2012.04.007.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2012.04.007</ArticleId>
						<ArticleId IdType="pubmed">22858215</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Depp CA, Mausbach B, Granholm E, Cardenas V, Ben-Zeev D, Patterson TL, et al. Mobile interventions for severe mental illness: design and preliminary data from three approaches. J Nerv Ment Dis. 2010;198:715&#8211;721. doi: 10.1097/NMD.0b013e3181f49ea3.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1097/NMD.0b013e3181f49ea3</ArticleId>
						<ArticleId IdType="pmc">PMC3215591</ArticleId>
						<ArticleId IdType="pubmed">20921861</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Depp CA, Ceglowski J, Wang VC, Yaghouti F, Mausbach BT, Thompson K, et al. Augmenting psychoeducation with a mobile intervention for bipolar disorder: a randomized controlled trial. JAffectDisord. 2014;174:23&#8211;30.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4339469</ArticleId>
						<ArticleId IdType="pubmed">25479050</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hidalgo-Mazzei D, Mateu A, Reinares M, Matic A, Vieta E, Colom F. Internet-based psychological interventions for bipolar disorder: Review of the present and insights into the future. J Affect Disord. 2015;188:1&#8211;13. doi: 10.1016/j.jad.2015.08.005.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/j.jad.2015.08.005</ArticleId>
						<ArticleId IdType="pubmed">26342885</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Javelot H, Spadazzi A, Weiner L, Garcia S, Gentili C, Kosel M, et al. Telemonitoring with respect to mood disorders and information and communication technologies: overview and presentation of the PSYCHE project. Biomed Res Int. 2014;104658.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4094725</ArticleId>
						<ArticleId IdType="pubmed">25050321</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miklowitz DJ, Price J, Holmes EA, Rendell J, Bell S, Budge K, et al. Facilitated Integrated Mood Management for adults with bipolar disorder. Bipolar Disord. 2012;14:185&#8211;197. doi: 10.1111/j.1399-5618.2012.00998.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2012.00998.x</ArticleId>
						<ArticleId IdType="pmc">PMC3412076</ArticleId>
						<ArticleId IdType="pubmed">22420594</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278&#8211;296. doi: 10.1111/j.2044-8260.1967.tb00530.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.2044-8260.1967.tb00530.x</ArticleId>
						<ArticleId IdType="pubmed">6080235</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ramos-Brieva JCA. Validaci&#243;n de la versi&#243;n castellana de la escala de Hamilton para la depresi&#243;n. Actas Luso-Esp Neurol, Psiquiatr Cienc Afines. 1986;14:324&#8211;334.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3776732</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatr. 1978;1:429&#8211;435. doi: 10.1192/bjp.133.5.429.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1192/bjp.133.5.429</ArticleId>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Colom F, Vieta E, Mart&#237;nez-Ar&#225;n A, Garc&#237;a-Garc&#237;a M, Reinares M, Torrent C, Goikolea JM, et al. Versi&#243;n espa&#241;ola de una escala de evaluaci&#243;n de la man&#237;a: validez y fiabilidad de la Escala de Young. Med Clin (Barc) 2002;119:366&#8211;371. doi: 10.1016/S0025-7753(02)73419-2.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1016/S0025-7753(02)73419-2</ArticleId>
						<ArticleId IdType="pubmed">12372167</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>First MB, Spitzer R, Gibbon M. Structured Clinical Interview for DSM-IV. Axis I Disorders. Washington: American Psychiatric Press Inc; 1997.</Citation>
				</Reference>
				<Reference>
					<Citation>Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE, Jr, et al. Development and Validation of a Screening Instrument for Bipolar Spectrum Disorder: The Mood Disorder Questionnaire. Am J Psychiatry. 2000;157:1873&#8211;1875. doi: 10.1176/appi.ajp.157.11.1873.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1176/appi.ajp.157.11.1873</ArticleId>
						<ArticleId IdType="pubmed">11058490</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sanchez-Moreno J, Villagran JM, Gutierrez JR, Camacho M, Ocio S, Palao D, et al. Adaptation and validation of the Spanish version of the Mood Disorder Questionnaire for the detection of bipolar disorder. Bipolar Disord. 2008;10:400&#8211;412. doi: 10.1111/j.1399-5618.2007.00571.x.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1111/j.1399-5618.2007.00571.x</ArticleId>
						<ArticleId IdType="pubmed">18402628</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Beck AT, Steer R, Brown GK. BDI&#8211;II. Beck Depression Inventory-Second Edition manual. San Antonio: The Psychological Corporation; 1996.</Citation>
				</Reference>
				<Reference>
					<Citation>Beck AT, Steer RA, Brown GK. Manual. BDI-II. Inventario de Depresi&#243;n de Beck-II (Adaptaci&#243;n espa&#241;ola: Sanz J, V&#225;zquez C) Madrid: Pearson; 2011.</Citation>
				</Reference>
				<Reference>
					<Citation>Beck A, Steer R. Beck Hopelessness Scale. Manual. New York: The psychological corporation Harcourt Brace Jovanovich, Inc; 1988.</Citation>
				</Reference>
				<Reference>
					<Citation>Aliaga J, Rodr&#237;guez L, Ponce C, Frisancho A, Enr&#237;quez J. Escala de Desesperanza de Beck (BHS): adaptaci&#243;n y caracter&#237;sticas psicom&#233;tricas. Revista de Investigaci&#243;n en Psicolog&#237;a. 2006;9:69&#8211;79.</Citation>
				</Reference>
				<Reference>
					<Citation>Spielberger CD, Goursch RL, Lushene RE. Cuestionario de Ansiedad Estado- Rasgo, STAI. Madrid: TEA Ediciones; 1982.</Citation>
				</Reference>
				<Reference>
					<Citation>Rosa AR, S&#225;nchez-Moreno J, Mart&#237;nez-Aran A, Salamero M, Torrent C, Reinares M, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5. doi: 10.1186/1745-0179-3-5.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.1186/1745-0179-3-5</ArticleId>
						<ArticleId IdType="pmc">PMC1904447</ArticleId>
						<ArticleId IdType="pubmed">17555558</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">37964558</PMID>
			<DateCompleted>
				<Year>2024</Year>
				<Month>03</Month>
				<Day>11</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2024</Year>
				<Month>03</Month>
				<Day>12</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1497-0015</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>69</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>2024</Year>
							<Month>Apr</Month>
						</PubDate>
					</JournalIssue>
					<Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title>
					<ISOAbbreviation>Can J Psychiatry</ISOAbbreviation>
				</Journal>
				<ArticleTitle>The Influence of Personality Disorder Symptoms on Treatment Outcomes in Bipolar Disorder: A Secondary Analysis of a Randomised Controlled Trial: L'influence des sympt&#244;mes du trouble de la personnalit&#233; sur les r&#233;sultats du traitement dans le trouble bipolaire : Une analyse secondaire d'un essai randomis&#233; contr&#244;l&#233;.</ArticleTitle>
				<Pagination>
					<StartPage>275</StartPage>
					<EndPage>287</EndPage>
					<MedlinePgn>275-287</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1177/07067437231213558</ELocationID>
				<Abstract>
					<AbstractText Label="OBJECTIVES">Many people who are diagnosed with bipolar disorder also have comorbid personality disorder. Few studies have explored how personality disorder may influence pharmacological treatment outcomes. The aim of this study was to conduct a secondary analysis of data from a clinical trial of adjunctive nutraceutical treatments for bipolar depression, to determine whether maladaptive personality traits influence treatment outcomes.</AbstractText>
					<AbstractText Label="METHODS">Scores on the Standardised Assessment of Personality - Abbreviated Scale screener were used to classify participants as having bipolar disorder with (
						<i>n</i>&#8201;=&#8201;119) and without (
						<i>n</i>&#8201;=&#8201;29) above threshold personality disorder symptoms (personality disorder). Outcome measures included: The Montgomery &#197;sberg Depression Rating Scale, Clinical Global Impressions and Improvement Severity Scales, Patient Global Impressions-Improvement scale, Bipolar Depression Rating Scale, Range of Impaired Functioning Tool, Social and Occupational Functioning Assessment Scale and Quality of Life and Enjoyment Scale (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form). Generalised estimated equations examined the two-way interactions of personality disorder by time or treatment and investigated personality disorder as a non-specified predictor of outcomes.
					</AbstractText>
					<AbstractText Label="RESULTS">Over time, the Patient Global Impressions-Improvement scores were significantly higher in those in the personality disorder group. No other significant differences in the two-way interactions of personality disorder by treatment group or personality disorder by time were found. Personality disorder was a significant but non-specific predictor of poorer outcomes on the Bipolar Depression Rating Scale, Range of Impaired Functioning Tool, and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, regardless of time or treatment group.</AbstractText>
					<AbstractText Label="CONCLUSIONS">This study highlights the potential impact of maladaptive personality traits on treatment outcomes and suggests that the presence of comorbid personality disorder may confer additional burden and compromise treatment outcomes. This warrants further investigation as does the corroboration of these exploratory findings. This is important because understanding the impact of comorbid personality disorder on bipolar disorder may enable the development of effective psychological and pharmacotherapeutic options for personalised treatments.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Sarmiento</LastName>
						<ForeName>Alessandra</ForeName>
						<Initials>A</Initials>
						<Identifier Source="ORCID">0009-0004-9094-9515</Identifier>
						<AffiliationInfo>
							<Affiliation>IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dean</LastName>
						<ForeName>Olivia M</ForeName>
						<Initials>OM</Initials>
						<AffiliationInfo>
							<Affiliation>IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kavanagh</LastName>
						<ForeName>Bianca E</ForeName>
						<Initials>BE</Initials>
						<Identifier Source="ORCID">0000-0002-1656-2775</Identifier>
						<AffiliationInfo>
							<Affiliation>IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Deakin Rural Health, Deakin University, Warrnambool, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mohebbi</LastName>
						<ForeName>Mohammadreza</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Faculty of Health, Biostatistics Unit, Deakin University, Geelong, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Berk</LastName>
						<ForeName>Michael</ForeName>
						<Initials>M</Initials>
						<Identifier Source="ORCID">0000-0002-5554-6946</Identifier>
						<AffiliationInfo>
							<Affiliation>IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Orygen, Parkville, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Centre for Youth Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dodd</LastName>
						<ForeName>Seetal</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Centre for Youth Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cotton</LastName>
						<ForeName>Sue M</ForeName>
						<Initials>SM</Initials>
						<AffiliationInfo>
							<Affiliation>Orygen, Parkville, VIC, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Centre for Youth Mental Health, University of Melbourne, Parkville, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Malhi</LastName>
						<ForeName>Gin S</ForeName>
						<Initials>GS</Initials>
						<AffiliationInfo>
							<Affiliation>Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, NSW, Australia.</Affiliation>
						</AffiliationInfo>
						<AffiliationInfo>
							<Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ng</LastName>
						<ForeName>Chee H</ForeName>
						<Initials>CH</Initials>
						<AffiliationInfo>
							<Affiliation>Professorial Unit, The Melbourne Clinic, Department of Psychiatry, The University of Melbourne, Richmond, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Turner</LastName>
						<ForeName>Alyna</ForeName>
						<Initials>A</Initials>
						<Identifier Source="ORCID">0000-0001-7389-2546</Identifier>
						<AffiliationInfo>
							<Affiliation>IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<Acronym>WT_</Acronym>
						<Agency>Wellcome Trust</Agency>
						<Country>United Kingdom</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>15</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Can J Psychiatry</MedlineTA>
				<NlmUniqueID>7904187</NlmUniqueID>
				<ISSNLinking>0706-7437</ISSNLinking>
			</MedlineJournalInfo>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D019587">Dietary Supplements</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D010554">Personality Disorders</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
			<OtherAbstract Language="fre" Type="Publisher">
				<AbstractText Label="OBJECTIFS">De nombreuses personnes qui re&#231;oivent un diagnostic de trouble bipolaire (TB) ont &#233;galement un trouble de la personnalit&#233; (TP) comorbide. Peu d&#8217;&#233;tudes ont explor&#233; comment le TP peut influencer les r&#233;sultats du traitement pharmacologique. La pr&#233;sente &#233;tude visait &#224; mener une analyse secondaire des donn&#233;es d&#8217;un essai clinique de traitements nutraceutiques compl&#233;mentaires pour la d&#233;pression bipolaire, afin de d&#233;terminer si les traits de la personnalit&#233; inadapt&#233;e influencent les r&#233;sultats du traitement.</AbstractText>
				<AbstractText Label="M&#201;THODES">Les scores &#224; l&#8217;&#201;chelle d'&#233;valuation standardis&#233;e de la personnalit&#233; abr&#233;g&#233;e (SAPAS) ont servi &#224; classifier les participants comme ayant un TB avec (n&#8201;=&#8201;119) et sans (n&#8201;=&#8201;29) au-dessus du seuil des sympt&#244;mes de TP (&#171; TP &#187;). Les mesures des r&#233;sultats incluaient : l&#8217;&#201;chelle d'&#233;valuation de la d&#233;pression de Montgomery &#197;sberg (MADRS), l&#8217;&#201;chelle des impressions cliniques globales et l&#8217;&#233;chelle de gravit&#233; des am&#233;liorations (CGI-I, CGI-S), Impressions globales des patients&#8211;am&#233;lioration (PGI-I), &#201;chelle d&#8217;&#233;valuation de la d&#233;pression bipolaire (BDRS), Gamme de fonctionnement alt&#233;r&#233; (LIFE-RIFT), Fonctionnement social et professionnel (SOFAS) et &#201;chelle de qualit&#233; de vie et de plaisir (Q-LES-Q-SF). Les &#233;quations estim&#233;es g&#233;n&#233;ralis&#233;es examinaient les interactions bidirectionnelles du TP selon le temps ou le traitement et investiguaient le TP comme pr&#233;dicteur non sp&#233;cifi&#233; des r&#233;sultats.</AbstractText>
				<AbstractText Label="R&#201;SULTATS">Avec le temps, les scores au PGI-I scores &#233;taient significativement plus &#233;lev&#233;s que ceux du groupe TP. D&#8217;autres diff&#233;rences significatives n&#8217;ont pas &#233;t&#233; trouv&#233;es dans les interactions bidirectionnelles du TP par groupe de traitement ou du TP par le temps. Le TP &#233;tait un pr&#233;dicteur significatif mais non sp&#233;cifique de mauvais r&#233;sultats aux &#233;chelles BDRS, LIFE-RIFT, Q-LES-Q-SF, peu importe le temps ou le groupe de traitement.</AbstractText>
				<AbstractText Label="CONCLUSIONS">La pr&#233;sente &#233;tude fait ressortir l&#8217;effet potentiel des traits de la personnalit&#233; inadapt&#233;e sur les r&#233;sultats de traitement, et sugg&#232;re que la pr&#233;sence d&#8217;un TP comorbide peut conf&#233;rer un fardeau additionnel et compromettre les r&#233;sultats du traitement. Ceci m&#233;rite plus d&#8217;investigation tout comme la corroboration de ces r&#233;sultats exploratoires. C&#8217;est important parce que comprendre l&#8217;effet du TP comorbide sur le TB peut permettre de d&#233;velopper des options psychologiques et pharmacoth&#233;rapeutiques efficaces pour des traitements personnalis&#233;s.</AbstractText>
			</OtherAbstract>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Trouble bipolaire</Keyword>
				<Keyword MajorTopicYN="N">adjunctive therapies</Keyword>
				<Keyword MajorTopicYN="N">bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">clinical trial</Keyword>
				<Keyword MajorTopicYN="N">depression</Keyword>
				<Keyword MajorTopicYN="N">d&#233;pression</Keyword>
				<Keyword MajorTopicYN="N">essai clinique</Keyword>
				<Keyword MajorTopicYN="N">mania</Keyword>
				<Keyword MajorTopicYN="N">manie</Keyword>
				<Keyword MajorTopicYN="N">neuroscience</Keyword>
				<Keyword MajorTopicYN="N">personality disorder</Keyword>
				<Keyword MajorTopicYN="N">psychiatrie</Keyword>
				<Keyword MajorTopicYN="N">psychiatry</Keyword>
				<Keyword MajorTopicYN="N">th&#233;rapies compl&#233;mentaires</Keyword>
				<Keyword MajorTopicYN="N">traitement</Keyword>
				<Keyword MajorTopicYN="N">treatment</Keyword>
				<Keyword MajorTopicYN="N">trouble de la personnalit&#233;</Keyword>
			</KeywordList>
			<CoiStatement>Declaration of Conflicting InterestsOMD has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC and ASBDD/Servier. She has also received in kind support from BioMedica Nutraceuticals, NutritionCare and Bioceuticals. MB has received grant/research support from National Health and Medical Research Council, Wellcome Trust, Medical Research Future Fund, Victorian Medical Research Acceleration Fund, Centre for Research Excellence CRE, Victorian Government Department of Jobs, Precincts and Regions and Victorian COVID-19 Research Fund. He received honoraria from Springer, Oxford University Press, Cambridge University Press, Allen and Unwin, Lundbeck, Controversias Barcelona, Servier, Medisquire, HealthEd, ANZJP, EPA, Janssen, Medplan, Milken Institute, RANZCP, Abbott India, ASCP, Headspace and Sandoz. G.S.M. has received grant or research support from National Health and Medical Research Council, Australian Rotary Health, NSW Health, Ramsay Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca, and Servier; has been a speaker for AstraZeneca, Janssen-Cilag, Lundbeck, and Servier; and has been a consultant for AstraZeneca, Janssen Cilag, Lundbeck, and Servier. C.H.N. had served as a consultant for Lundbeck, Grunbiotics, Servier, Janssen-Cilag and Eli Lilly, received research grant support from Lundbeck, and speaker honoraria from Servier, Lundbeck, Sumitomo, Bristol-Myers Squibb, Organon, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Astra-Zenaca, and Pfizer. S.M.C. has received grant support from the NHMRC, the Stanley Medical Research Institute, BeyondBlue, Movember, The University of Melbourne, Australian Catholic University, ARHRF, and Mental Illness Research Fund (Victoria Department of Human Services). A.T. has received travel or grant support from the NHMRC, Deakin University, AMP Foundation, National Stroke Foundation, Hunter Medical Research Institute, Helen Macpherson Smith Trust, Schizophrenia Fellowship NSW, SMHR, ISAD, and the University of Newcastle.</CoiStatement>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="medline">
					<Year>2024</Year>
					<Month>3</Month>
					<Day>11</Day>
					<Hour>6</Hour>
					<Minute>43</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>15</Day>
					<Hour>6</Hour>
					<Minute>43</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>15</Day>
					<Hour>3</Hour>
					<Minute>45</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pmc-release">
					<Year>2023</Year>
					<Month>11</Month>
					<Day>15</Day>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">37964558</ArticleId>
				<ArticleId IdType="pmc">PMC10924579</ArticleId>
				<ArticleId IdType="doi">10.1177/07067437231213558</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. Lancet. 2020;396(10265):1841&#8208;1856.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">33278937</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Wood D, Crapnell T, Lau Let al. et al. Emerging adulthood as a critical stage in the life course. In: Halfon N, Forrest CB, Lerner RM, Faustman EM, editors. Handbook of life course health development. Cham: Springer; 2018. p. 123&#8208;143.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">31314293</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Livesley WJ. An empirically-based classification of personality disorder. J Pers Disord. 2011;25(3):397&#8208;420.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">21699399</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Turley B, Bates GW, Edwards J, Jackson HJ. MCMI-II personality disorders in recent-onset bipolar disorders. J Clin Psychol. 1992;48(3):320&#8208;329.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1602021</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Pica S, Edwards J, Jackson HJ, Bell RC, Bates GW, Rudd RP. Personality disorders in recent-onset bipolar disorder. Compr Psychiatry. 1990;31(6):499&#8208;510.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2265534</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Carpenter D, Clarkin JF, Glick ID, Wilner PJ. Personality pathology among married adults with bipolar disorder. J Affect Disord. 1995;34(4):269&#8208;274.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">8550952</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>O'Connell RA, Mayo JA, Sciutto MS. PDQ-R personality disorders in bipolar patients. J Affect Disord. 1991;23(4):217&#8208;221.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1791267</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Peselow ED, Sanfilipo MP, Fieve RR. Relationship between hypomania and personality disorders before and after successful treatment. Am J Psychiatry. 1995;152(2):232&#8208;238.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7840357</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Dunayevich E, Strakowski SM, Sax KW, et al. Personality disorders in first- and multiple-episode mania. Psychiatry Res. 1996;64(1):69&#8208;75.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">8888366</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Koenigsberg HW, Kaplan RD, Gilmore MM, Cooper AM. The relationship between syndrome and personality disorder in DSM-III: Experience with 2,462 patients. Am J Psychiatry. 1985;142(2):207&#8208;212.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3970245</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Latalova K, Prasko J, Kamaradova D, Sedlackova J, Ociskova M. Comorbidity bipolar disorder and personality disorders. Neuro Endocrinol Lett. 2013;34(1):1&#8208;8.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23524617</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders: Fifth edition DSM-5. Arlington, VA: American Psychiatric Publishing; 2013.</Citation>
				</Reference>
				<Reference>
					<Citation>Kesebir S, Vahip S, Akdeniz F, Yuncu Z, Alkan M, Akiskal H. Affective temperaments as measured by TEMPS-A in patients with bipolar I disorder and their first-degree relatives: a controlled study. J Affect Disord. 2005;85(1-2):127&#8208;133.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15780683</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Dunyevich ESK, Keck P, Jr, McElroy S, Sorter M, McConville B, Strakowski S. Twelve-month outcome in bipolar patients with and without personality disorders. J Clin Psychiatry. 2000;61(2):134&#8208;139.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">10732661</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gasperini MLA, Cogrossi S, Zanardi R, Smeraldi E. Lithium treatment: relationship between relapses and personality disorders. In: Placidi GF, Dell&#8217;Osso L, Nistic&#242; G, Akiskal HS, editors. Recurrent mood disorders. Berlin, Heidelberg: Springer; 1993. p. 169-173.</Citation>
				</Reference>
				<Reference>
					<Citation>Post RM, Leverich GS, McElroy S, et al. Relationship of comorbid personality disorders to prospective outcome in bipolar disorder. J Affect Disord. 2020;276:147&#8208;151.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">32697693</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bieling PJ, Green SM, Macqueen G. The impact of personality disorders on treatment outcome in bipolar disorder: a review. Personal Ment Health. 2007;1(1):2&#8208;13.</Citation>
				</Reference>
				<Reference>
					<Citation>Kavanagh BE, Ashton MM, Cowdery SP, et al. Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders. J Affect Disord. 2021;279:711&#8208;721.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">33197840</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2011;188(3):361&#8208;365.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4750381</ArticleId>
						<ArticleId IdType="pubmed">21641663</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Swartz HPP, Pilkonis PA, Frank E, Proietti J, Scott J. Acute treatment outcomes in patients with bipolar I disorder and co-morbid borderline personality disorder receiving medication and psychotherapy. Bipolar Disord. 2005;7(2):192&#8208;197.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15762861</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Preston GA, Marchant BK, Reimherr FW, Strong RE, Hedges DW. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord. 2004;79(1-3):297&#8208;303.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15023511</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kavanagh BE, Brennan-Olsen SL, Turner Aet al. Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: A protocol for a systematic review and meta-analysis. BMJ Open. 2019;9(4):e025145.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6502230</ArticleId>
						<ArticleId IdType="pubmed">31048431</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Turner A, Malhi Get al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med. 2019;17(1):18.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6346513</ArticleId>
						<ArticleId IdType="pubmed">30678686</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sheehan DV, Lecrubier Y, Sheehan KHet al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22&#8208;33.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">9881538</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382&#8208;389.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">444788</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Moran P, Leese M, Lee T, Walters P, Thornicroft G, Mann A. Standardised Assessment of Personality &#8211; Abbreviated Scale (SAPAS): Preliminary validation of a brief screen for personality disorder. Br J Psychiatry. 2003;183(3):228&#8208;232.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12948996</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kavanagh BE, Williams LJ, Berk M, et al. Personality disorder and functioning in major depressive disorder: A nested study within a randomized controlled trial. Braz J Psychiatry. 2020;42(1):14&#8208;21.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC6986492</ArticleId>
						<ArticleId IdType="pubmed">31116261</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Berk M, Malhi GS, Cahill Cet al. The Bipolar Depression Rating Scale (BDRS): Its development, validation and utility. Bipolar Disord. 2007;9(6):571&#8208;579.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17845271</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429&#8208;435.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">728692</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Guy W, National Institute of Mental Health (U.S.). Psychopharmacology research branch, division of extramural research programs. In: ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare; 1976.</Citation>
				</Reference>
				<Reference>
					<Citation>Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28&#8208;37.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC2880930</ArticleId>
						<ArticleId IdType="pubmed">20526405</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: A review of measures of social functioning. Am J Psychiatry. 1992;149(9):1148&#8208;1156.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1386964</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Keller MB, Lavori PW, Friedman B, et al. The longitudinal interval follow-up evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44(6):540&#8208;548.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3579500</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacol Bull. 1993;29(2):321&#8208;326.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">8290681</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>IBM Corp. IBM SPSS statistics for windows. Armonk, NY: IBM Corp; 2021.</Citation>
				</Reference>
				<Reference>
					<Citation>Ashton MM, Mohebbi M, Turner A, et al. Physical activity as a predictor of clinical trial outcomes in bipolar depression: a subanalysis of a mitochondrial-enhancing nutraceutical randomized dontrolled trial. Can J Psychiatry. 2020;65(5):306&#8208;318.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC7265618</ArticleId>
						<ArticleId IdType="pubmed">31775518</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Russell SE, Wrobel AL, Ashton MM, et al. Does post-traumatic stress disorder impact treatment outcomes within a randomised controlled trial of mitochondrial agents for bipolar depression? Clin Psychopharmacol Neurosci. 2023;21(3):457&#8208;465.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC10335917</ArticleId>
						<ArticleId IdType="pubmed">37424414</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Karaszewska DM, Ingenhoven T, Mocking RJT. Marine Omega-3 fatty acid supplementation for borderline personality disorder: A meta-analysis. J Clin Psychiatry. 2021;82(3). doi: 10.4088/JCP.20r13613.</Citation>
					<ArticleIdList>
						<ArticleId IdType="doi">10.4088/JCP.20r13613</ArticleId>
						<ArticleId IdType="pubmed">34004088</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Saccaro LF, Schilliger Z, Dayer A, Perroud N, Piguet C. Inflammation, anxiety, and stress in bipolar disorder and borderline personality disorder: a narrative review. Neurosci Biobehav Rev. 2021;127:184&#8208;192.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">33930472</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>George EL, Miklowitz DJ, Richards JA, Simoneau TL, Taylor DO. The comorbidity of bipolar disorder and axis II personality disorders: Prevalence and clinical correlates. Bipolar Disord. 2003;5(2):115&#8208;122.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12680901</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Bassett D. Borderline personality disorder and bipolar affective disorder. Spectra or spectre? A review. Aust N Z J Psychiatry. 2012;46(4):327&#8208;339.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">22508593</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Malhi GS, Tanious M, Fritz Ket al. et al. Differential engagement of the fronto-limbic network during emotion processing distinguishes bipolar and borderline personality disorder. Mol Psychiatry. 2013;18(12):1247&#8208;1248.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4429860</ArticleId>
						<ArticleId IdType="pubmed">23439484</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Miller JD, Sleep CE, Lamkin J, Vize C, Campbell WK, Lynam DR. Personality disorder traits: Perceptions of likability, impairment, and ability to change as correlates and moderators of desired level. Personal Disord. 2018;9(5):478&#8208;483.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">29120195</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mohebbi M, Dodd S, Dean OM, Berk M. Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder. Eur Psychiatry. 2018;53:17&#8208;22.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">29859377</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ng TH, Burke TA, Stange JPet al. et al. Personality disorder symptom severity predicts onset of mood episodes and conversion to bipolar I disorder in individuals with bipolar spectrum disorder. J Abnorm Psychol. 2017;126(3):271&#8208;284.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC5380154</ArticleId>
						<ArticleId IdType="pubmed">28368159</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Molz AR, Black CL, Shapero BG, Bender RE, Alloy LB, Abramson LY. Aggression and impulsivity as predictors of stress generation in bipolar spectrum disorders. J Affect Disord. 2013;146(2):272&#8208;280.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3514622</ArticleId>
						<ArticleId IdType="pubmed">22871530</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Johnson SL. Life events in bipolar disorder: towards more specific models. Clin Psychol Rev. 2005;25(8):1008&#8208;1027.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC3137243</ArticleId>
						<ArticleId IdType="pubmed">16129530</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Malkoff-Schwartz S, Frank E, Anderson BPet al. et al. Social rhythm disruption and stressful life events in the onset of bipolar and unipolar episodes. Psychol Med. 2000;30(5):1005&#8208;1016.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">12027038</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hayashi N, Igarashi M, Imai A, et al. Pathways from life-historical events and borderline personality disorder to symptomatic disorders among suicidal psychiatric patients: A study of structural equation modeling. Psychiatry Clin Neurosci. 2015;69(9):563&#8208;571.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">25645160</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Muhtadie L, Johnson SL, Carver CS, Gotlib IH, Ketter TA. A profile approach to impulsivity in bipolar disorder: The key role of strong emotions. Acta Psychiatr Scand. 2014;129(2):100&#8208;108.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pmc">PMC4346162</ArticleId>
						<ArticleId IdType="pubmed">23600731</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Loftus ST, Jaeger J. Psychosocial outcome in bipolar I patients with a personality disorder. J Nerv Ment Dis. 2006;194(12):967&#8208;970.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">17164638</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Kavanagh BE, Stuart AL, Berk Met al. Personality disorder increases risk of low quality of life among women with mental state disorders. Compr Psychiatry. 2020;102:152193.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">32730960</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Newton-Howes G. The impact of mental state disorder and personality on social functioning in patients engaged in community mental health care. Australas Psychiatry. 2014;22(1):19&#8208;22.</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">23996666</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation IndexingMethod="Automated" Owner="NLM" Status="MEDLINE">
			<PMID Version="1">34990968</PMID>
			<DateCompleted>
				<Year>2022</Year>
				<Month>03</Month>
				<Day>31</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>04</Month>
				<Day>01</Day>
			</DateRevised>
			<Article PubModel="Print-Electronic">
				<Journal>
					<ISSN IssnType="Electronic">1879-1379</ISSN>
					<JournalIssue CitedMedium="Internet">
						<Volume>146</Volume>
						<PubDate>
							<Year>2022</Year>
							<Month>Feb</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of psychiatric research</Title>
					<ISOAbbreviation>J Psychiatr Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Influence of adjuvant clonidine on mania, sleep disturbances and cognitive performance - Results from a double-blind and placebo-controlled randomized study in individuals with bipolar I disorder during their manic phase.</ArticleTitle>
				<Pagination>
					<StartPage>163</StartPage>
					<EndPage>171</EndPage>
					<MedlinePgn>163-171</MedlinePgn>
				</Pagination>
				<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2021.12.035</ELocationID>
				<ELocationID EIdType="pii" ValidYN="Y">S0022-3956(21)00737-8</ELocationID>
				<Abstract>
					<AbstractText Label="BACKGROUND">While the favorable effect of adjuvant clonidine in the treatment of acute mania has been observed already about 40 years ago, this line of treatment has not been further investigated. Here, we resumed this topic, and we tested the effect of adjuvant clonidine, an antihypertensive stimulating the alpha-
						<sub>2</sub> central adrenergic receptor, on symptoms of mania, cognitive performance, and subjective sleep. To this end, we performed a randomized, double-blind and placebo-controlled clinical trial among inpatients with bipolar disorder I during their acute phase of mania.
					</AbstractText>
					<AbstractText Label="METHODS">A total of 70 inpatients (mean age: 37.40 years; 15.7% females) with diagnosed bipolar disorder I and during their acute manic phase were randomly assigned either to the adjuvant clonidine (0.2&#160;mg/d to a maximum of 0.6&#160;mg/d) or to the placebo condition. Standard medication was lithium at therapeutic dosages. At baseline, participants completed a series of self-rating questionnaires covering sociodemographic information and subjective sleep. Subjective sleep was re-assessed 24 days later at the end of the study. Experts rated participants' acute state of mania with the Young Mania Rating Scale at baseline and at day 12 and day 24. Participants' cognitive performance was assessed at baseline and at day 24&#160;at the end of the study.</AbstractText>
					<AbstractText Label="RESULTS">Over time, mania scores significantly decreased (large effect size), but more so in the clonidine condition, compared to the placebo condition (medium effect size). Likewise, over time, subjective sleep improved (large effect size), but more so in the clonidine, compared to the placebo condition (medium effect size). Over time, cognitive performance improved (medium effect size), irrespective from the study condition.</AbstractText>
					<AbstractText Label="CONCLUSIONS">Compared to placebo, adjuvant clonidine to lithium improved symptoms of mania, as rated by experts', and subjective sleep quality. Adjuvant clonidine had no further favorable (or detrimental) impact on cognitive performance.</AbstractText>
					<CopyrightInformation>Copyright &#169; 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Ahmadpanah</LastName>
						<ForeName>Mohammad</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Research Center for Behavioral Disorders and Substances Abuse, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Pezeshki</LastName>
						<ForeName>Rana</ForeName>
						<Initials>R</Initials>
						<AffiliationInfo>
							<Affiliation>Research Center for Behavioral Disorders and Substances Abuse, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Soltanian</LastName>
						<ForeName>Ali Reza</ForeName>
						<Initials>AR</Initials>
						<AffiliationInfo>
							<Affiliation>Modeling of Non-Communicable Diseases Research Center, Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jahangard</LastName>
						<ForeName>Leila</ForeName>
						<Initials>L</Initials>
						<AffiliationInfo>
							<Affiliation>Research Center for Behavioral Disorders and Substances Abuse, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>D&#252;rsteler</LastName>
						<ForeName>Kenneth M</ForeName>
						<Initials>KM</Initials>
						<AffiliationInfo>
							<Affiliation>Psychiatric Clinics of the University of Basel, Division of Substance Use Disorders, University of Basel, Basel, Switzerland; Center for Addictive Disorders, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Keshavarzi</LastName>
						<ForeName>Amir</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Research Center for Behavioral Disorders and Substances Abuse, Hamadan University of Medical Sciences, Hamadan, Iran. Electronic address: Drkeshavarzi@yahoo.com.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Brand</LastName>
						<ForeName>Serge</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Center for Affective, Stress and Sleep Disorders (ZASS), Psychiatric University Hospital Basel, 4002 Basel, Switzerland; Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; Substance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health, University of Basel, Basel, Switzerland; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: serge.brand@unibas.ch.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
				<ArticleDate DateType="Electronic">
					<Year>2021</Year>
					<Month>12</Month>
					<Day>21</Day>
				</ArticleDate>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>J Psychiatr Res</MedlineTA>
				<NlmUniqueID>0376331</NlmUniqueID>
				<ISSNLinking>0022-3956</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>MN3L5RMN02</RegistryNumber>
					<NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D014150">Antipsychotic Agents</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="Y" UI="D001714">Bipolar Disorder</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003000">Clonidine</DescriptorName>
					<QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
					<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D000087122">Mania</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D012890">Sleep</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
			<KeywordList Owner="NOTNLM">
				<Keyword MajorTopicYN="N">Bipolar disorder</Keyword>
				<Keyword MajorTopicYN="N">Clonidine</Keyword>
				<Keyword MajorTopicYN="N">Cognitive performance</Keyword>
				<Keyword MajorTopicYN="N">Mania</Keyword>
				<Keyword MajorTopicYN="N">Subjective sleep quality</Keyword>
				<Keyword MajorTopicYN="N">alpha(2) central adrenergic receptors</Keyword>
			</KeywordList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="received">
					<Year>2021</Year>
					<Month>6</Month>
					<Day>6</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="revised">
					<Year>2021</Year>
					<Month>12</Month>
					<Day>10</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="accepted">
					<Year>2021</Year>
					<Month>12</Month>
					<Day>17</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="pubmed">
					<Year>2022</Year>
					<Month>1</Month>
					<Day>7</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2022</Year>
					<Month>4</Month>
					<Day>1</Day>
					<Hour>6</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>2022</Year>
					<Month>1</Month>
					<Day>6</Day>
					<Hour>20</Hour>
					<Minute>22</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">34990968</ArticleId>
				<ArticleId IdType="doi">10.1016/j.jpsychires.2021.12.035</ArticleId>
				<ArticleId IdType="pii">S0022-3956(21)00737-8</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
</PubmedArticleSet>